Estimating the prevalence of chronic medical co-morbidities in the seriously mentally ill in primary care: a modelling framework by Banarsee, Reethoodhwaj
 
 
  
 
 
 
 
 
 
 
Estimating the prevalence of chronic medical co-morbidities in the 
serious mentally ill in primary care. 
 
         
       A modelling framework 
 
 
       REETOODHWAJ BANARSEE 
 
 
 
      A thesis submitted in partial fulfilment of the requirements for the 
degree of  
Doctor of Philosophy 
 
 University of West London  
 
 
September 2013 
 
 
 
Abstract 
 
An increasing body of evidence suggests that, in comparison to the general 
population, patients with severe mental illnesses such as schizophrenia or 
bipolar disorder have worse physical health and a far shorter life expectancy, 
due primarily to co-morbid chronic diseases.  
 
The standardised mortality ratio for all forms of mental disorder is at least 1.5 
and varies with the type and severity of the disorder.  Whilst data on the 
prevalence of chronic diseases in primary care is available nationally, there is 
a lack of health intelligence on medical co-morbidities associated with chronic 
mental illnesses. 
 
The aim of this PhD was to develop and validate epidemiological models for 
predicting expected prevalence of two major chronic medical conditions 
namely, coronary heart disease (CHD) and chronic obstructive pulmonary 
disease (COPD), on  general practice data for people with concurrent serious 
mental illness (SMI) group.  
 
The study probed the national epidemiological synthetic estimation of the two 
physical disorders to determine their prevalence within a local primary care 
setting and their co-existence within the serious mentally ill (SMI) group 
identified through the Quality Framework dataset (QOF) within GP practices 
and their localities. The expected prevalence was compared with recorded 
cases. 
 
 
Methods 
The national model used multinomial regression to arrive at odds ratios based 
on a basket of variables including age, sex, ethnicity, rurality and smoking 
status. This study examines the possibility of using a similar multi-nomial 
logistic regression model in conjunction with other locally sensitive data to 
map the expected risk at very small area level (GP practice level) in order to 
derive the expected prevalence of the two medical conditions at local levels.  
 
The model takes into account local variations with adjustments made to obtain 
a more accurate estimation. These were applied to the local SMI datasets 
(QOF data) to establish co-morbidity levels. Validation was carried out using 
external data, including population-based epidemiological data and case-
finding initiatives. The co-morbidity estimation of SMI with each and both 
conditions was derived using Bayesian methodology. 
 
Results 
Risk factors, odds of disease and expected prevalence of CHD and COPD 
were consistent with external data sources and supported trends from HsFE. 
Higher prevalence rates were associated with population deprivation, poorer 
quality and supply of primary health care services and poorer access to them. 
For both medical conditions they were under reported at local levels. The ratio 
of recorded to expected prevalence were significantly different (p < 0.001). 
 
 
 
 
Medical co-morbidity prevalence associated with SMI was 2.5 fold greater 
than the general population. Case findings showed strong evidence of 
difference between expected and actual prevalence of the two diseases in the 
localities (p < 0.001).  
 
Conclusion 
The physical health of patients with severe mental illnesses is too often 
neglected, thus contributing to a compounded health disparity. The 
reintegration of psychiatry and medicine, with the ultimate goal of providing 
optimal services to this vulnerable patient population, represents the most 
important challenge for psychiatry today, requiring urgent and comprehensive 
action from health care commissioners.  
 
The model predicts more accurately individual local cases in a given area, 
which a national model cannot because of the low size of population. By 
aggregating the local units of GP practices within an area and expressing the 
result as the relative probability of predicting number of cases is very practical 
for local commissioning as it enables better planning.     
Epidemiological prevalence models based with local datasets and national 
data sources such as NHS Comparators, data from Public Health 
Observatories and a number of national reports could be invaluable for health 
care planners. Early experience suggests that they are useful for guiding 
 
 
case-finding at practice level and improving and regulating the quality of 
primary health care. Comparisons with external data, in particular prevalence 
of disease detected by general practices, suggest that model predictions may 
be useful tools to help Health Commissioners. 
 
Local practice-level analyses indicate a trend of undiagnosed disease 
prevalence together with the unreliability of QOF datasets suggest a 
fundamental problem of local health intelligence and subsequently a flaw in 
health commissioning and planning. A more effective method of achieving 
more accurate prediction for co-morbidity in the SMI population and  
undiagnosed medical conditions  at local levels is for a more collaborative 
approach to validate and compare modelling methods using a framework that 
is more sensitive to local information. National leadership is needed to further 
develop and implement disease models. It is likely that prevalence models will 
prove to be most useful for identifying undiagnosed diseases with a slow and 
insidious onset, such as CHD, and COPD among the mentally ill. Such early 
detection will contribute to addressing the health inequalities. 
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1. Introduction 
 
1.1 Background 
The health needs of a population are derived from knowledge gained from the 
prevalence of diseases, i.e. the numbers of people suffering from different 
types of illnesses. However, looking only at the numbers of patients currently 
being treated for a disease does not show the true prevalence and its impact 
on the population’s health. At any given time there are many people who have 
a disease but are unaware because they have not yet been diagnosed. 
 
A robust and well-designed disease prevalence model can help health 
commissioners to assess the true needs of their community, calculate the 
level of services needed and invest in the appropriate level of resources for 
prevention, early detection, treatment and care. Prevalence models provide 
estimates of underlying prevalence derived from population statistics and 
scientific research on the risk factors for specific disease.  
 
Whilst there has been progress in determining population (large scale) 
prevalence trends, there has been a relative shortage of research on local 
area (small area estimation (SAE) prevalence estimation modeling. An 
intrinsic problem is the lack of population-based data on key metrics, such as 
risk factor and disease prevalence at primary care and local authority (LA) 
level which has resulted in a total reliance on national datasets such as the 
Health Survey for England (HSfE). 
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This issue is highlighted in Securing Good Health for the Whole Population, 
Wanless (2008), which noted that…” the information collected nationally is 
often poor and there is no regular mechanism by which a PCT or LA can 
gather reliable information on its own population”. It proposes that in order to 
“improve understanding of prevalence of disease and to enable proactive 
management of personal risk factors, much greater use needs to be made of 
primary care data systems”. Assessing the potential population benefit of a 
health intervention requires consideration of many elements including disease 
prevalence and population characteristics, effectiveness and cost (Department 
of Health 2007). 
 
The challenge is already being taken up by “Informing Healthier Choices”, the 
Department of Health’s (DH) public health information and intelligence 
strategy, (Department of Health 2007),  which states that prevalence models 
will need to be generated for the common health problems which 
commissioners need to address. These will allow the current situation in an 
area or population group to be evaluated against an expected level of need. 
 
Local area modelling using statistical models to link national surveys outcome 
variables, such as disease indicators, to local area predictors, regional 
demographic and socioeconomic variables, are needed so that prevalence 
rates for small areas can be predicted. According to the Department of Health 
(2007) and Druss et al (2001) social indicator variables such as age, 
race/ethnicity, gender, education, income, family structure and employment 
status are commonly used to define high-risk sub-populations for targeting 
 
 
3 
health promotion and disease prevention. Relating health status, behaviour 
and disease  
prevalence statistics for small areas like counties to these demographic and 
socioeconomic predictors provides a direct calibration of the indicators to the 
outcomes of interest. SAE methods are applied to cases where the number of 
area-specific sample observations is not large enough to produce reliable 
direct estimates (Druss 2001). 
 
One area which has not been addressed to-date is the modelling of the 
prevalence estimate for concurrent co-morbidity and in particular for those 
linked with mental illness. The co-existence of more than one chronic 
condition (co-morbidity) is a generally recognised feature of older people. It is 
estimated that for those over 65 this could range between 60-90%. What is 
not well known is the extent of multi-morbidity among the mentally ill and in 
particular those with chronic problems.  According to a morbidity survey by 
Osborne et al (2010), more than 68 percent of adults with a mental disorder 
had at least one medical condition. Co-morbidity is associated with elevated 
symptom burden, functional impairment, decreased length and quality of life 
and increased costs. According to Phelan et al (2001) the pathway causing 
co-morbidity is complex and bi-directional. Medical disorders may lead to 
mental disorders and mental conditions may place a person at risk for certain 
medical disorders. However, mental and medical disorders may share 
common risk factors (Phelan et al 2001; Harris & Barraclough 1998).  
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This study covers the research needed to address two main issues at the 
heart which face the commissioning process. The first is the need for an 
approach that enables a more sensitive prevalence estimation of chronic 
disease within small areas.  The second is to develop a framework to estimate 
the presence of these illnesses within the serious mentally ill (SMI). The two 
problems are intrinsically linked. It is anticipated that this approach will enable 
local primary care commissioners to improve their local health intelligence, 
through better data management, which will enable more accurate local 
estimations.  
 
The study focuses on two medical conditions, namely chronic obstructive 
disorders (COPD) and coronary heart disease (CHD) to make this case. 
 
1.2 Aims and Objectives 
 
Aims 
There have been many studies that have researched the various 
epidemiological aspects of common conditions such as diabetes, HIV, CVD 
and others. To date no prevalence models have been developed for medical 
morbidities that co-occur with mental illnesses in small areas such as locality-
based services. 
Population prevalence is a method used to estimate and forecast the number 
of people in the population with a particular condition and monitor how that 
might change over time. This approach to population estimates allow us to: 
 Describe the pattern of disease in a population,  
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 Estimate the number and pattern of undiagnosed cases,  
 Plan and deliver services in a rational way, 
 Monitor performance. 
The effectiveness of a prevalence model lies within its validity to provide 
robustness, reliability over time and fitness of purpose. The initial proposal 
contained the two broad aims of developing methods for prevalence 
estimation, of both disease and risk factors and their concurrent association 
with chronic mental illnesses. The research aim therefore proposed to gather 
and assess the fitness of general practice (GP) data, for the purpose of the 
prevalence estimation and to develop new methodologies, to adjust primary 
care data for sources of bias and to factor in estimates from mental health 
data to support healthcare commissioning.  
 
Research Questions 
 How should the prevalence of medical co-morbidity of chronic diseases in SMI 
be estimated? 
 How valid are the prevalence estimate models? 
 How do different chronic disease prevalence estimation methods compare in 
terms of their validity? 
 What is the best available methodology, given the requirements for 
prevalence models for co-morbidity? 
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Objectives 
The objectives of the study were to: 
 Develop a methodology for local prevalence estimation and modelling of 
chronic disorders for people with SMI, initially by extending logistic regression 
modelling to examine predictors of chronic obstructive pulmonary disease 
(COPD), coronary heart disease (CHD), stroke and hypertension using the 
HSfE datasets, 
 Developing an adjustment ratio to calculate the prevalence of SMI in the 
estimated prevalence of the chronic diseases i.e. SMI as a subset of main 
data sets,  
 Determine new prevalence estimates and future projections at PCT and GP 
level and support their use by PCTs (now Clinical Commissioning Groups 
(CCG)), practices and other agencies, 
 Explore the use of risk factor prevalence to model future disease prevalence 
in relation to those people with serious mental illness, 
 Undertake a validation of one or more disease prevalence models, through 
testing case-finding strategies at practice level, involving data from a West 
London primary care services, 
 Explore the links between registered and estimated disease prevalence and 
primary and secondary healthcare utilisation, with the aim of developing 
specific utilisation ratios which can be used to project future healthcare 
capacity requirements. 
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1.3 Outputs / benefits 
In the first instance, a methodology paper will be published on the physical 
disease prevalence model for the mentally ill. Later publications will include 
validation studies and case-finding strategy results. 
Subsequent publications will explore the links between disease prevalence, 
health determinants and healthcare factors, ideally through practice-level 
analyses. Current person-based ONS survey data is available via the UK Data 
Archive. It was not clear at the outset whether the same level of access by 
researchers to person-based data would be permitted for other sources 
e.g. HES, but this would be an ideal eventual data linkage. The data and its 
implications for health policy will be presented to local health care 
commissioners and the wider network. 
 
1.4 Study framework 
The study was conducted over a number of phases: 
Phase one (Chapter 1)  
A study of the literature was undertaken to review  two  areas namely: 
 Serious Mental Illness, its definitions (clinical and operational) and how 
services are commissioned and managed within community,  
 Explore the concept of “prevalence modelling” and its application in public 
health epidemiology. 
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Phase two  (Chapter 2) 
Mental health needs assessment 
A mental health needs assessment was undertaken to provide local 
information required for the modelling exercise, both from a broader 
community and local mental health delivery perspective. The exercise also 
assessed the fitness for purpose of general practice (GP) data for the 
prevalence estimation. 
 
Phase three – Chapter 3 
Definition of the methodological framework for study.  
It is anticipated that a more sensitive prevalence estimation that was sensitive 
to variations and develop a “method” for a public health-driven primary care 
mental health delivery service. 
 
Phase four (Chapter 4/5) 
Development and validation of the synthetic prevalence estimate model using  
two chronic (medical) disorders as exemplars. 
Using national datasets, the prevalence estimates of two chronic diseases 
were validated and then applied to local settings. Local health intelligence and 
information were linked to broader health determinants as explored in the 
needs assessment.  
A rough prevalence estimate of the level of serious mentally ill (SMI) health 
based on existing Quality Outcome Framework datasets (QOF) was used as 
the baseline. 
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Phase five – Technique for estimating co-morbidity 
Development of an adjustment factor for the prevalence estimate models 
The rationale was to use an extrapolation (from national prevalence 
estimates) to determine relative co-morbidity in the SMI groups. The approach 
used Bayesian methodology to extract local estimates from existing datasets 
for co-morbidity estimation.  
Stage six (Chapter 6) 
Discussion and recommendations 
The study was reviewed with considerations to its merit, 
weaknesses, usefulness and application it has in public health 
practice. 
 
 
Ethics 
As the PhD involved secondary data analysis the study did not conform to 
research governance criteria requirements and therefore did not require an 
ethical opinion. 
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2. Review of the literature 
2.1. Serious mental illness and medical co-morbidity 
Serious Mental Illness (SMI), although widely considered a severe long term  
condition, has been marked over time by a difficulty to formerly define. Even in 
2013 there is still no nationally recognised definition in the UK. Traditionally, 
definitions have comprised of three elements - a medical condition of the 
brain; with significant functional impairment; over a significant period of time. 
This definition became summarised by ‘the three Ds’, diagnosis, disability and 
duration. Goldman et al. formalised this definition in 1981, explicitly stating 
relevant diagnoses, the level of disability and required duration of illness. Later 
in the 1980s, McLean and Leibowitz (1989) continued the three Ds approach, 
adding emphasis of patients’ continued and regular contact with health 
services.  
 
The next advances in the UK came in the 1990’s. In 1995, the Department of 
Health continued the above theme, adding two further areas to be considered 
when diagnosing SMI. They included the safety of the patient and/or others 
and a requirement for community as well as medical support (Department of 
Health 1995). In 1999, the UK’s National Service Framework (NSF) for Mental 
Health reverted to a broader definition, requiring simply the diagnosis of a 
mental disorder with either recognised severity or significant health service 
use. Despite small modifications, the NSF for Mental Health definition of SMI 
is broadly that still used in the UK. Internationally, the situation mirrors the UK. 
In the United States for example, according to Drake et al (2007), where a 
diagnosis is required to access publically funded mental health service; 
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definitions encompassing the three Ds are used across federal health care 
providers. 
 
The word ‘serious’ within the phrase SMI, has the power to suggest other 
mental disorders are ‘non-serious’. The term is merely used to represent 
conditions commonly grouped together. The definitions of SMI above 
encompass a range of conditions and clinical diagnoses. They can, however, 
still be considered useful. Grouping conditions based on severity will be 
especially useful for service providers and commissioners. In other words, 
although heterogeneous in medical diagnoses, the group is homogeneous in 
terms of service use and need.  
The definitions above stem from a service administration or commissioner 
perspective, one where the severity and burden on the health system are 
critical to the definition. The first stage in identifying this group will, however, 
require a clinical diagnosis. There is no single clinical definition of SMI; it is a 
suite of disorders. Khatana et al (2001) supported the views of Wang et al 
(2002) that frequently, operationalised definitions of SMI cover three domains 
of the Diagnostic and Statistical Manual of Mental Disorders classification 
(DSM); mood disorders, anxiety disorders and non-affective psychoses. The 
DSM is a set of clinical codes used to define known mental disorders and map 
to the International Classification of Diseases (ICD).  
 
In the US, Schinnar (1990) suggested that a patient had a severe mental 
illness when he or she had the following: a diagnosis of any non-organic 
psychosis; a duration of treatment of two years or more; dysfunction, as 
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measured by the Global Assessment of Functioning (GAF) scale (American 
Psychiatric Association 1987; Khatana et al. 2011). Specifically, the two levels 
of dysfunction defined by cut-off points of the GAF are tested: moderate or 
severe dysfunction a GAF score of 70 or less, indicating mild symptoms or 
some difficulty in social, occupation or school functioning; or only severe 
dysfunction a GAF score of 50 or less, indicating severe symptoms or severe 
difficulty in social, occupational or school functioning. The broad definition; the 
`two-dimensional definition' is based on the fulfilment of the latter two criteria 
only (American Psychiatric Association Diagnostic and Statistical Manual of 
Mental Disorders 2002). 
 
Yet more simple definitions include only specific disease groups. Three 
conditions, schizophrenia, schizoaffective disorder and bipolar disorder, were 
considered by the National Institute for Health and Clinical Excellence (NICE) 
(National Institute for Health and Clinical Excellence 2009) for use as the 
Quality and Outcome Framework (QOF) indicators relating to SMI. Finally, 
recent work by the Mental Health Foundation (2007), included psychosis, 
bipolar disorder, schizophrenia, schizoaffective disorder and puerperal 
psychosis within SMI. These small numbers of conditions, especially 
schizophrenia, schizoaffective disorder and bipolar disorder do cover a large 
proportion of the total SMI cases. This group of clinical definitions is not used 
universally, with different variants of DSM IV domains. They are however the 
most common, covering the majority of conditions considered as an SMI. 
 
Prevalence 
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Recent data in the UK from the Information Centre for Health and Social Care 
(2011), the QOF reported a national prevalence of 0.8 percent (438,000 
patients). This covers patients registered with primary care who have a 
diagnosis of schizophrenia, bipolar disorder or other psychoses and who are 
considered to have serious morbidity. The prevalence varies between primary 
care trusts (PCTs), ranging from 0.5 to 1.5 percent as documented by the 
National Institute for Health and Clinical Excellence (2009).  
 
Epidemiological data concentrating broadly on SMI are scarce. According to 
the Information Centre for Health and Social Care (2009), all psychotic 
disorders, not solely cases defined as ‘serious’, have estimated prevalence 5 
per 1,000, with an incidence of 31.7 per 100,000 in England. Schizophrenia is 
the most common psychotic disorder, affecting approximately 400,000 in 
England. Point prevalence estimates vary from 1.1 to 2.4 percent (National 
Institute for Health and Clinical Excellence 2009) with an estimate of lifetime 
prevalence of 8.7 per 1000. Recent estimates, from systematic review, place 
incidence in England at approximately 15 per 100,000 person years (Halliwell 
et al. 2007). Finally, estimates of schizoaffective disorder remain scarce; 
indeed debates remain as to whether it is a discrete condition, or merely co-
occurrence of schizophrenia and mood disorders. Lifetime prevalence, 
according to Halliwell et al. (2007), estimates range from 2 to 10 per 1,000. 
Raw data suggest the prevalence may match schizophrenia, however, not 
when accounting for its diagnostic uncertainty.  
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The National Institute for Health and Clinical Excellence (2009) reported that 
bipolar disorder affects an estimated 545,000 patients in the UK. International 
estimates report a lifetime prevalence of bipolar disorder of between 0.9 and 
2.1 percent and a prevalence of bipolar disorder with manic episodes of 
approximately 1 percent (Halliwell et al. 2007). There is variation between 
populations with estimates of the prevalence without manic episodes 
especially varied, between 0.2 and 2.0 percent. Khatana at al (2011) again 
supports the views of Pini et al (2005) that an estimate of the incidence of 
bipolar disorder across three UK cites, in those aged 16 to 64 years, was 4.0 
per 100,000, although this varied from 1.7 in Bristol to 6.2 in London. More 
generally, estimates place annual incidence at 7 per 100,000, with a lifetime 
prevalence of bipolar disorder with manic episodes of between 4 and 16 per 
1,000 as documented by the National Institute of Excellence (2006). A recent 
Finnish study, using a nationally representative population-based screening 
study, placed lifetime prevalence slightly higher than previous estimates at 2 
per 1000 (Piri et al. 2007).  
 
Demographics patterns in SMI  
Evidence of differences in SMI across population sub-groups is varied, but 
generally is believed to affect men and women equally. Lifetime prevalence of 
schizophrenia and bipolar disorder, according to The National Institute for 
Health and Clinical Excellence (2009) and Kirkbride et al (2012), is equal 
between the sexes. A review on available literature by Abrams et al (2008) 
showed schizoaffective disorder may have a greater impact in women, 
although as discussed above, the literature on this condition remains sparse. 
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Although the overall prevalence is equal between sexes, the patterns in 
incidence with age differ. Both schizophrenia and bipolar disorders have an 
earlier onset in men compared with women (The National Institute for Health 
and Clinical Excellence 2009; Information Centre for Health and Social Care 
2009; Kirkbride 2012), both occur most frequently between late adolescence 
to early adulthood. Schizophrenia typically has first onsets between the ages 
of 20 and 30 years, with estimates of a mean age of 21 in men and 27 in 
women. Bipolar disorder presents between the ages of 17 to 29 years (Pini et 
al. 2005; Halliwell et at. 2007), with estimates of a mean of 30 years in men 
and 35 in women, typically later than schizophrenia. Schizoaffective disorder 
has a marginally wider range, covering the modal ages of the two conditions 
above. The incidence of all declines with age, however, schizophrenia can 
have a secondary peak in incidence in the mid to late-forties (Loranger 1984). 
 
There are differences in many common mental illnesses across socio-
economic position (SEP), with the most deprived suffering a greater 
prevalence. The relationship with incidence appears weaker. Social 
fragmentation may promote incidence in deprived communities; however, this 
remains under-studied, with methodological weaknesses. Most importantly, 
little work has used longitudinal data to establish whether low SEP is causal of 
or caused by SMI.  
 
Knowledge about ethnic variations in mental illness and specifically SMI is 
more established. Notably, the population from black ethnic backgrounds, 
both of African and Caribbean origin, suffer a higher burden of SMI (Sharpley 
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et al. 2001). Remarkably, this is a relationship not found elsewhere in the 
world. According to the results of the AESOP study (Lloyd et al. 2005), the 
diagnosis of both schizophrenia and bipolar disorder is more common in the 
black population in the UK compared with other ethnic groups. Meta-
regression suggests black African and Caribbean groups have a relative risk 
of 4.7 to 5.6 for all psychotic disorders, compared with baseline population 
group in England (Kirkbride 2012). Traditionally, the impact of SMI has been 
considered equal in Asian and white ethnic groups; however, evidence is 
emerging of an increased risk in certain south Asian populations. There is 
evidence of a raised risk of schizophrenia in women of Pakistani or 
Bangladeshi ethnic backgrounds, with some suggestion of an increased risk of 
bipolar disorder. Finally, urbanicity, once controlling for age, sex and ethnicity, 
stands as an independent risk factor for schizophrenia (Kirkbride 2012).    
  
Recent trends in SMI 
Evidence behind recent trends in SMI is highly variable in terms of quality and 
the outcomes studied. Overall, there appears to be no change in incidence 
over approximately the last half a century (Kirkbride et al. 2009; Kirkbride et al. 
2012), a similar picture to that of wider mental health conditions. Incidence of 
schizophrenia has remained stable, although there is a suggestion of 
increased rates in London. These, however, stem from studies not accounting 
for the changes in the ethnic make-up of the population (Kessler et al. 2005). 
Some studies have shown a decline in psychotic disorders, but again there 
are limitations. When accounting for different diagnostic practices over time, 
this relationship is lost (Kirkbride et al. 2012). Finally, one area with significant 
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increase over time is drug-induced psychosis, with up to a 15 percent increase 
each year (Kirkbride et al. 2009; Kirkbride et al. 2012).  
 
Economic burden of SMI 
SMIs have a considerable burden on society, with substantial disability and 
economic impacts (Insel 2008). Indeed, the impact of SMIs far outstrips their 
prevalence. All diseases have indirect costs - costs not directly from the 
medical or social care, but from wider societal impacts. Mental illness, most 
notably SMI are remarkable for their burden of indirect costs (Das Gupta 
2002). There are few estimates on the cost of SMI specific to the UK. Bipolar 
disorders were estimated to cost the UK £2 billion in 2000 (The Sainsbury 
Centre of Mental Health 2003). Recent experimental estimates of the cost of 
all mental illness in the UK placed the burden at approximately £77 billion in 
2003. Only 16 percent of this was from health and social care; with £41.8 
billion in human costs, for example from losses to quality of life; and £23.1 
billion from losses in economic output. These figures do not contain social 
security payments which were not considered a cost, merely a transfer of 
spending power from the state to individuals (Kessler et al. 2008). This is, 
however, an opportunity cost, with spending diverted from other causes. In 
2003, these social security payments amassed to an estimated £9.5 billion. 
Unemployment and sickness absences stand as a particular cost for SMIs, 
with up to 46 percent unemployment in patients with bipolar disorder (The 
Sainsbury Centre of Mental Health 2003).  
Unemployment in patients with SMI particularly impacts patients i.e. more than 
the state: analysis from the United States estimated a $16,300 (£12,600 in 
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2012) per year reduction in earning in patients with SMI (Centorrino et al. 
2009).  
 
Patients with SMI induce increased health care spending. In a Swedish 
cohort, for patients with bipolar disorder compared with match general 
population controls; prescription expenditure was 6 times greater, emergency 
department 5 times, inpatient cost 5 times, and outpatient cost three times 
more. Just comparing subsets with other morbidities, for example patients with 
bipolar disorder and CVD compared with CVD alone, differences dropped but 
were still large. In-patient costs were four times greater, out-patient two times 
greater and emergency department costs three times greater. This 
relationship held across a range of diagnosed co-morbid conditions, but was 
especially great for diabetes and metabolic syndrome. Even restricting further 
to specific aspects of prescribing within specific conditions, spending was still 
greater in patients with bipolar disorder. Spending on controlling glycaemia in 
patients with diabetes, for example, was 50 percent higher per patient with 
bipolar disorder (Kessler et al. 2001). Generally, patients with SMI have high 
health service use. Estimates place patients with bipolar disorder more likely 
to use health services than all conditions except for those with panic and 
psychotic disorders (Pini et al. 2005). 
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SMI  and co-occurrence of physical medical diseases  
Patients diagnosed with an SMI suffer generally poorer health compared with 
the general population. This is borne out most clearly by their life expectancy. 
Estimates place the life expectancy of patients with SMI at between 15 and 30 
years lower than the general population (Druss 2007; Jones et al.2004), 
although possibly a ten year difference in those with schizophrenia compared 
with those without  (Drapalski et al. 2008). There is further worrying evidence 
in recent years from the United States that this gap may be growing. In 
general, poor health outcomes stem from a combination of poor health 
behaviours, direct impacts of the SMI, impacts of medication and fragmented 
care (Drapalski et al. 2008). Patients with SMI have poor help-seeking 
behaviour, which particularly impacts on poor outcomes. It is, however, not the 
SMI directly that has greatest impact on mortality: it is secondary conditions 
that add significantly to morbidity and mortality (Druss 2007). These co-morbid 
conditions (presenting in conjunction with the index disease), contribute 
significantly to poor health outcomes. From a large sample of Medicaid 
recipients in the US, estimates suggest over 70 percent of patients with an 
SMI had a second diagnosed chronic condition, with 50 percent having two or 
more (Carney et al. 2006). When examining co-morbidity with SMI, authors 
conclude that patients are at an increased risk of diseases affecting every 
organ of the body (Felker et al. 1996). Notably, although incidence rates of co-
morbid conditions are increased, there is evidence that mortality rates are 
increased to a greater degree (Kilbourne et al. 2011). This is an important 
finding, indicating that once diagnosed with co-morbid conditions, care 
outcomes are significantly worse (McIntyre et al. 2006). There finally is a 
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greater amount of undiagnosed diseases, so patients with SMI are less likely 
to be aware that they have a co-morbid condition even if diagnosed (Radke et 
al. 2010).  
Co-morbid conditions exacerbate the impact of SMI. For example, in a sample 
of patients suffering from manic episodes, the presence of a physical co-
morbidity increased inability to work (a two-fold increase comparing one co-
morbidity with none) (Kilbourne et al. 2005). There is further evidence of an 
association between greater co-morbidity with lower income, greater benefits 
claims and medical consultation. There is even evidence of a dose response 
as the number of co-morbidities increase (Kilbourne et al. 2005). 
 
Although the co-morbid conditions affect the entire body, certain co-morbid 
conditions are particularly common in patients with SMI. Older SMI patients, 
for example, suffer an especially greater burden and circulatory and 
pulmonary co-morbidity (Hennekens et al. 2005). CVD is the most frequent 
cause of death in patients with bipolar disorder, followed by cancer and 
respiratory disease. Below the evidence behind a number of co-morbid 
conditions is reviewed in greater detail.  
 
Cardiovascular Diseases (CVD) 
The cardiovascular diseases (CVD) are the leading cause of death in both 
patients with schizophrenia and bi-polar disorder, with coronary heart disease 
(CHD) being the single biggest cause (Osby et al. 2001; Miller et al. 2006; 
Goff et al. 2005). Estimates place patients with an SMI at between a 2 to 3-
fold increased risk of a CVD event compared with the general population ( 
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Drapalski et al. 2008; Osby et al. 2001; Goldstein et al. 2009; Osborn et al. 
2007), with a similar 2 to 3-fold increased risk of death (Druss 2007). One 
review of data for patients with schizophrenia concluded that approximately 
two thirds of this population are expected to die from CVD, compared with 
approximately half of the general population (Osby et al. 2001). For patient 
sub-groups, women may have a greater increase in CVD risk than men. There 
is also an earlier onset of CVD. In one US survey, patients with CHD were on 
average 13 years younger if they had a SMI co-morbidity (Osborn et al. 2007). 
 
The best English data comes from over 40,000 patients with SMI in the 
general practice research database (GPRD) - a nationally representative 
collection of primary care records. Under the age of 50 years, patients with 
SMI had a 3-fold increased risk of CHD mortality and 2.5 times increased risk 
of stroke; over 50 years these were both 2-fold increases (Johannessen et al. 
2006). The increased risk of a first CVD event, did not match that for mortality, 
with in fact no increased risk for those aged 50 years and over.  
 
The main cause behind this substantial co-morbidity and cause of mortality is 
clear. Patients with SMI have substantially poorer CVD risk factor profiles than 
the general population. A large review of published data from the United 
States clearly indicates the problem. Patients with schizophrenia have a 
higher smoking prevalence; poorer control of blood lipids; a marginally higher 
prevalence of hypertension (19 vs. 15 percent) and considerably more obesity 
(Osby et al. 2001). The increased risk of hypertension is less clear. In one 
Swedish sample incidence was significantly higher in patients with bipolar 
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disorder, but not for those with schizophrenia. Other data suggests only a 
slight increase in patients with SMI.  
 
Similar data from the UK shows patients with schizophrenia have the entire 
suite of CVD risk factors, much worse than the general population. This 
includes more smoking, obesity, physical inactivity, poor lipid profiles and poor 
diet (McCreadie 2003). Osborn et al. reported recent data on the 
cardiovascular health in SMI patients in UK general practice (Osborn et al. 
2006). Compared with the general population, SMI patients were twice as 
likely to have a raised global CVD risk scores, with a higher median risk score. 
The difference in global risk was especially apparent for younger ages. There 
was a higher smoking prevalence, lower HDL cholesterol, higher total 
cholesterol, a small increase in raised BP and a higher diabetes prevalence 
(diabetes being an independent  risk factor for CVD) (McCreadie 2003) (see 
page 23). Older patients have smaller differences in CVD risk factors, 
probably due to a healthy survivor effect (Johannessen et al. 2006).  
 
Two particular risk factors for CVD (as well as risk factors for other poor health 
outcomes) stand out in groups of patients with SMI. Estimates of smoking 
prevalence for those with SMI are between 60 and 90 percent, approximately 
3 times those in the general population (Drapalski et al. 2008; Osby et al 
2001). There is also evidence of an even higher difference in the prevalence 
of very heavy smoking (Drapalski et al. 2008). Increased smoking rates are 
likely for many reasons, including the alleviation of symptoms and social 
acceptance. Adding to these problems, there is evidence from routine care, 
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that smoking cessation efforts can be less effective than in the general 
population. This critically does not have to be the case. Trials show smoking 
cessation can be effective in patients with SMI, especially if tailored for the 
patient and drug therapy is included (Osby et al 2001). 
 
The second risk factor to particularly impact patients with SMI is obesity. An 
American sample suggested an approximately two-fold increase in 
prevalence, with an especially large increase in highly obese women 
(Dickerson et al. 2006). Women with SMI suffer a higher burden of obesity 
compared with men (Drapalski et al. 2008). Of greater concern to 
cardiovascular health is the increase in abdominal obesity compared with  
obesity per se (Drapalski et al. 2008) (see page 25). In addition to risk factors, 
deficiencies in care outlined above have an impact on mortality rates; 
including poor prevention and acute care. UK data show the increased risk of 
CVD mortality is significantly greater than the first event; secondary prevention 
and acute care for CVD remains suboptimal in patients with SMI 
(Johannessen et al. 2006).  
 
Respiratory Illness and other conditions  
Respiratory illness is another significant co-morbidity for patients with SMI. 
One US study, showed COPD was the single greatest co-morbidity (Carney et 
al. 2006). Similarly, in another study, COPD and asthma in SMI group were 
the second and third most prevalent (point prevalence) conditions after 
hypertension (Sokal et al. 2004). There is evidence that respiratory diseases 
in this group shows a greater increase in standardised mortality than the 
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general population, when compared with circulatory disease and diabetes. 
There is increased risk of many respiratory illnesses, including COPD, 
bronchitis and asthma (Drapalski et al. 2008; Himelhoch et al. 2004). Data 
suggest a three to four-fold increase in chronic bronchitis, a five-fold increase 
in asthma risk and approximately two-fold increase in COPD (Drapalski et al. 
2008; Sokal et al. 2004). Although largely due to smoking prevalence, this 
may not be the only factor. Second hand smoke, as well as other as yet 
unknown factors may be important (Drapalski et al. 2008; Sokal et al. 2004). 
As discussed above, patients with SMI are believed to be at increased risk of 
co-morbidities affecting the entire body. There is evidence of higher HIV 
prevalence in some SMI populations (Drapalski et al. 2008). For example in 
one US sample, patients with schizophrenia had a 1.5 times greater adjusted 
prevalence and a four-fold increase in patients with affective disorders (Bank 
et al. 2002). There is some evidence of women with SMI having an increased 
risk of obstetric complications (Thornton et al. 2010). Finally, the impact of 
how patients with SMI interact with health services is highlighted in paper 
which describes late presentation with appendicitis and how this  results in 
poorer outcomes and more complications (Cooke et al. 2007). 
 
Diabetes  
Diabetes (and impaired fasting glycaemia (IFG)/ impaired glucose tolerance 
(IGT) has an established and significantly increased impact for patients with 
SMI. There is a clear increased incidence and prevalence of diabetes in 
patients with SMI. Older estimates from the US indicate a 1.5 to two fold 
higher prevalence of diabetes, although this may now be higher (Osby et al. 
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2001; Bushe 2004). More recent estimates quote this figure as a three to four 
fold increase compared with the general population (Drapalski et al. 2008; 
Bushe 2004; Goldstein et al. 2009). One significant international study, 
including 220,000 respondents from 52 countries showed diabetes prevalence 
in patients with SMI varied considerably between countries, ranging from 
nearly zero to eleven percent (Nuevo et al. 2011). Finally, there is some 
evidence that if diabetic, SMI patients are more likely to have complications 
(Felker et al. 1996; Nuevo et al. 2011). This indicates poor glycaemic control, 
which is likely in part to be due to poorer care and delayed diagnosis, but this 
together with anti-psychotic medication also potentially important (Nasrallah et 
al. 2006; Holt et al. 2010). 
 
Despite being evident, there is considerable debate over the cause of this 
increased risk. Reasons include, poor health behaviours and lifestyle which 
are evident  in patients with SMI (Bushe 2004; Osby et al. 2001); weight gain 
and insulin resistance caused by anti-psychotic medication (Bushe 2004; 
Osby et al. 2001); or an unknown physio-pathological cause, potentially 
through a direct genetic link or inflammatory mechanisms (Nuevo et al. 2011; 
Thakore 2005). Current studies can, at times, offer contradictory views. One 
longitudinal study in Wales found, in a sample of patients presenting with 
psychosis, that before contact with the health service, diabetes prevalence 
was equal to the general population. After the first encounter, however, 
incidence doubled (Le Noury et al. 2008). This, the authors concluded, 
suggested treatment for SMI was responsible for diabetes. A second study of 
note showed that as psychotic symptoms increased, there was linear increase 
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in the prevalence of diabetes. This was independent of SMI diagnosis, 
medication and known metabolic risk factors. This suggests a more direct link 
between symptoms and diabetes, although how this might occur is entirely 
unknown (Nuevo et al. 2011). Finally, there is evidence of an increased 
prevalence of aspects of ‘the metabolic syndrome’ (see below) in patients with 
SMI, of more severe symptoms and of more limited impacts of treatment 
(McIntyre et al. 2010). In reality, it seems likely that both lifestyle and the 
medications are implicit in the diabetes risk, with potential for a third, less 
understood pathway.  
 
Metabolic syndrome  
The metabolic syndrome is a cluster of conditions relating to metabolic 
abnormalities, and stemming from a small number of common causes 
(Grundy et al. 2004). These are risk factors for a number of diseases, most 
notably CVD and diabetes. Numerous definitions exist, but generally the 
cluster includes abdominal obesity, raised blood pressure, dyslipidemia, 
hyperglycaemia and micro-albuminuria. Although one can consider them as 
merely risk factors for other diseases, these tend to be grouped due to their 
common causes. Between 50 and 60 percent of SMI patients are considered 
to have the metabolic syndrome internationally, the prevalence of metabolic 
syndrome in bipolar disorder ranges from approximately 20 to 55 percent. The 
two share both lifestyle and patho-physiological risk factors. The depressive 
side of bipolar disorder, for example, increases eating and therefore weight 
gain. There are also metabolic traits shared by the conditions, for example 
gluco-corticoid resistance and immune system abnormalities. Recent genetic 
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analyses show that metabolic syndrome, and indeed CVD itself share basic 
genetic pathways (de Almeida et al. 2012). 
 
As mentioned above, anti-psychotic drugs (neuroleptics) may be implicit in the 
metabolic syndrome. These drugs cause weight gain, although there is 
variation between agents.  Two medications, Clozapine and Clanzapine, may 
be especially associated with metabolic syndrome, increasing total weight 
gain, abdominal adiposity, insulin resistance and affecting lipid metabolism 
(Newcomer 2007). In a randomised trial comparing anti-psychotic medication 
with a placebo, there was a 1.2 to 5 fold increase in impaired glucose 
tolerance and evidence of up to 4kg in weight in 10 weeks when taking the 
medication (Druss 2007). Increased risk of metabolic syndrome, therefore of 
CVD and diabetes, is complex in patients with SMI and multi-factorial in its 
causes.  
 
Mental co-morbidity  
Other mental co-morbidity, despite potentially not having the same impact on 
mortality as some conditions, does represent a significant burden on morbidity 
in patients with an SMI. The majority of patients with bipolar disorder have at 
least one other axis-1 disorder, with estimates of lifetime prevalence of 
upwards of 65 percent and a point prevalence of one third (Pini et al. 2005; 
McElroy et al. 2001). The greatest single mental co-morbidity is anxiety 
disorder, with some lifetime estimates of prevalence reaching 65 percent (Pini 
et al. 2005; McElroy et al. 2001). The risk is not restricted to anxiety disorder, 
with for example a ten-fold increased risk of panic disorder. The prevalence of 
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concurrent mental co-morbidities is exemplified by data from patients in one 
English mental health unit from the 1990s (Pini et al. 2005). Twenty percent of 
patients with an SMI reported a second mental health diagnosis from within 
the previous six months (Virgo et al. Journal of Mental Health 2011). 
 
Substance misuse is highly prevalent in patients with SMI. Although now 20 
years old and from the US, the largest general population survey of mental 
health co-morbidity exemplifies this. The rate of lifetime alcohol or drug use 
disorder in the general population was approximately 17 percent. This was 
compared with 47 percent for people with schizophrenia, 56 percent for 
people with bipolar disorder and around 30 percent for people with other mood 
disorders or an anxiety disorder. Overall, across SMI this was summarised as 
a 50 percent lifetime prevalence (Regier et al. 1990), with a 25 to 35 percent 
point prevalence. Comparing the odds of risk with the general population, 
there is 10 to 20 times higher odds of alcohol abuse and up to 30 to 40 times 
increased odds of illicit substance abuse in both patients with bi-polar disorder 
and schizophrenia (Felker et al. 1996; Nuevo et al. 2008). 
 
Despite this bleak prognosis, there is evidence of successful inventions for 
what is called the “dual diagnosis”, SMI with substance abuse. Trials using 
peer-support, longer residential interventions and even intensive outpatient 
intervention can all reduce substance abuse. No data currently assess the 
cost incurred by health systems from these co-occurring mental conditions. It 
is, however clear, that patients with an SMI require wider care for their mental 
health than the index condition alone.  
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2.2 Commissioning for patients with SMI  
There is evidence of poorer acute care, including follow-up after disease 
events and hospital in-patient care, in-patients with SMI (England et al. 2005; 
NHS Diabetes Commissioning Mental Health and Diabetes Services 2001). 
Again in a national US sample, patients with SMI were less likely to receive 
hospital care for CVD and diabetic complications. Similarly, despite evidence 
of increased need, patients with SMI are significantly less likely to receive 
appropriate care following a CVD event, patients with SMI were up to three 
times less likely to receive necessary procedures (England et al. 2005).  
 
Following heart failure, there is evidence that SMI patients are less likely to 
receive follow-up care and more likely to face re-admission. One final piece of 
evidence concerning the quality of care, suggests that patients with 
schizophrenia have a greater rate of adverse events in hospital, compared 
with the general population (Mechanic 1995). 
 
The reasons behind limitations in care and the quality of care are complex and 
remain understudied. Generally, it is the evidence based and more cost 
effective practices that are underused, whereas some areas, such as use of 
emergency departments, can be overused. One of the largest weaknesses in 
care provision is the separation of mental health services from other aspects 
of care. This separation can be geographic, through funding, through 
organisation and expertise, or the culture of providers. Although possibly the 
most simple difference, the geographic separation is likely to be vital. There is 
direct evidence that co-location of wider medical and preventative services 
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with mental health services can increase the use of a suite of services and 
result in better patient outcomes, including blood pressure control.  
 
One thing that is clear is that integrated care is of paramount importance for 
patients with SMI. As such, primary care has been proposed as the best 
setting to improve patients’ health. Primary care practitioners, have the 
greatest experience of holistic and integrated care. For this to happen, 
however, a number of barriers must be overcome. There firstly needs to be 
collaboration between primary care and psychiatric services. Primary care 
doctors can be unfamiliar with psychiatrists, which can limit access to care 
resulting in ? generally face poor co-ordination and collaboration (Cooke et al. 
2007). Secondly, primary care clinicians must accept psychiatric conditions do 
not inhibit routine medical care. Clinicians can view patients with SMI as 
disruptive to their practice, cite time constraints as a barrier or simply be 
uncomfortable with the situation. All of these stop general practitioners 
managing patients with SMI. Qualitative work does, however, suggest general 
practitioners are willing to take a central role, not only in the diagnosis of, but 
also the routine care of patients with SMI (Johannessen et al. 2006).  
 
The appropriate site of health care for patients with SMI is still debated. 
Psychiatrists often acknowledge they should provide physical care. This, 
however, frequently does not happen. Psychiatrists can delegate care and 
need not keep up to date with evidence-based practice outside their specialty. 
Some psychiatrists, although a minority, do not consider the physical health of 
their patients, which contributes to the morbidity. 
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These barriers are frequently caused by the SMI itself, and include forgetting 
required care, a lack of knowledge of how to access care and difficulties in 
communication.   
 
There is little specific guidance on commissioning services for patients with 
SMI, and less evidence on the effectiveness of different strategies. One 
certainty is that both continuity of care and integrated care play particular 
importance for patients with SMI (England et al. 2005; NHS Diabetes 
Commissioning Mental Health and Diabetes Services 2001). They must be 
able to ‘seamlessly’ navigate between aspects of care, especially mental 
health care – but also physical care. Integration is particularly important 
because patients with SMI are amongst the most socially excluded (England 
et al. 2005); therefore have fewer opportunities for care and the condition can 
make it hard to negotiate care pathways. They also require care over 
prolonged periods, a situation in which integration is vital (England et al. 2005; 
Mechanic 1995). 
 
Integration is especially difficult for patients with SMI. Jurisdiction for care can 
span many bodies, for example mental health trusts, secondary trusts, primary 
care and social services. Integration requires both the co-ordination and co-
location of services. Shared training and learning amongst practitioners may 
also be important (England et al. 2005). Finally, a model in which patients are 
assigned a single, multi-disciplinary team to manage physical health need 
may be effective. These teams can co-ordinate, but also support those in 
direct contact with patients, reducing fragmentation (Mechanic 1995).  
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A number of considerations for commissioning services for patients with SMI 
emerge from the evidence above, with a particular focus on co-morbidities. 
Firstly, and important to consider for all commissioning decisions, given the 
differential increase in mortality compared with disease incidence for patients 
with SMI, there is a very real need to improve the routine care in those with 
diagnosed disease (NHS Diabetes Commissioning Mental Health and 
Diabetes Services 2001). Commissioning services that allow for regular 
physical assessment may be effective. Following a formal guide, such as one 
for diabetes produced by NHS diabetes may also enable the correct 
processes for evidence based commissioning (NHS Diabetes Commissioning 
Mental Health and Diabetes Services 2001).   
 
The setting of physical care may be important. Firstly, there is evidence that 
distance to care can be especially inhibitive for patients with SMI. Co-location 
of physical care with mental health services may be effective. At the very least 
there has to be a clear statement of where physical healthcare is received and 
who is responsible. This will prevent patients with SMI from falling in between 
providers, thus missing out on care. Mental health nurses are considered, due 
to their relationship and contact with patients, to be in an excellent position to 
help improve the physical health of the SMI. Frequently, however, they are 
lacking competencies and training. Using evidence based health improvement 
profiles (HIPs) and training may promote this care pathway to reach its full 
potential (Robson et al. 2007). 
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 Patients with SMI suffer poorer than average outcomes from national 
screening programmes, largely due to decreased uptake. An alternative 
approach to screening or at least extra focus on patients with SMI may be 
warranted. Bespoke interventions for patients with SMI to reduce CVD risk 
can be effective (Smith et al. 2007).  Currently CVD risk in those without 
diagnosed vascular disease is the focus of the NHS Health Check 
programme. Incorporating patients with SMI into the programme, but like one 
London PCT, separate performance management to promote uptake is a 
possible solution (NHS Diabetes Commissioning Mental Health and Diabetes 
Services 2001). Bespoke interventions for ‘dual diagnosis’ (SMI and 
substance abuse) can also be effective. Finally, dental care is poorer in 
patients with SMI than the general population. Although there are few 
evidence-based interventions, focus must be placed on access to care and 
good oral hygiene, with particular focus on provision for in-patients.  
 
In conducting this review, several gaps in the literature on mental health and 
medical co-morbidity became evident. First, most of the existing literature on 
co-morbidity examines the impact of particular co-morbid conditions on an 
index medical or mental illness (e.g., diabetes and depression). While there is 
value in these specific, clinically-focused approaches to understanding co-
morbidity, patients with co-morbid conditions share many common features 
that make them valuable to examine as a distinct population of interest. They 
are, in many ways, analogous to racial and ethnic disparities groups who are 
monitored separately and often require tailored quality improvement 
programs. Second, nearly all of the current evidence for this population 
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focuses on clinical models rather than organisational or systems level 
approaches to implementing those models. Comparative effectiveness trials 
will be needed to compare organisational approaches to delivering and 
sustaining these evidence-based approaches to improving care for persons 
with co-morbid conditions. Finally, health reform will include a broad range of 
changes in insurance coverage and care delivery that could have a 
disproportionate impact on persons with co-morbid medical and mental 
conditions. Tracking the impact of this legislation on costs, burden and 
outcomes of care for this population could provide important information to 
inform future iterations of health legislation. 
 
2.3 Prevalence modelling  
Prevalence modelling is a technique used to estimate the number of people 
with a particular condition or risk factor in a population when direct evidence is 
not available (American Psychiatric Association Diagnostic and Statistical 
Manual of Mental Disorders 2002). Direct evidence may be lacking because 
surveys or data collection have not been undertaken, are technically 
impractical, or are unreliable. 
 
Methods for generating synthetic or modelled estimates range in complexity 
from simple to highly sophisticated. Crude estimates of the number of cases 
can be generated by applying known prevalence rates to a different 
population, for example applying national rates measured in a large survey to 
a local population; or applying local rates for a recent year to a projected 
future population. However, many factors such as age, gender, deprivation 
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and ethnicity can influence the prevalence of a behaviour, risk factor or 
disease and more complex epidemiological modelling techniques are required 
in order to take such factors into account. 
 
The need for prevalence Modelling 
In many cases, routine data are not available to measure directly the 
frequency and distribution of diseases or behaviours in local populations 
(Diez-Roux 2000). Modelling is often the best alternative for quantifying 
prevalence in the absence of reliable direct measures. Typically, direct 
measures are not available at local level for lifestyle behaviours such as 
smoking or alcohol consumption, or for diseases that are generally managed 
in primary care, for example diabetes or hypertension. 
 
Understanding the distribution of behaviours that affect health (either 
positively or negatively) is increasingly important in the allocation of public 
health resources and the delivery of interventions (Congdon 2006; Congdon et 
al. 2007). Prevalence modelling can be used to assess need and help identify 
those communities that will most benefit from public health initiatives. 
Modelled estimates of prevalence can also be helpful in explaining variations 
in care utilisation and outcomes (Congdon et al. 2007). 
 
The quality and completeness of routine datasets, such as the Quality and 
Outcomes Framework (QOF) for primary care, are improving, and QOF is now 
a reasonable basis for prevalence estimates of many diseases. However, the 
measured prevalence is limited to diagnosed disease (Congdon 2008; Cooper 
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et al. 2002). Modelled estimates that include undiagnosed disease in the 
population can offer additional information that can inform case-finding 
initiatives and highlight areas where under-diagnosis could be an issue. 
 
There is considerable interest in obtaining estimates of expected prevalence 
at various geographies and for different subgroups of the population, for 
example ethnic groups or age cohorts, to assist in understanding and tackling 
health inequalities (Congdon et al. 2007). 
 
Methods 
Many methods exist for creating synthetic estimates of prevalence, and in 
many cases methodologies are combined and adapted to make best use of 
the information and data available (Homer et al. 2006). There is often a 
balance to be struck between increasing the complexity of the model by 
incorporating more contributory factors and the availability of good quality data 
at local level to populate the model. These input requirements of a model are 
often restricted by what information is available (Gunners-Schepers 1989). 
Complex models can also suffer from difficulty of interpretation, which negates 
the benefit of increased accuracy. 
 
2.4 How does the model work? 
All models are based on assumptions. Good models clearly state the 
assumptions that have been made and good interpretation of modelled 
estimates takes into account the limitations of the assumptions. 
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1) Regression models using demographic characteristics from large 
surveys 
Multiple variables from large surveys can be used to model the risk factors for 
a behaviour or disease, using techniques such as multi-nomial logistic 
regression. However, it is important to limit the factors considered to those for 
which data are available in the population of interest. For example, cholesterol 
level or family history of disease may be important risk factors which were 
recorded in the source survey, but such information is not usually available at 
population level and therefore these are not appropriate variables to be 
included in a disease prevalence model. 
 
National surveys are usually limited to people living in private households and 
omit populations such as the homeless, those living in institutional care, 
‘special populations’ (armed forces and prisoners) who are the people 
particularly likely to decline to participate. For some disease areas, notably 
some types of mental illness, these omitted populations can be particularly 
important. Despite this limitation, national surveys are often the best source of 
prevalence information available, but where possible should be used in 
conjunction with other evidence about the likely extent to which they miss 
cases. Models can then be adjusted to take account of the resultant under-
estimation of prevalence. 
 
Although regression models most commonly use survey data, other data 
sources, for example information recorded in general practices, can also be 
used to create this type of prevalence model. 
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2) Capture-recapture methods 
Capture-recapture methods are used to estimate the number of people with a 
disease or behaviour, for example the total number of injecting drug users, 
including those unknown to any services. A random sample of people is taken 
(‘captured’) from the whole population, and examined for the characteristic of 
interest. ‘Sample 1’ is the number of individuals found to have the 
characteristic. A second random sample of the whole population is then taken 
and ‘Sample 2’ is defined similarly as those found to have the characteristic. 
Some people will appear in both Sample 1 and Sample 2 and the proportion of 
Sample 2 that was also in Sample 1 is calculated. This proportion is assumed 
to be equivalent to the proportion of all the people with the characteristic in the 
whole population that were captured in Sample 1. Hence, by dividing Sample 
1 by this proportion an estimate of the total number with the characteristic is 
obtained.  
 
3) Combining multiple sources 
Often there are several estimates of prevalence rates available from larger 
and smaller scale epidemiological studies, which need to be integrated. For 
example, regional prevalence rates from large national surveys can provide 
control totals for smaller geographies for which synthetic estimates are 
generated. Each source will have strengths and weaknesses: national surveys 
may have robust sampling and include a wide range of risk factors, but can 
lack local detail, whereas local studies may use more elaborate methods, for 
example capture-recapture techniques, but may focus on unrepresentative 
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areas. Combining prevalence estimates requires critical appraisal of the 
appropriateness of each source and development of mathematical 
methodology, to integrate the variance estimates from unrelated sources to 
produce an overall confidence interval for the synthetic estimate. 
 
Meta-analysis techniques have been developed to combine multiple estimates 
of prevalence, each of which may have data quality issues, to produce one 
triangulated estimate with improved quality at small area level. Estimates from 
a wide range of sources can be combined, including prevalence estimates 
from surveys, data from primary care and modelled synthetic estimates.  
Bayesian statistical methods can be employed to synthesise a diverse set of 
available data into a prevalence estimate. For example, Goubar et al (2008) 
combined an array of information, including routine surveillance data and 
anonymous surveys, to estimate HIV prevalence in various risk groups using 
Markov chain Monte Carlo simulation. 
 
2.5 Validation, confidence intervals and robustness 
Prevalence model validation is problematic for a number of reasons. There is 
no other major or definitive source of the national HSfE prevalence data to use 
for the models, apart from population-based prevalence research for specific 
diseases. The literature search before developing each model revealed what 
studies currently existed and this was also useful for initially validating the 
models. The accuracy of model outputs depends on the predictive power of 
the model and on the accuracy of the input data. Models should be subjected 
to validation checks to ascertain their robustness and general applicability. 
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Estimates of the accuracy of prevalence estimates based on simple models 
can be generated by combining the uncertainty in prevalence rates from the 
source study or trial with the stochastic variation expected given the size of 
the local population. This approach results in a range estimate for the 
prevalence, rather than confidence intervals. The range estimates are 
calculated using the same methods as those used to derive the control limits 
for funnel plots.  
 
However, if there is uncertainty around both the population data and the input 
data, the calculation of confidence intervals can be complex. Bootstrapping 
methods are commonly used in such situations. 
 
Four ways of validating models  
a.    Sensitivity testing 
Sensitivity testing can be useful in assessing how the uncertainty in input data 
affects prevalence estimates. For some models, very small variations in the 
input data will have a large effect on the results. Other models may be 
relatively insensitive to variability in input data. For example, 10 different 
sources of practice level smoking prevalence data were input into the APHO 
chronic obstructive pulmonary disease (COPD) models. Estimated COPD 
prevalence in general practices ranges from 1% to 7%. In 92% of cases, 
changing the source of smoking prevalence data made an absolute difference 
of less than 0.3% in the COPD prevalence estimate. Estimates generated 
using different smoking prevalence source data were strongly correlated with 
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each other (r2 > 0.95). 
One-way sensitivity analysis such as this evaluates the impact of a change in 
one variable on the model results. Multi-way sensitivity analysis is more 
powerful and can be used to assess the impact of changing two or more 
variables simultaneously. 
 
    b.    Internal validation 
One method of assessing the performance of a model is to use it to predict the 
response for each subject in the source data (e.g. a large survey). These 
predictions are called fitted values. The differences between the fitted and the 
observed values are called residuals. Residual analysis can be used to check 
the adequacy of any assumptions used when creating the model. It can also 
be used to identify whether any additional factors should be included. 
To check the accuracy of the model, the predicted ‘classification’ of each 
individual (i.e. whether or not they have the disease or behaviour that is being 
modelled) can be compared with their actual classification. This will result in a 
‘misclassification’ (also known as a ‘contingency’ or ‘confusion’) (Table 1). 
 
  
Table: 1.  Misclassification table of modelled results 
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 c.   External validation 
   One method of assessing external validity is to map observed and expected 
prevalence and investigate associations with a low ratio of observed to 
expected cases, at both local authority, PCT and/or practice levels. The gold 
standard validation would be comparison of model predictions with a 
comprehensive population survey or case-finding efforts in a number of 
differing populations: deprived and advantaged, rural and urban, etc.  
 Receiver-Operating Characteristic (ROC) Analysis 
ROC analysis is a useful way of assessing the accuracy of a model by 
understanding the trade-off between the sensitivity (in this sense referring to 
the true positive rate; Table 2) and the specificity (the true negative rate). The 
method was developed to assess the accuracy of distinguishing signal from 
noise in radar systems and has since been applied in many other settings, 
including clinical diagnostic testing and the evaluation of regression models 
that classify cases into two categories, for example diseased and non-
diseased. Sensitivity is plotted against 1-specificity (specificity subtracted from 
one) over a range of values and the area under the curve (AUC or AUROC) is 
used as a summary of the predictive or diagnostic accuracy. A ‘perfect’ model 
that accurately predicts every case has AUROC = 1. Typically, models have a 
convex ROC curve and an AUROC between 0.5 (equivalent to random 
chance) and 1. A model with AUROC < 0.5 is less accurate than random 
chance. 
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2.6 Projections and forecasting using models 
Prevalence models can often be adapted to predict future prevalence. The 
sophistication of projected prevalence estimates depends on the modelling 
methodology adopted, and falls into three broad categories: 
a. Same risk, changing (e.g. increasing and/or ageing) population. Use the 
same model coefficients or risks of disease but incorporate population 
projections. For example, what will be the prevalence of coronary heart 
disease (CHD) in 2020 if we assume that the age- specific risks do not 
change but we take into account the aging population? This is sometimes 
called the ‘prevalence ratio method’ 
b. Same population, changing risk. Use the same demographic information 
but change the risk profile. For example, what will be the prevalence of 
CHD if smoking prevalence reduces? 
c. Modify the population and the risks to produce ‘scenario models’ e.g. what 
will be the CHD prevalence with an ageing population and reduction in 
smoking. 
 
One of the characteristics of complex systems such as health is, that no 
matter how tightly the present state of the system is specified the future state 
cannot be confidently predicted. Extra care should be taken in interpreting 
modelled estimates of projected prevalence as the assumptions inherent to 
the model may not hold in the future. 
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2.7 Using prevalence models 
It is important to remember that prevalence figures generated by models are 
synthetic estimates of the expected prevalence of disease. They are not ‘real’ 
measures of prevalence. It must be remembered that ‘all models are wrong 
but some are useful.’ Discrepancies between modelled estimates and other 
sources of data (such as primary care disease registers) may be due to local 
variations not captured by the model and cannot be solely attributed to 
weaknesses in directly measured prevalence data. For local populations that 
differ significantly from a ‘typical’ population (e.g. a large black and minority 
ethnic (BME) population that has a very different smoking pattern to the 
national average) the assumptions of a model may not apply and 
discrepancies may occur. Local expert opinion (e.g. local GPs’ knowledge of 
the pattern of disease) can be invaluable in interpreting and applying synthetic 
estimates of prevalence.  
 
A typical use of prevalence estimates is to compare expected prevalence with 
recorded prevalence, for example from the QOF in England. Such an 
approach needs to be taken with care. Are the two populations comparable, or 
are you trying to compare adult prevalence with all-age prevalence? Is the 
definition of disease used in the modelled estimates the same as the clinical 
definition used for diagnosis in primary care? Does the model include an 
estimate of undiagnosed disease or not? An understanding of these issues 
and differences is vital in interpreting any comparisons made between 
synthetic estimates and measured prevalence. 
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Because modelled prevalence is an estimate of expected prevalence, 
generally with the assumption that the local area behaves in the same way as 
the population from which the source data were derived, it is not straight 
forward to use synthetic estimates to evaluate the impact of a local 
intervention. For example, low modelled prevalence of binge drinking in a local 
area that has invested heavily in action to decrease alcohol misuse is not 
proof that the investment has reduced binge drinking. It is only an indication 
that the area can expect a low prevalence, given its demographic 
characteristics. Local interventions or prioritisation of an issue may explain 
discrepancies between modelled and directly measured prevalence, but the 
discrepancy does not prove that an intervention or policy is effective. It is not 
advisable to use prevalence models for performance management or to 
evaluate the impact of a local programme. 
 
It is also inappropriate to use modelled estimates to monitor changes over 
time. Changes in estimated prevalence could be due to updated local input 
data (e.g. demographics) or changes in the source data used to generate a 
new version of the model. There may also have been adjustments in the 
modelling methodology used if source data have been re-modelled. 
 
2.8 Issues with Small Area Estimates (SAE) 
A geographical area is regarded as "small" if the area sample is insufficient to 
yield direct estimates with adequate precision and reliability. In order to make 
estimates for small areas with adequate levels of precision, it is standard to 
use indirect estimates that utilise information from outside areas with similar 
 
 
46 
characteristics to the area of interest. Generally, a statistical model is used to 
obtain indirect estimates for geographical areas considered to be "small". The 
information from respondents who are outside the geographical area and 
other geographical characteristics are incorporated through the use of a 
statistical model. Small area estimates of the prevalence is important where 
risk factors vary widely, but are important for decision and policy makers, and 
their quality is a crucial concern. One example is in health promotion, when 
addressing area-specific health issues or lifestyle behaviours. In some 
deprived areas people might have more restricted access to screening 
programmes or preventive healthcare campaigns, or they may have a higher 
level of certain risk factors. Knowledge of the prevalence of risk factors in 
small areas is essential to make health promotion strategies more effective. 
 
Small area estimation is conducted in two stages. In the first stage, regression 
analysis is performed modelling survey data (e.g. HSfE) against predictors of 
the condition under investigation. This analysis is conducted for the subset of 
areas covered by the survey. The output from this first stage is a set of 
parameter estimates. At the second stage each area of the population, the 
coefficients of the predictor variables obtained from the first stage model, are 
attached to the identical set of variables at the small area level to produce an 
estimate for the area as a whole.  
Synthetic modelling for small areas uses a number of methods to generate 
estimates: 
a. Simple (non-modelled) methods using indirect standardisation, 
b. Models using individual level covariates only, 
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c. Models combining individual and local area-level covariates, 
d. Models using area level covariates only, 
e. Other approaches for larger areas of geography, 
 
Only two (a and c) of the methods are reviewed here as they are more 
applicable to the study in question.  
a) Indirect standardisation 
This involves applying national estimates derived from national surveys to 
area-level population counts to generate area estimates. An example of this 
approach – If we have to calculate the proportion of men smoking in a 
particular ward would involve (a) using national estimates of smoking patterns 
and (b) applying these to the local population, weighted by the proportion of 
persons in the sub-group in the small area.  
 
This model has an intuitive appeal in its generally easy and inexpensive to use 
(Nacul et al. 2007). The major drawback is that it assumes that the national 
rates of each subgroup are applicable uniformly across all areas.  
 
b) Using covariates from census 
This is an extension of the above method. It uses the information regarding 
the relationship between individual health behaviour measures obtained from 
surveys against a set of predictor variables for the same individuals.  
These models estimate the probability that a person with specific known 
characteristics (e.g. age, gender) currently smokes, is obese etc. The model-
based probabilities are then converted into estimated proportions in each 
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subgroups defined by the covariates who fall into relevant health category. 
These proportions are then applied to the covariate counts available from the 
census to derive an overall estimate for the small area in much the same way 
for indirect standardisation. The major drawback concerns its data 
requirements. This form of synthetic estimation requires exact 
correspondence between the covariates used at national and local level.  
 
The two methods above are all at the individual level. An alternative model is 
the multi-level models incorporating random effects (also known as mixed 
models). Their importance to small area estimation lies in the fact that a 
random effects specification assumes that significant systematic variation 
between small areas remains after the effects of covariates in the model have 
been accounted for. Such ‘unexplained’ variation is modelled through the 
addition of small area specific random coefficients to the fixed effects. Such 
multilevel models give rise to more complex ways of building a model for 
health behaviour measures; generating small area estimates from these 
models parameters and thus calculating the confidence interval for them.  
Using this technique, a model can be applied to survey data that 
simultaneously account for individual and area influences on health 
behaviours such as smoking. 
 
Conceptually and methodologically, the model is more useful than simple 
models as it combines both individual and geographic level data. However, it 
also requires stringent data requirements (as above) and estimating standard 
errors are infinitely more complex. 
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2.9 Summary 
So how should the “fitness for purpose” of prevalence models, including 
validity, be defined? In the case of disease risk scores, the technical criteria 
are widely agreed. The accuracy of a risk prediction score can be judged on 
two main components—calibration and discrimination. A well-calibrated score 
is one in which the predicted risk is similar to the observed risk. The more 
important component of accuracy is discrimination or the ability of a score to 
differentiate between people who will have an event from those who will not, 
over a defined period of time. 
 
Similarities and differences are discussed in the sections dealing with model 
development. In the absence of more robust local data QOF data is useful to 
an extent. However, use of case-finding in practice populations is seriously 
considered as a good predictor. In general, it is expected that modelled 
prevalence estimates to exceed QOF registered prevalence for 90 per cent of 
practices, with previously described model limitations leading to under 
prediction in perhaps ten percent of practices. 
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3. MENTAL HEALTH NEEDS ASSESSMENT 
3.1. Background 
The health and social care costs of mental health in England are around 22.5 
billion per year (New Economic Foundation 2011) and mental ill health 
accounts for more than 12% of the NHS budget. The number of people with 
mental health problems is likely to rise by 14.2% to 9.88 million by 2026 (The 
Royal College of Psychiatrists 2008; Murali et al. 2004).  
 
NHS Brent has a priority for commissioning mental health services. Part of the 
commissioning process requires a comprehensive needs assessment of the 
community to make decisions about delivery of an optimum service. This 
needs assessment needed to be evidence-based via three strands:  
1. geographical information mapping, 
2. framework to improve equity of access and,  
3. a process to improve mental health well-being and health promotion.  
 
An effective needs assessment exercise has to be inclusive of normative, 
comparative and social needs. It must have the robustness to represent the 
various spectrums into the mix of understanding the mentally ill’s needs 
(Marmot Review Team 2011; North East Public Health Observatory 2012). 
Felt and expressed need are usually obtained from interviews and surveys 
while normative and comparative needs are based on more grounded 
research and professional opinion (Smiley 2005).  
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Normative studies of needs assessments usually incorporate for instance, 
prevalence rates of a particular group while comparative needs focus on a 
comparison of services of a particular group.  
 
Several factors affect the estimation of mental health needs of the community. 
The prevalence of people at high risk of admission to a mental health service 
will be only one of many  factors which affect the need for care, as expressed 
as number of inpatient beds, outpatient slots and community mental health 
and primary care slots (and corresponding clinical resources) needed 
(Institute of Public Health 2011). Some of these influencing factors, among 
others, are likely to be: 
 
 Number (and trend) of cases in community, 
 Number of presenting cases in community per year (incidence), 
 Catchment population for the facilities, 
Clinical criteria and severity thresholds for those criteria, are used to make the 
clinical decision for referral from each part of the service to another  
(‘discharge’ threshold 
 
As part of this PhD study, a mental health needs assessment (MHNA) was 
conducted to identify and appraise the current and future level of service 
provision for the long term mentally ill. In addition to collating current data and 
intelligence as part of a better commissioning process, the exercise was to 
further refine a tool for the more accurate estimation of the prevalence of 
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mental health in the community and offer some projections with regard to 
changes in mental health needs over the next ten years.  
 
3.2. Aims 
The specific aims of this MHNA were:  
 To provide a broad health profile of the localities, with specific focus of the 
prevalence of mental illness in the London Borough of Brent.  
 Explore patterns of access to primary services.  
 Highlight areas of unmet need and gaps in provision.  
 Highlight the limitations in available data and intelligence and expose gaps in 
understanding.  
 Provide health intelligence for the development of a tool for a more accurate 
estimation of mental health prevalence and associated co- morbidities.  
 
Approach  
The structure of the needs assessment involved a population approach of 
identifying the chronic mentally ill group with a focus on areas of needs, 
supply, and demand. The concept of “need”, from a public health perspective, 
incorporates those needs felt and expressed by local people as well as those 
defined by professionals. It moves beyond the concept of demand and takes 
account of people’s capacity to benefit from health care and public health 
programmes. Supply refers to the number, type and distribution of services 
and resources available from all providers within Brent, public, private and 
third/voluntary sector. Demand is defined as the services that people ask for 
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and use, and can be difficult to measure. In this report, “activity” (i.e. numbers 
of people accessing and using services) can be used as a “proxy” for demand.  
 
3.3. Methodology of the needs assessment  
The needs assessment used rapid participatory appraisal (RPA) technique to 
complete a community health profiling (CHP). The latter has been described 
as an attempt to understand and describe the locality in order to prioritise 
need and has also been viewed as a ‘snapshot’ of the population, providing a 
systemic approach to assessing community health needs and resources 
(North East Public Health Observatory 2012).  
 
This technique is often used in public health to gain community perspectives 
of local health and social needs with aims  to translate these findings into 
action. Some researchers (Bowen 2008) considers RPA as a form of “action 
research” in that the researchers and participants undertake a collective, self 
reflective inquiry in order to understand and improve  upon practices in which 
they participate and situations in which they find themselves. Some primary 
data were obtained through local services delivery units (NHS, Local Authority 
and the 3rd sector) – this information, as part of the PCT data collection 
routine, not only represented real-time service activity but also provided 
general information on local mental health delivery programme to enable a 
profiling of the local mental health community.  
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The RPA provides a robust framework in an adaptable structure (information 
triangle) that holds together data from various sources. It uses a multi-method 
approach and incorporates data that is immediately available from primary 
and secondary sources including the national census. This enables the 
researcher to draw inferences, conclusions or assessments in a limited period 
of time and is thus relevant to health service evaluation. Data collected from 
one source were validated or rejected by checking with data from at least two 
other sources or methods of collection. Informants are not selected randomly 
but “purposefully”—that is, asking a range of people who are in the best 
position to understand the issues. The approach allows only a brief time frame 
and uses limited resources.  
 
The technique has limitations and statistics so produced must be interpreted 
cautiously as they may be based on routinely collected data, which may be of 
questionable accuracy, completeness, and reliability. However, the term 
“rapid” should not necessarily be taken to imply a “quick and dirty” method 
lacking in rigor. The inherent triangulation of sources of data and methods of 
data collection provides opportunities for cross-checking and validating 
findings throughout (Koelen, Vaandrager, & Colomer, 2001; Rhodes et al, 
1999; Tones & Green, 2004). The cyclical process also provides the potential 
for members of the community to reflect on findings as they take shape, and 
encourages their active participation in the research process (Koelen et al., 
2001). 
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3.3.1. Data extraction: - Exploring data sources (data mining) 
The primary method was to explore local, regional and national datasets for a 
comparison of prevalence estimates and a basket of indicators reported 
and/or known about service usage, giving profiles at both Borough and locality 
levels.  
 
Secondary analysis of the wider determinants of physical health and wellbeing 
in terms of healthcare services that supply either in primary or secondary care 
were considered.  
 
Much of the epidemiological analysis in this profile has been undertaken using 
an anonymised patient-level dataset from GP practices in Brent (QOF 
registers) and some Hospital Episodes Statistics (HES). Data from the Public 
Health GP dataset are recorded using Read codes and the date of extraction 
can vary across GP practices. The data source is in the appendix 3. 
Discrepancies in numbers when comparing information from QOF and the 
Public Health GP datasets are due to the method of extraction and coding of 
disease conditions. 
 
Secondary data was extracted using Dr Foster data and Local Authority. Dr 
Foster is a health informatics service that is used by the NHS to monitor the 
acute services (http://www.drfosterhealth.co.uk/). The information routinely 
processed by Dr Foster include key information on admissions, discharges, 
length of hospital stay, demographics (including language and ethnicity), 
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behavioural and clinical risk factors, key conditions, details on the control and 
management of conditions, key medications and interventions. 
 
3.3.2. Collecting data on service usage 
 
All NHS Commissioners including Brent community Trust are required to 
organise meetings with stakeholders and healthcare professionals to  explore 
and examine patients experiences of their care journeys. This enables  the 
gathering of intelligence  with regards to the usage of specific services and 
identified issues and performance details.  The nature of information is 
inclusive of  qualitative material from the “Quality Framework” service 
evaluations schemes which carried out routinely. Data for the mapping come 
from a variety of sources including nationally available statistics – the NHS 
Information Centre for Health and Social Care, Dr Foster  and the local 
authority. 
 
The study used this opportunity, as part of the needs assessment, to profile 
the mental health services delivery programme. Through a number of iterative 
discussions the exercise produced the mapping of existing health and social 
provisions in relation to model patient pathways and service uptake. Routine 
information was collated on service provisions, uptake, complaints, 
satisfaction of services and  included identified gaps in current services and 
other provisions.  
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3.3.3. Analysis framework 
Analysis framework 
Based on material uncovered, the study provided recommendations for ways 
to further improve both the services and ways by which they can be managed.  
It must be noted that any analysis involving service provision is difficult due to 
the fact that there is a great deal of change in service provision at the present 
time. This is due to NHS re-organisation and the economic climate. 
Subsequent meetings of the project group confirmed that the focus of the 
needs assessment was a population approach of identifying at-risk groups 
and areas of need, including the prevalence of mental health problems. The 
MHNA was a complex exercise and required a critical pathway for logistic 
reasons and other practicalities. As such, the exercise was undertaken and 
built up through a number of stages.  
 
3.3.4. Case definitions for serious mental illness 
There is no clear global definition of severe and enduring mental illness (Gask 
et al 2000, Slade et al 2002). However, the Audit Commission (1994) defined 
severe mental illness as affecting those patients with a diagnosis of psychosis 
and compulsory admissions, or aggregate of one-year stay in hospital over a 
five-year period, or three or more admissions in the previous five years. The 
definition outlined by the DH (1995) considers diagnoses of psychosis, severe 
neurotic illness, personality disorder, dementia, with aspects such as a history 
of self-harm, self-neglect or violence. 
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For this study, the QOF definition (as used by the commissioners) of SMI is 
used.  This includes the ICD 10 diagnosis groups F20-29 (schizophrenia and 
delusional disorders), F30-39 (affective disorders like depression), and F60-69 
(personality and behavioural disorders). For the diagnosis groups F 20-29 the 
terms ‘psychotic disorders’ and ‘functional psychosis’ are used 
interchangeably. These categories are in keeping with the ONS Psychiatric 
Morbidity Survey. The needs assessment excluded dementia and drug and 
alcohol dependencies.  
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3.4. Profile of the London Borough of Brent 
 
Brent district covers 43.2 square kilometres and is located in the North West 
of London. Officially it has a population of 270,000 (ONS 2006) although 
Council-commissioned research suggests that this figure could be over 15,000 
higher and is growing steadily. Recent figures indicate significant numbers of 
people moving into the borough creating new emerging communities, as well 
as significant numbers of transient people within the borough.  
 
 
 
Figure 1. London Borough of Brent and its localities  
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The GLA predicts that Brent’s population will increase by roughly 10,000 
people every ten years and is predicted to be 305,575 by 2018.  
 
Figure 2. Brent projected population 
 
Diversity 
Dynamic population movements have resulted in Brent becoming the most 
ethnically heterogeneous borough in the country (Office of Statistics). It is one 
of only two local authorities serving a population where the majority of people 
are from ethnic minorities, and these groups are growing faster than any other 
borough (Fig 2).This means that the chances of 2 people in Brent being from 
different ethnic groups are higher than anywhere else in the country. Black 
and minority ethnic (BME) groups make up the majority of the population at 
54.7% including 18.5% Indian, 10.5% Black/Black British Caribbean and 7.8% 
of Black (other). Approximately 130 languages are spoken in schools in Brent 
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and it has the highest proportion of people born outside the EU in England 
and Wales.  
 
In the next 10 years the BME population is expected to increase to 60% of the 
population. The largest increase is expected to be in the Asian population 
which is expected to increase to just under a third of the population (32%) by 
2014. Substantial increases are expected in the numbers of people in BME 
groups aged 30-65 years and smaller increases in people aged 65 years or 
over. This will have implications for the demand for health care as Asian 
groups tend to have higher rates of diabetes and heart disease and develop 
these diseases about 10 years earlier than white groups, whilst black groups 
have higher rates of diabetes, hypertension and stroke and also develop these 
diseases earlier  
 
Different ethnic groups are concentrated in different parts of the borough. The 
highest concentrations of black residents are in Stonebridge and Harlesden 
wards. Asian residents tend to be located towards the west of the borough 
and the white population towards the east. Kilburn, Mapesbury and Dollis Hill 
wards have the highest numbers of white Irish residents. 
 
Due to the fact that ethnicity was not routinely collated as part of the GP 
dataset (before 2011) we have an incomplete picture. However, the available 
data shows that, within GP practice, the ethnicity of 32.74% of people on the 
severe mental illness register is unknown. This may introduce a bias into any 
further analysis of the ethnicity data as it is not possible to say whether the 
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people with unknown ethnicity follow a similar prevalence to those that are 
unknown.  
 
Deprivation 
Brent has an IMD (Index of Multiple Deprivation) score of 29.22, which means 
that it ranks 53rd out of the 354 boroughs in the country i.e. it is in the 15% 
most deprived local authorities in the country. The indices combine 
information on economic, social and physical issues to produce scores for 
small areas across the whole of England. These indicators are used as 
proxies for levels of deprivation and socio-economic status. All mortality rates, 
admission rates and prescribing data have been linked with the Index of 
Multiple Deprivation by electoral ward. The higher the score, the more 
deprived the ward.   
 
For the purposes of this mental health needs assessment the Index of Multiple 
Deprivation 2007 (IMD) has been used, primarily because it is the most 
comprehensive of the available indicators, as it takes into account not only 
employment status, but also broader determinants of health such as 
education, housing and geographical access to services.   
 
However, Brent has also large sections of the community which are relatively 
affluent; The neighbourhoods experiencing the highest deprivation are largely 
located in the south of the borough. Our most deprived residents also have 
the lowest income levels, highest unemployment levels, poor and 
overcrowded housing and the worst health outcomes (Figure 3).  
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Figure 3. Deprivation scores (IMD) by localities. 
 
Life Expectancy 
There is a 9.3 year gap in life expectancy between the lowest (Harlesden- 
south) and highest wards (Northwick Park – north). Differences in health 
within Brent are dramatically illustrated by examining male life expectancy 
along the Bakerloo line. A journey of 3.5 miles takes you from Harlesden, 
which has the lowest life expectancy for men, to south Kenton, where male life 
expectancy is approximately 9 years higher.  
 
The gap in life expectancy in Brent has persisted over a number of years. 
Recent figures show a slight reduction in the gap; however, this is because of 
a reduction in life expectancy in Northwick Park rather than an improvement in 
Harlesden. Life expectancy for women in Brent is 83.4 years; this is 
significantly greater than the England average of 80.9 years and London at 
82.0 years (2007-2011). Life expectancy for men is 78.2 years which is 
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approximately equal to the England and London average of 77.4 years (2004-
2006).  
 
 
Figure 4: Life expectancy in the Borough. Shows a 7 year gap between north 
and south (within a distance of 3.5 miles). 
 
Life style and health profile of Brent 
Below (figure 5) is a summary of data collected annually for the locality. These 
reflect the overall pattern of lifestyle across the borough. It does not give an 
distribution across the various localities of Brent.  
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 Figure 5. Summary of the Borough’s health profile (2010-11) 
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3.5. Disease profile  - 
    Mortality 
Standardised mortality ratios (SMRs) are a measure of how more or less likely 
a person living in a particular ward is to die compared to that of the standard 
population, in this case England and Wales. This measure takes in account 
differences in the age and sex structure of a population. A value of 100 
indicates that there is no difference in mortality compared to the rest of 
England, a higher value suggests that mortality is higher than England and 
vice versa. 
 
SMRs for both males and females have improved considerably over the past 
decade. Males, aged 15-64, SMR has decreased from 146 in 1993 to 106 in 
2011. The SMR for females, ages 15-64, has decreased from 131 in 1993 to 
98 in 2011. There has also been a significant reduction in mortality rates from 
circulatory diseases and cancers. But there pockets of relatively high social 
deprivation and no data exist on the local variations with regards to SMR 
estimation 
 
   Morbidity 
QOF 
Quality and Outcomes Framework (QOF) is a voluntary incentive scheme for 
GP practices in the UK, rewarding them for how well they care for patients. It 
contains groups of indicators, against which practices score points according 
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to their level of achievement and gives an indication of the overall 
achievement of a practice through a points system.  
 
Since 2004 there has been a central collection of information from GPs about 
how many of their registered patients have certain conditions as part of the 
QOF. This provides information about the prevalence of key conditions in 
Brent and compares it to similar information for the rest of NHS London 
Strategic Health Authority and the rest of the country. There are limitations to 
the data. It should be remembered that not everyone with these conditions will 
be registered with a GP and of those that are, not all will be reported by the 
GPs practice. In some conditions, such as diabetes, the true prevalence will 
be higher than the QOF data suggests, because many people have the 
disease for some time before they develop symptoms and are diagnosed. 
 
3.6. Selective profile of physical diseases common to SMI 
population  
 
Key Facts (refer figure 6) : 
 QOF average data revealed that during 2010-11, 63,396 patients were 
on Smoking Register (prevalence 18.10%). Overall cardiovascular 
diseases (e.g. hypertension, CHD, stroke) prevalence was about 15%. 
Prevalence of CVD related diseases conditions (obesity, diabetes, 
CKD) was 13.5%.  
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 Cardiovascular diseases and cancers are Brent’s biggest killers, and 
mortality rates are up to 50% higher within the most deprived wards. 
Healthy lifestyles and early intervention can have a major impact on 
these deaths. 
 Respiratory disorders are a major cause of mortality, morbidity and 
health inequalities in Brent. 
 There are likely to be large numbers of individuals with COPD who 
remain  undiagnosed. 
 There has been a large increase in the emergency hospital admission 
rate for asthma over the last few years. 
 Rates of admission due to pneumonia are significantly higher than the 
rest of London. 
 Chronic disease and Long Term Conditions (LTCs) are endemic in 
Brent; for example, diabetes prevalence is amongst the highest in the 
country (and second highest in London) at 5.61% of the population 
diagnosed and additional undiagnosed cases of circa 2%. 
 The prevalence of diabetes is expected to increase to around 8.5% of 
the adult population by 2014. In addition, prevalence of key diseases 
such as hypertension, CHD and COPD will increase over the next 5 
years. 
 Rates of tuberculosis (TB) in Brent are amongst the highest in the 
country. 
 The number of people over 75 with dementia is expected to increase 
from 2,027 to 2,226 between 2009 and 2014. 
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Figure 6: Reported prevalence of diseases linked with SMI population  
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3.7. Mental health profile 
Serious mental illness (SMI) 
It is estimated that severe mental illness affects around 1% of the population . 
Almost 0.9% of registered patients in the borough are registered as being 
followed up or treated for a severe mental health problem in primary care 
(similar to national figures).  Under the mental health clinical area, practices 
are asked to maintain a register of those with Serious Mental Illness, defined 
as those suffering from schizophrenia or bipolar disorders or other psychoses. 
It does not include the sizeable group of individuals suffering from personality 
disorder or severe depression.   
 
QOF registers are used routinely to manage the serious mentally ill. Currently 
they provide the following statistical evidence for each GP practice in Brent 
using the 6 registers namely: 
 MH9: The percentage of patients with schizophrenia, bipolar affective disorder 
and other psychoses with a review recorded in the preceding 15 months. In 
the review there should be evidence that the patient has been offered routine 
health promotion and prevention advice appropriate to their age, gender and 
health status. 
 MH8: Is a register of people with schizophrenia, bipolar disorder and other 
psychoses. 
 MH6: The percentage of patients on the register who have a comprehensive 
care plan documented in the records agreed between individuals, their family 
and/or carers as appropriate. 
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 MH7: The percentage of patients with schizophrenia, bipolar affective disorder 
and other psychoses who do not attend the practice for their annual review 
who are identified and followed up by the practice team within 14 days of non-
attendance. 
 MH4: The percentage of patients on lithium therapy with a record of serum 
creatinine and TSH in the preceding 15 months. 
 MH5: The percentage of patients on lithium therapy with a record of lithium 
levels in the therapeutic range within the previous 6 months. 
 
3.8. QOF information 
a. Case registers  
In 2010-11, 0.98% of the Brent registered population (all ages) were on the 
primary care serious mental health register, a total of 3455 individuals.  An 
apparent increase between 2008/09 and 2009-10 may reflect more specific 
criteria for inclusion on the SMI register.  Using the 2009 reconciled population 
base (lower than the unadjusted 2008 population base), the rate is 0.90%. 
Practice rates varied from 0..4% to 1.8%. Overall the locality prevalence rate 
is above national and SHA levels with some practices incurring almost twice 
the national level (approximately 67%).  As expected, there is wide differences 
within the geographical region with some practices showing very low level of 
mental illness (< 0.04%) as shown in figures 6 and 7 below. The 
commissioners needs t seek re-assurances on the accuracy of the data to 
explain the wide variations. 
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These indicators are the proportion of people registered to GPs who are on 
the QOF register with severe mental health problems schizophrenia, bipolar 
disorder and other psychoses in primary care. The data should not be 
interpreted as ‘disease prevalence’. QOF data do not necessarily present an 
accurate picture of disease burden, as disease prevalence reported as low 
could be explained by under-recording or unmet need within the practice 
population.  This information is more a measure of service use, practice 
recording and service quality for people with severe mental health problems 
managed in primary care. Figures 7 and 8 show the pattern of activity for the 
MH09 registers.  
 
 
Figure 7:  An overview of the SMI (QOFs) across the various localities. 
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Figure 8: Mental health raw prevalence as indicated by the QOF register in 
Brent and compared to the UK. 
 
b. Physical review recorded for those on SMI register  
Patients with serious mental health problems are at considerably increased 
risk of physical ill-health than the general population and shorter life 
expectancy (Phelan et al. 2007). It is therefore good practice for a member of 
the practice team to review each patient’s physical health on an annual basis. 
Health promotion and health prevention advice is particularly important for 
people with serious mental illness. However, there is good evidence that they 
are much less likely than other members of the general population to be 
offered these kinds of checks.  
Overall, 91% of those who are on the SMI register and eligible for an annual 
review are recorded as receiving one (QOF Indicator MH09).  Figure 9 shows 
the percentage of patients with schizophrenia, bipolar affective disorder and 
other psychoses who had an annual review is high and compares favourably 
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with the national level. The PCT scores compares favourably against national 
figures (figure 9). However, the Trust needs to explore the patterns of 
exceptional reporting on its chronic mentally ill patients. shows that there was 
little variation by locality. Seven practices had a percentage less than 80%. 
    
Figure 9:  QOF Performance 
 
c. Care plans for those on the SMI registers 
QOF guidance states that patients on the mental health register should have a 
documented primary care consultation that acknowledges, especially in the 
event of a relapse, a plan for care. The care plan which should be reviewed 
annually should include the views of their relatives or carers where 
appropriate. 
Up to one half of people who have a serious mental illness are seen only in a 
primary care setting. For these patients, it is important that the primary care 
team takes responsibility for discussing and documenting a care plan in their 
primary care record. However, if a patient is treated under the care 
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programme approach (CPA), then they should already have a documented 
care plan discussed with their community key worker available.  
Overall 88% of those on the SMI register are recorded are having a care plan 
(QOF indicator MH6).  This figure should be 100% as a care plan should be 
developed for all those on the SMI register either with primary care or for 
those on CPA with the patient’s care-coordinator.  
 
d. Comprehensive care plans 
QOF MH06 is an index of measurement of patients who had had a 
comprehensive care plan documented in the records. 21% of practices did not 
conform to this clinical guideline with some variations along geographical 
settings. 13% of practices had exceptional reporting in this category (figure 
10). Although it is below the national average, it is imperative to understand 
this variation. If patients are being exceptionally reported it may be that some 
are   falling through the net and may eventually get compromised.   
 
Figure 10: QOF care plans 
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Within the borough, the proportion of patients on the practice registers from 
0.29% up to 3.9% (3.9% were registered by the Harness group in Harlesden. 
This practice provides services for homeless and transient individuals). Other 
practices with more than 1.2% on the register included practices largely in the 
south of the borough.  
 
Analysis also showed that a significant number (65%) of SMI tend to  be 
clustered around Central Middlesex Hospital (the acute mental services).  This 
clustering nexus has been reported by Congdon (2011) for other parts of the 
UK. This geo-location of SMI is an interesting phenomenon which is further 
explored in the study as part of the COPD prevalence estimate.  
 
Other key facts 
The majority of people with severe mental disorders, as picked up in the 
assessment, are within the 18-64 age range, with 71% of females and 81% of 
males falling within this range. The male-female split is even with only 18 
different between the two; however there are a higher percentage of females 
of an older age than males. 
 
Psychotic disorders and bipolar disorders account for 90% of all the diagnoses 
(62% and 28% respectively). Local data confirmed the national rates from the 
Psychiatric Morbidity Survey 2010 that showed that more females than males 
would be expected to have a psychotic disorder within the 16-74 age range. 
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The data shows that, when grouped into quintiles of deprivation by Medium 
Super Output Area (MSOA), that the more deprived the area is the higher the 
prevalence of severe mental health issues. This is based on the deprivation of 
where the people actually live rather than on the deprivation scores of the 
practice as used in the QOF section. This would suggest a direct link between 
deprivation and severe mental illness.  
 
Within Brent as a whole under 10% of patients who are on a GP severe 
mental illness register have not had a recorded review in the previous 15 
months as at 31st March 2010.  
 
The percentage of patients who are on a GP severe mental illness register 
and not followed up for non-attendance of a review is lower than 10%. 
However, there is a large variation across the locality with only 3.9% of 
patients not followed up in Wembley and 16.5% in the Harness locality.  
 
The percentage of patients who are on a GP severe mental illness register 
and do not have a care plan is documented as being just under 11%. There is 
little variation across the PCT having the lowest percentage at 9.6% and the 
highest at approximately 13%.  
 
3.9. Ethnicity and mental health   
There is good evidence that there is an unequal distribution of mental health 
problems among black and various minority groups. As mentioned previously, 
Brent has the UK’s most ethnically diverse population. Marginalised groups 
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such as asylum seekers and the homeless who are likely to have experienced 
traumatic life events are more likely to have complex mental health problems 
and therefore vulnerable to deliberate self-harm. Brent is committed to target 
its health promotion campaigns to these communities. A crucial factor is 
accessibility to service.  
 
The rate of admissions for BME population is below that expected – 
significantly less than the London rate, and below the national rate (table 2 ). 
Similarly the white ethnic group admission ratios are significantly low 
compared to other parts of London (figure 11).  However, this reflect the ethnic 
composition of Brent.  
 
 
Table 2: The percentage of community using mental health services in Brent.  
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Figure 11: Use of services – A comparison with London and UK. 
 
Co-morbidity 
Co-morbidity is the presence of two disorders or illnesses occurring 
simultaneously in the same person.  Surveys show that drug abuse and other 
mental illnesses are often co-morbid.  Six out of ten people with a substance 
use disorder also suffer from another form of mental illness. 
 
The prevalence of co-morbid alcohol, other drug, and mental disorders in the 
UK total community and institutional population is estimated to be around 
22.5% for any non-substance abuse mental disorder, 13.5% for alcohol 
dependence-abuse, and 6.1% for other drug dependence-abuse.  Among 
those with a mental disorder, the odds ratio of having some addictive disorder 
was 2.7, with a lifetime prevalence of about 29% (including an overlapping 
22% with alcohol and 15% with another drug disorder).  The highest mental-
addictive disorder co-morbidity rate was found for those with drug (other than 
alcohol) disorders, among whom more than half (53%) were found to have a 
mental disorder with an odds ratio of 4.5. 
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Physical review recorded for those on SMI register  
Patients with serious mental health problems are at considerably increased 
risk of physical ill-health than the general population and shorter life 
expectancy (Marder et al. 2004). It is therefore good practice for a member of 
the practice team to review each patient’s physical health on an annual basis. 
Health promotion and health prevention advice is particularly important for 
people with serious mental illness. However, there is good evidence that they 
are much less likely than other members of the general population to be 
offered these kinds of checks. Overall, 91% of those who are on the SMI 
register and eligible for an annual review are recorded as receiving one (QOF 
Indicator MH09). There was little variation by locality. Seven practices had a 
percentage of less than 80%. 
 
Co-morbidity 
Co-morbidity is the presence of two disorders or illnesses occurring 
simultaneously in the same person.  Surveys show that drug abuse and other 
mental illnesses are often co-morbid.  Six out of ten people with a substance 
use disorder also suffer from another form of mental illness. 
 
The prevalence of co-morbid alcohol, other drug, and mental disorders in the 
UK total community and institutional population is estimated to be around 
22.5% for any non-substance abuse mental disorder, 13.5% for alcohol 
dependence-abuse and 6.1% for other drug dependence-abuse.  Among 
those with a mental disorder, the odds ratio of having some addictive disorder 
was 2.7, with a lifetime prevalence of about 29% (including an overlapping 
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22% with alcohol and 15% with another drug disorder).  The highest mental-
addictive disorder co-morbidity rate was found for those with drug (other than 
alcohol) disorders, among whom more than half (53%) were found to have a 
mental disorder with an odds ratio of 4.5. 
 
3.10. Factors influencing need for mental health services 
The community prevalence of those people at high risk of admission to a 
mental health service will be only one of the several factors, noted above, 
which affect the need for care, as expressed as number of inpatient beds, 
outpatient appointments and community mental health and primary care 
appointments (and corresponding clinical resources) needed. Influencing 
factors, among others, are likely to be: 
 Number (and trend) of cases in community (prevalence)  
 Number (and trend) of new presenting cases in community per year 
(incidence) 
 Catchment population of the facilities 
 Which clinical criteria and severity thresholds for those criteria are used to 
make the clinical decision to admit to services 
 Availability (i.e. amount of) and development of service quality and quantity in 
each locality 
 Which clinical criteria and severity thresholds for those criteria, are used to 
make the clinical decision for referral from each part of the service to another 
(‘discharge’ threshold) 
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3.11. Service provision in community services 
Primary care services 
Primary care provides a wide array of services and is diverse in terms of its 
organisation, the services offered and the professionals involved. The services 
for patients with mental ill health that are provided by primary care 
practitioners include health promotion; assessment and detection/diagnosis; 
management, advice and information, treatment including medication, 
psychological interventions or complementary therapies and referral; follow-up 
and continuing care of chronic and recurring disease; rehabilitation after 
illness; and co-ordination of services. 
 
GP Services 
There were 166 Whole Time Equivalent (WTE) GPs working in 72 GP 
practices in Brent as of 1st January 2009 included:  
 19 single handed practices  
 6 PCT salaried practices 
 12 PMS practices providing a range of services for refugees and asylum 
seekers, the homeless population and those who are unregistered  
 There were 351,000 patients registered with a Brent GP as of the 1st January 
2011. Patient turnover at approximately 20% per annum is high. The number 
of WTE GPs per 100,000 population weighted by age and need was 68.8 per 
100,000 in 2006. This is higher than the England rate of 61.8 per 100,000 and 
the 15th highest in London. Analysis of primary care data within Brent shows a 
higher percentage of smaller practices as compared with national averages. 
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70% of Brent practices are one and two handed practices compared to 54% in 
London and 42% in England.  
 GP practices list sizes are varying from just under 2,000 to about 15,000 
patients. Overall highest list size is observed in Kilburn. Most of the smaller 
practices have about 2,000 or fewer patients. Most of the GP practices, except 
in Kilburn localities, have maximum between 8,000 to 11,000 patients.  
 
Service uptake  
Overview 
There were a total of 769 admissions and 789 discharges to inpatient services 
in year 2008/9. Some patients may have been readmitted more than once in 
the year.  Half of all patients are discharged with the three weeks and patients 
will usually spend less than six months on an acute inpatient ward, although 
problems with discharge may mean that this is not achieved in practice.  
Analysis of the admission data highlights a number of issues. Males have 
higher admission rates for schizophrenia and delusional disorders than 
females, which reflects national prevalence rates for these conditions. Whilst 
females have nearly double the admission rates for mood affective disorders 
which reflects national prevalence rates for these conditions. Since 2005 there 
has been an increase of 20.8% in the total number of mentally ill in Brent. 
A significant number of Brent patients with a mental health diagnosis are also 
admitted to acute hospital wards.  In many cases, these are short stay for 
alcohol related mental health problems.  Some may be admitted via acute 
A&E and then be transferred to specialist MH providers.     
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The rate for personality disorders provides an interesting local picture. 
Nationally men have a higher prevalence rate for these conditions, but Brent 
in-patient data illustrates that it is females who have higher admission rates 
than males.  
 
Generally the number of admissions for schizophrenia and affective disorders 
is in line with predictions based on deprivation and demographics.  There is 
however some variance in some wards. Brent standardised admission rates 
are generally lower than national rates, except for schizophrenia. Senility and 
organic mental disorders are rising over the last 4 years. There is an upward 
trend in number of alcohol-related disorders.  
 
The rate of admissions for schizophrenia and related disorders was between 
240 and 280 cases over the last 5 years. Apart from senility related disorders, 
most diagnostic groups do not showing any significant trend. 
 
It should be noted that the arithmetic mean or 'average' is often used to 
compare stay lengths between different hospitals.  This is not an ideal method 
as averages can be badly distorted by small numbers of long-stayers.  The 
most appropriate figure to reflect overall stay length for an in-patient unit is the 
median – i.e. the number of days by which 50% of admissions will have 
finished.  For Brent over the last 5 years the median (13 days) is considerably 
lower than the average (50 days). 
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Key details 
Analysis of the admission data highlights a number of issues. Males have 
higher admission rates for schizophrenia and delusional disorders than 
females, which reflects national prevalence rates for these conditions. Whilst 
females have nearly double the admission rates for mood affective disorders 
which reflects national prevalence rates for these conditions. Since 2005 there 
has been an increase of 20.8% in the total number of mentally ill in Brent.  
A significant number of Brent patients with a mental health diagnosis are also 
admitted to acute hospital wards. In many cases, these are short stay for 
alcohol related mental health problems. Some may be admitted via acute A&E 
and then be transferred to specialist MH providers.  
The rate for personality disorders provides an interesting local picture. 
Nationally men have a higher prevalence rate for these conditions, but Brent 
in-patient data illustrates that it is females who have higher admission rates 
than males.  
The rate of admissions for schizophrenia and related disorders was between 
240 and 280 cases over the last 5 years. Generally the number of admissions 
for schizophrenia and affective disorders is in line with predictions based on 
deprivation and demographics. There is however variance in some wards.  
 
3.12. Commissioning model  
The study sought to explore needs, demands, use and outcomes within 
mental health services using a more refined local prevalence index and how 
these can be framed into a framework that could enhance commissioning. The 
fundamental relation between these variables is complex.  
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Essentially, the mediating factor relating need, demand and activity (e.g. how 
much need is turned into demand) are the clinical  decisions at each stage, 
including patients’ decisions whether to seek services. To appreciate this 
dynamic, it is best to use a framework to explore the relationship. This can be 
summarised by this schematic diagrams (figures 12 and 13) below.  
 
 
Figure 12: Schematic diagram showing the decision flow for service 
commissioning  
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Figure 13: Schema for service commissioning using clinical decision flow. 
 
However, the other factors are equally important in mediating the transition 
from need to activity, via ‘demand’ and together produce a feedback loop 
increasing (or decreasing) ‘supply induced demand’, which is often ‘supply 
awareness demand.’  
 
This makes it difficult to use epidemiological estimates of prevalence of mental 
disorders to estimate ‘need for mental health care’. This is because the ‘need’ 
depends on the thresholds of severity at which the clinical deciders use to 
define a ‘case’ requiring treatment. In turn, this severity decision depends on 
the effectiveness of treatments: some treatments might only be effective on 
mild cases; other treatments might only be suitable for more severe cases 
because they have side effects which are only worth being exposed to if the 
severity of need (and therefore potential benefit) is large.  
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It is more difficult to use the epidemiological ‘need for care’ (even assuming 
that thresholds of admission to various mental health services are 
operationally agreed and adhered to in practice) because treatment activity is 
incompletely effective and suboptimal outcomes either prolong treatment or 
require readmission to services, thus increasing the amount and kind of 
mental health service provision required.  
 
Therefore, the appropriate commissioning/planning question is not how many 
mental health service resources of various kinds do we need. The appropriate 
question is, given the reality of present patterns of resources, what kind of 
information do we require to have an effective commissioning outcomes? 
 
This whole complexity of public health planning depends ultimately on the 
need to have good epidemiological information and good prevalence 
estimates are essential to this process.  
 
This suggests  that prevalence of severe mental illness, a widely used proxy 
for levels of long term mental health care need in local populations, can be 
effectively modelled using regularly updatable population data published by 
the Office of National Statistics area-type classification with local primary care 
data.  
 
3.13. Limitations of the needs assessment 
There are gaps in the needs assessment - what is presented is for areas 
where data is available, and what is possible within the time limits of the 
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project. It was not possible to carry out a full assessment of user engagement 
in the commissioning process. Other areas not covered that could be 
considered in future needs assessments include the mental health needs of 
people with other types of disability, including visual impairment, HIV and 
physical disability. 
 
Date Quality 
The reliability of data is crucial in the whole aspects of service design, 
planning and delivery.  Quality data underpins everything from needs 
assessment, to pathway development from service redesign to defining 
positive outcomes for users. 
 
However, there is a national consensus that data generated from this area is 
at best contestable. Mental health data has a reputation for being of poor 
quality and reliability. This is an area that needs to be addressed urgently. It is 
applicable across primary and secondary care. Raising awareness amongst 
clinicians and practitioners in primary and secondary care on the importance 
of good clinical coding should be seen as an important element of their work 
not a tedious bureaucratic exercise. 
 
A further development that would greatly advance the relevance and accuracy 
of such comparisons would be to feedback information to each participating 
trust, so that each could decide on a knowledge-based plan to improve 
specified areas of practice in anticipation of a subsequent further appraisal, 
thus continuing and enriching the audit cycle. 
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3.14. Conclusion 
The prevalence of enduring mental illness identified is over three times that 
which was expected using national prevalence data underlining the particular 
challenges of mental ill health in deprived localities. The overall prevalence of 
patients identified as suffering a long-term mental illness was three per 1000 
patients registered, but rates varied widely between practices, in part due to a 
higher prevalence of patients with psychotic disorders in the more 
disadvantaged areas, which was not unexpected. The methods used here 
would not have identified long-term mentally ill patients in the community who 
had not been in touch with any health or social services for some time, such 
as the homeless. 
 
In the south of the borough there were some  high mean general practitioner 
consultation rate of 8.1 consultations per year in some areas compared with 
the rate of 6.5 per year found in the north sector. Though few in number, most 
long-term mentally ill patients are demanding of general practitioners' time. 
However, 29 patients (7% of the total) had had no recorded contact with their 
general practitioners for a year. This confirms suspicions that some disabled 
long-term mentally ill patients are not seen regularly by their general 
practitioners, although they seem to be few in number in these practices. 
 
According to practice records, most contacts with general practitioners were 
for minor physical problems, repeat prescriptions and sickness certificates. It 
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is possible, however, that mental state review occurred more often and was 
not specifically recorded in the notes. 
 
The findings presented here suggest that patients in long-term contact with 
specialist services cannot be taken as representative of the whole population 
with long-term mental illness.  
 
This study has demonstrated that long-term mentally ill patients can be readily 
identified in general practice. General practitioners could perhaps use their 
contacts with these patients to play a greater role in monitoring their mental 
state and psychotropic medication.  
 
Future direction 
For effective planning and commissioning, the commissioners need 
information on: 
 The prevalence of disorders in the present and in the future 
 The prevalence of the determinants of mental illness 
 Current service activity and predictions of likely future activity 
 
The commissioners should work with acute mental health services to develop 
accurate, comprehensive and timely data on each of these four areas.  The 
first two are for the most part not directly under the control of the 
commissioning process and developments in this should be about developing 
a resource / database of local and national data sources which are of benefit 
in planning, forecasting and commissioning services.  The APHO report on 
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mental health Indications of Public Health in the English Regions (APHO, 
2007) provides a useful starting point but not sufficient. At regional level it 
presents a wide range of data on the factors which can give rise to poor 
mental health, the mental health status of populations, provision of 
interventions of care for mental illness, effectiveness of partnerships, service 
user experience, workforce capacity and traditional outcomes such as suicide.  
 
To develop service intelligence on activity and outcomes, there are a number 
of relevant initiatives that need to be considered. It is important to combine the 
national mental health observatory (mental health minimum data set) with a 
local pathfinder site minimum data set for a better prevalence estimate within 
small area population. Locally, links should be made to relevant agencies to 
understand what data they might hold, its strengths and weakness and how it 
might be used to support the commissioning process.  
 
Finally, the use of MHNA as a methodology to understand and analyse risk 
factors at neighbourhood level cannot be emphasise too highly. In an area like 
Brent, the mobility of its resident is fluid. Annually, there is around 30% of the 
population shift, particularly in areas such as Harlesden and Kilburn. National 
prevalence estimates are not sufficiently sensitive to these  changes. Routine 
MHNA can help commissioners with a useful guide for health investment in 
areas of needs. This is a powerful tool in shaping better local health 
prevalence measures.  
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4. Local area estimate prevalence modelling  
4.1. A methodological framework 
Health commissioners and public health departments depend on good local 
health intelligence to plan services. Where it is not possible to obtain local 
prevalence data, the only way is to estimate the number based on national 
prevalence and local resident population. This makes the assumption that the 
national prevalence estimates apply and reflect the local population setting. 
Chronic conditions like cardiovascular and respiratory diseases risk factors 
such as high blood pressure, cholesterol, smoking, diabetes and physical 
inactivity are linked to socio-economic determinants such as working 
conditions, housing, or social relationships. These parameters vary from 
locality to locality within and between borough and districts. As such crude 
estimates based on national surveys which ignore local differences can be 
sometime misleading and may have a serious impact on service delivery. This 
scenario is further complicated when dealing with a population suffering from 
co-morbidities. 
 
A pragmatic model that derives information from national estimates and 
factors local variances into national predictions is proposed. This approach 
aimed to provide a more “realistic” prevalence estimates of CHD and COPD 
within primary care was discussed and was supported by the local 
commissioners and the public health department.  
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The study aimed to generate a model to estimate local level prevalence rate of 
two diseases namely CHD and COPD in the first instance and to further refine 
this estimation at GP locality area level. The model is then applied to 
determine the prevalence of a sub population group namely the SMI with  
concurrent medical morbidities of the two conditions (as single disease entity 
or a combination of both).  
 
The definition of a “local level” refers to a borough/metropolitan area of 
approximately between 300,000 - 450,000 patients (size of a typical PCT). A 
“GP locality”, on the other hand is a small area covering between 10,000 – 
25,000 patients.  The approach does this specifically through an adaptation of 
the methodology used by the UK’s office of national statistics, known as 
synthetic regression estimation fitted using local level co-varieties. The choice 
to focus of two conditions namely CHD and COPD was based on the 
epidemiological differences including is a significant volume of “undiagnosed” 
cases in COPD (in relation to CHD) as highlighted by APHO (2008). Osborn et 
al (2007) also suggest that the people with SMI suffer from COPD co-
morbidity due to the fact many of them are smokers and live in socially 
deprived and challenging areas. 
 
The estimate modelling is done through an iterative process involving a 
number of phases. This approach facilitates sequentially the extraction of the 
data with each phase feeding the next step. In the first instance, there is a 
need to establish how the chosen physical medical condition prevalence is 
estimated at regional level. The next step is to derive a local prevalence 
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estimate model for each of the co-morbidities. It is important to remember that 
the prevalence figures generated by existing models are estimates of the 
expected prevalence of disease for national levels. Due to local variances for 
a wide range of factors, discrepancies between modelled estimates at practice 
level and other sources of data such as QOF disease registers may be due to 
local variations not captured by the model and cannot be solely attributed to 
weaknesses in QOF data. For practices with populations that significantly 
differ from a ‘typical’ population (e.g. large black or ethnic minority population 
that has very different smoking pattern to the local average) the assumptions 
of the model may not apply and discrepancies may occur. 
 
In summary, this is an iterative sequential process that draws from the 
national prevalence estimates to predict the prevalence of a chronic physical 
disease within the local practices population base. This is done through the 
following sequence: 
1. Determine the estimate prevalence model of a small population area for a 
stated disease condition 
2. Develop the local template to adjust regional estimation for that disorder 
3. Apply the local template to estimate the prevalence of that disorder within the 
SMI population using a probability estimate  
 
a. Local area prevalence estimate  
A multivariate modelling analysis using data from Health Survey For England 
(HsFe) and regression models are used to estimate of both CHD and COPD 
at CCG (PCT) level. The variables include  demography, socio-economic 
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factors, smoking behaviours, QOF data and attributes associated with the 
named conditions. The study also used geographically weighted regression 
(GWR) to associate geographical patterns to disease conditions namely 
COPD. Geo-location habitat patterns for chronic diseases have become a 
concern for public health. They create “health ghettos”  that makes planning 
and delivery of care harder. 
 
b. Developing estimate template for smaller areas (GP 
practice level). 
Using the regional prevalence rates, the re-adjustment of the number of 
patients is calculated using an approach suggested by Nacul et al (2008) and 
recommended by APHO. The rationale takes consideration of the local health 
inequalities and makes an adjustment. The assumption is that increased 
mortality (SMR) of a condition will reflect an equivalent increase in that 
disease prevalence, thus using an SMR ratio for the adjustment factor. For 
example, the national estimates suggest if a condition (A) in Brent has an 
estimated SMR of 155, then the prevalence in each GP in the locality is 
increased by 55%.  
 
Since all GP practices in the borough will have different levels of deprivation 
(as measured by UV67 for each practice), an adjustment factor is introduced. 
This factor (multiplication factor) takes into account the local deprivation 
scores (based on UVF). 
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The proposed algorithm is as follows: 
Calculating a locally adjusted prevalence estimate 
Step 1 
 
 
 
Step 2 
 
 
Step 3 
 
 
   
Step 1 
Using national estimates, a prediction of the prevalence rate is made for the 
practice. It takes account of local variances within Brent. In the absence of 
sufficiently precise published data on the relationship between deprivation and 
condition (x), the model makes an assumption that areas with higher mortality 
rates have a comparably higher prevalence of that disease. For example, 
assuming condition (x) in Brent is reported to have an SMR of 117, then the 
model increased the predicted prevalence in each practice in the locality by 
17%.  
 
Y = mx ± c * m = gradient   
* x  = UVF (Brent deprivation 
score)   
* c  = intercept      
Multiplication factor (mf)    
 
Y = (mx ± c)/100 
 
X = UVF (locality score) 
Locally adjusted 
prevalence 
Locally adjusted SMR 
 

Loc_ adj _ SMR
Nat _ SMR
mf
Formatted: French (France)
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Step 2 – The multiplication factor 
This step establishes a multiplication factor (mf) which will be used to correct 
the local differences. The APHO endorses this form of statistical adjustment in 
modelling framework (Technical Briefings 3, 2008). This is derived from a 
linear regression equation of (Y = mx +/- C), where m is the slope and (+/-)C 
is intercept. The mf is derived by dividing the above equation by 100 namely,  
mf = ((Expected local SMR  x UV scores)) / 100. Applying this factor to a ratio of 
the adjusted disease SMR (local) to national SMR will yield an a more locally 
sensitive prevalence rate.   
Thus, a GP locality with a UV67 score of 20% (level of deprivation) will yield a 
linear relationship like : Cond(x) SMR = (2.604xUV67)+25.97, where the slope 
is  4.39 and 16.04 is  intercept. The mf is calculated for each locality (based 
on UVF scores) and will be factored in the adjusted prevalence estimation. 
Worked example 
For example, let us assume that Brent’s standardised mortality ratio (SMR) for 
condition (x) was 140 - Increased the predicted prevalence of Brent by 40%. 
Locality Harlesden 
SMR prediction (borough) 140 * based on national  
estimates 
UV67 score  
(for a practice ) eg E84077 
35 * based on 2001 Census 
Regression line:  

Cond(x)(4.389*UV67)+16.04 
Adjusted SMR 169 (4.389*35) + 16.04 
Derived multiplication factor 1.69 * ((4.389*35) + 16.04)/100 
 
Step 3 – Prevalence (local estimate - adjusted)   
Adjusted prevalence rate (AP) = (SMR (calculated on local UV67 
scores)/national (SMR estimates))/multiplying factor  
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C. Determining the prevalence estimate of SMI with physical co-
morbidity 
 
Having established the prevalence estimate for condition (x) for the locality, 
the next step is to calculate the likelihood of the presence of that condition 
from our SMI population. Ideally, we should also have developed a local 
estimate of SMI using the above technique, but due to technical and clinical 
issues, this is not possible to date. The APHO is currently developing an 
approach to resolve this problem. Instead, we use the QOF data (routinely 
collected by GPs) to have a crude estimate of the number of SMI within the 
locality.  The estimation of concurrent co-morbidity is carried out through 
probability modelling (using Bayesian statistics). A schematic illustration is 
presented below (figure 14). 
 
 
Figure 14 : Schematic diagram to describe algorithm for establishing prevalence 
estimation for co-morbidity among SMI at local levels 
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Here, the study sought to establish the probability that two conditions e.g. 
CHD and COPD (A, B) are prevalent in our local SMI group. This necessitated 
an estimation of what are the chances all, none or one of these conditions 
given that they have SMI. To calculate this, we must to determine: 
1. The probability of having 2 disorders  
2. The probability of having none of these conditions 
3. The probability of having one of the conditions 
 The probability of having 2 conditions is a product of the separate 
prevalence: P(A,B) =  (P(a))(P(b)) 
 The probability of having one of the diseases, namely 
  P(1)  = {(Pa)(1-P(b))} {(Pb)(1-P(a))}  
 The probability of having two (2) diseases, 
  P(2)  = {(Pa)(1-P(b))} {(Pb)(1-P(a))}  
 probability of having none of the conditions, 
 P(0)  = (1-P(a))(1-P(b)) 
These probability estimates are then applied to the local data sets of GP 
practices.  
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5. Disease prevalence model development  
5.1. Introduction 
 
The Association of Public Health Observatories (APHO) has produced 
estimates of the number of people in each primary care trust (co-terminous 
with local authorities) who they estimates have CHD. Whilst this is useful it is 
probably more useful to examine this at practice level. The accuracy of the 
estimates depends on the modelling methodology.  This section considers the 
development of a model for coronary heart disease (CHD). 
 
5.2. Coronary heart disease model (CHD) 
Coronary heart disease (CHD) is the UK's biggest killer, with one in every four 
men, and one in every six women dying from the disease. Nationally, around 
300,000 people have a heart attack each year, and 1 in 50 people have 
angina, an estimated 1.2 million people with the condition (Minnino et al. 
2000).  It is widely recognised that coronary heart disease is a major cause of 
health inequality and a major course of premature mortality under 75 years of 
age.  Nationally, just over a quarter of deaths in people under 75 years of age 
are due to circulatory disease, and of these, over half (57%) are due to 
coronary heart disease,  In addition, coronary heart disease alone is estimated 
to cost the UK more than £7 billion each year (Jordan et al. 1998). 
 
The HSfE for 2006 estimated, based on respondents’ self-reports of doctor-
diagnosed CHD, that the prevalence is about 6.5 per cent in men and 4.0 per 
cent in women, and this increases markedly with age (Minnino et al. 2000). 
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This prevalence has remained static over the last ten years. However, the 
QOF, covering over 8,000 practices and 53 million patients, shows a GP-
registered unadjusted prevalence of only 3.5 per cent (but note that 
unadjusted prevalence rates show these registers as a percentage of the 
total practice list size i.e. for all ages) (Jordan et al. 1998; Phelan et al. 2001). 
 
The disparity between CHD prevalence estimates from large surveys, in 
particular the HSfE, and the number of patients diagnosed with CHD and 
registered in QOF led to demand for a CHD prevalence model at PCT and 
Local Authority level that gives an accurate estimate of true prevalence 
(Druss et al. 2001). The Association of Public Health Observatories (APHO) 
published a simple prevalence model to support development of 2009-10 Local 
Delivery Plans. However, it was acknowledged that this was a crude model 
and that more was needed to make sensitive model for local use.  
 
Prevalence terminology 
The term CHD can be confusing and this may often mask its true 
identity and this may lead to various methods of estimating CHD 
prevalence. Questionnaire responses such as those used in HSfE to define 
CHD, may be less accurate than clinical diagnosis. Conversely, reliance on a 
medical diagnosis may under-estimate prevalence, as patients with 
unrecognised angina or very mild symptoms may not attend (or be correctly 
identified by) their GP. 
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Defining  prevalence    
There   are   differences   between   various   methods   of   estimating   CHD  
 
prevalence.     Questionnaire   responses   such   as   those   used   in   HSfE  
 
to   define   CHD,   may   be   less   accurate   than   clinical   diagnosis.   Con
versely,,   reliance   on   a   medical   diagnosis   may   underestimate   preval
ence,  as  patients  with  unrecognised  angina  or  very  mild  symptoms  may 
 not  attend  (or   be  correctly  identified  by)  their  GP.      A   Belgian   analys
is   of   the   records   of   four   large   Belgian   epidemiological   studies   duri
ng   the   past   30  years   compared   clinical   and   electrocardiographic   (E
CG)   findings showed 
that  Q   wave  patterns,  ST  segment  depression  or  elevation,  T  wave  inv
ersion  or  flattening,  and  left   bundle   branch   block   are   often   seen   as 
  indications   of   silent   myocardial   ischaemia.      The   occurrence   of   isc
haemia-
like   findings   on   the   ECG      was   comparable   between   men   and   wo
men   (9.0%   v   9.8%).      The   results   from   this   and   other   studies   co
nsistently   show   that   ischaemia-like  ECG  changes  are  associated  with  
an  approximately  twofold  increased  risk  of   dying  of  CHD.  
 
In the British Regional Heart Study (BRHS), there was considerable overlap of 
questionnaire and ECG evidence of CHD and high agreement between self-
report and medical record for diagnosed CHD: for example, 80 per cent of 
men with a GP record of angina, reported their diagnosis and 70 per cent of 
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men who reported an angina diagnosis had confirmation of this from the 
record review (National Institute of Excellence 2010; Department of Health 
2010). The prevalence of diagnosed angina in 1992 in these older men was 
10.1 per cent according to self-reported history and 8.9 per cent according to 
GP record review.  
 
However, only half of those with a definite electrocardiogram could recall a 
medical diagnosis of CHD (Department of Health 2010). Even in patients with 
severe (grade 2) angina, 40 per cent could not recall being told that they had 
heart disease. Overall, only one in five of those regarded as having CHD were 
able to recall such a diagnosis having been made by a doctor, and these were 
likely to be those most severely affected. 
 
It must be noted that there was substantial agreement between self-report 
and GP record of angina (Information Centre for Health & Social Care 
2009). The BRHS subsequently combined two questionnaire-based 
definitions to define prevalence: either current angina symptoms, which 
were defined as a positive response to standard World Health Organisation 
(Rose) questionnaires (overall prevalence 11.1 per cent); or history of 
diagnosed CHD was defined as subject recall of ever having had a doctor's 
diagnosis of either angina or heart attack (overall prevalence also 11.1 per 
cent) (Information Centre, NHS, 2008). 
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Table  3: Percentage  prevalence of IHD, by survey year, age and gender. 
Source: HSfE, Information Centre 
 
While CHD mortality has greatly declined in the last four decades, the use of 
age-adjusted rates to describe CHD mortality obscures the fact that the 
decline largely represents the postponement of CHD deaths until older age. In 
fact, the overall burden of CHD is increasing in parallel with the increase in life 
expectancy. As the burden of prevalent CHD is increasing, identifying persons 
with CHD, measuring its incidence and outcome and how these vary over time 
and across populations is essential to understanding the determinants of the 
trends in CHD. This in turn is crucial to define the relative contributions of risk 
factor reduction and therapeutic improvements, which is necessary to design 
effective interventions to reduce CHD. 
 
Community surveillance is a comprehensive approach designed to track 
disease at the community level and is less costly and more efficient than 
cohort studies. In the US several community surveillance studies have 
reported on temporal trends in CHD prevalence e.g. the Atherosclerosis 
Risk in Communities study, the Minnesota Heart Survey the Olmsted County 
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Study and the Worcester Heart Attack Study (Information Centre for Health & 
Social care 2009). An analysis of US NHANES data on participants aged ≥ 40 
years who attended the medical examination, the age-adjusted prevalence of 
angina pectoris, self-reported myocardial infarction and ECG-defined 
myocardial infarction were 5.8% of 9255, 6.7% of 9250 and 3.0% of 
8206 participants, respectively (De Bacquer 2000). The age-adjusted 
prevalence of coronary heart disease defined by the presence of any of 
these conditions was 13.9% among men and 10.1% among women. These 
studies suggested that in the US medical care of clinical CHD was the main 
contributor to the mortality decline (Walker et al. 1998). 
 
Outside the USA, the World Health Organisation’s (WHO) MONICA 
(Multinational Monitoring of trends and determinants in cardiovascular 
disease) Project was established in the early 1980s to monitor trends in 
cardiovascular diseases and to relate these to risk factor changes. Its central 
goal was to explain the trends in cardiovascular disease mortality observed 
from the 1970s. There were 32 MONICA centres in 21 countries (Walker et al. 
1998). In these populations, the decline in coronary disease mortality is 
mostly related to the decline in CHD events, thereby pointing to primary 
prevention as the main source. However, the study populations excluded over 
65s in whom most CHD occurs. 
 
In a survey of a rural Indian population, CHD was diagnosed based on past 
documentation, response to WHO - Rose questionnaire, or changes in ECG. 
The prevalence of CHD (clinical + ECG criteria) was 3.4% in males and 3.7% 
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in females. According to ECG criteria only, it was 2.8% in males and 3.3% in 
females and according to Q-waves only, it was 1.6% in males and 0.9% in 
females (Shaper et al. 1984). In a Finnish population survey, Ahto et al found the 
prevalence of angina symptoms was 9.1% among men and 4.9% among 
women aged 64-97 (Shaper et al. 1984). Ischaemic ECG findings were 
common: 32.9% of men and 39.3% of women had such changes. An 
international systematic review and meta-analysis found that angina 
prevalence varied widely across populations, from 0.73% to 14.4% (population 
weighted mean 6.7%) in women and from 0.76% to 15.1% (population 
weighted mean 5.7%) in men (Lampe et al. 2001). 
 
In the UK, Carroll et al used GP records in London and found a prevalence 
of 8 per cent of men and 5 per cent of women over 44 years of age - 
although this may be lower than the true national average (Alexander et al. 
2003). There was a history of myocardial infarction in 30 per cent of men and 
22 per cent of women with CHD. Lampe and colleagues examined trends 
in the prevalence of CHD in men participating in the BRHS. The authors 
demonstrated a decrease in the prevalence of current angina symptoms: 
the age adjusted annual percentage change in odds was -1.8%. However, 
there was no evidence of a trend in the prevalence of history of diagnosed 
CHD (Information centre. NHS 2008). 
 
A study by Davies et al examined trends in CHD incidence prevalence, and 
mortality in the UK between 1996 and 2005, using the THIN GP database (a 
total of 5 million patients). The results indicate that, while CHD mortality 
 
 
108 
declined, CHD incidence decreased less than mortality, resulting in an 
increase in CHD prevalence (Shaper et al. 1984). From 1996 to 2005, 
age-standardised incidence of CHD decreased by 2.2% in men and 2.3% in 
women per year (average percentage change). Age-standardised, all-cause 
mortality among those with CHD, decreased by 4.5% in men and 3.4% in 
women per year (average percentage change). Age-standardised prevalence 
increased by 1.3% in men and 1.7% in women per year (average percentage 
change). The decline in incidence had some impact on limiting the increase in 
prevalence, but its effect was offset by the increase in prevalence occurring as 
a result of improved survival among people with CHD. Although patients with 
nitrate prescriptions were also included, this study relied mainly on CHD 
diagnostic codes which may underestimate actual prevalence. 
 
5.2.1. Local area prevalence estimation framework 
The APHO used regression models to estimate prevalence and used the 
HSfE as its main source of data. This approach does not take account of 
geographic context, exemplified by interactions between demographic risk 
factors and geographic locations, or by effects of local geographic variables 
e.g. cultural norms. For example, assumptions do not hold for minority ethnic 
populations e.g. South Indian women.  
 
The proposed local model incorporates both national survey information 
(HSfE) on patient risk factors and local geographic data (Moran et al. 2010). 
This approach is applied to drive micro area prevalence estimates, 
specifically estimates of CHD for the locality of Brent. The model incorporates 
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prevalence differentials by age, gender and ethnicity from the national survey. 
Whilst national model uses random effect that allows for spatial correlations, 
local area information takes account of health inequalities relating to poverty 
and urbanity.     
 
Model Construction 
A regression model for prevalence includes person level attributes (age, 
gender, ethnicity, etc.) that are known to have significant CHD risk gradients.  
 
Data source 
a.    Populations 
The CHD prevalence model used ONS 2009 mid-year LA population 
estimates by ethnic group, age and sex. Five ethnic groups were used: white, 
black, Asian, mixed and other. In order to calculate estimate prevalence of 
CHD in the future, population projections were incorporated into the model. 
ONS has not published population projections by ethnic group, so the 2009 
(LA) distribution of ethnic groups was used to generate population estimates 
to 2020.  
Local population data were data to this mix. This provided a “more realistic” 
scenario for local estimates. 
b.   Ethnicity 
The proportion of practice population in ethnic groups was supplied by the 
Care Quality Commission (CQC). HES is the only routine dataset which 
includes GP practice and patient ethnicity and has high levels of completion 
and data quality. It is assumed that the hospital admissions (excluding 
 
 
110 
maternity and mental health) reflect the true ethnic population of the practice 
and there is no systematic bias. The proportions by ethnic group for each 
practice were calculated by dividing admissions within each ethnic category 
by the total admissions for the practice. The same ethnic distribution is 
applied across all age bands as there are insufficient hospital admissions to 
robustly calculate the distribution of ethnic groups by age and sex for practices. 
c.  Deprivation 
Deprivation scores are taken from IMD 2008. Deprivation scores for PCTs 
were calculated by taking a population weighted average of the scores for 
each Medium Super Output Area (MSOA) which in turn was calculated by 
taking a weighted average of the IMD2004 scores of each Lower Super 
Output Area (LSOA) within the PCT. Five deprivation categories are used in 
the model. Note that these categories are based on quintiles of IMD score at 
LSOA level (Table 5). When the cut-offs are applied to larger geographies (LA 
or PCT) there is not an even distribution across all categories. 
 
 
 
 
 
 
 
 
Table 4  : Index of multiple deprivation banding 
  
Rank IMD IMD Number % 
HSfE 2006 HSfE 2007 
 1 0.59 -8.34 .55 – 9.02 3,803 17.87 
 2 8.35 – 13.71 9,03 -14.14 3,573 16.79 
 3 13.72 – 21.15 14.15 – 21.17 3,788 17.80 
 4 21.16 – 34.20 21.18 – 33.52 4,551 21.38 
 5 34.21 – 86.36 33.53 – 85.69 5,571 26.17 
   Total 21,286 100 
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d.   Smoking status 
National (England) proportions of smokers, ex-smokers and current smokers 
by age and sex are taken from HSfE (2007-2009 pooled). These 
proportions were then adjusted for each LA/PCT using the synthetic 
estimates of smoking prevalence for 2006- 2009, using the following 
algorithm:  
 
 
Local prevalence of smokers to (age, sex, category) = national prevalence of 
smoking in (age, sex, category) * local overall smoking prevalence / national 
overall smoking prevalence . Local ex-smokers in (age, sex) category not 
adjusted. 
 
Nasl = 1 – Easl – Sasl 
 
where 
 
S= proportion of population who are smokers 
E= proportion of population who are ex-smokers 
N= proportion of population who have never smoked 
L= local 
N= national 
as= by age and sex 
 
This approach assumes that the proportion of ex-smokers in each age-sex 
category is fixed and the number of never-smokers increases as the number of 
smokers decreases. Regional analysis of the relationship between 
prevalence of smokers and ex-smokers in the HSfE shows no systematic 
relationship and therefore it was decided that the ex-smoking rate should not 
be locally adjusted (see figures 15).  
 
 

Sasl  Sasn 
Sl
Sn
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Figure 15: Prevalence of smoking in the UK (gender) 
 
The same smoking prevalence rates are applied across all ethnic categories. 
This was partly due to the fact that no data (by ethnicity) existed at the time of 
the study. Also future changes in smoking prevalence are not taken into 
account in the CHD prevalence projections. This is because of the uncertainty 
associated with predictions of smoking prevalence and the lag time between 
smoking cessation and improved health. Even if there was a rapid drop in the 
number of smokers over the next few years, any associated decrease in CHD 
would not be seen for many years. 
 
Operationally, three issues had to be considered. First, the modelling predicts 
the number of people with identified CHD within each population, taking 
account only of the demographic distribution of the population. The prevalence 
of patient-reported doctor-diagnosed CHD in each age/sex stratum is based 
on national data from the HSfE. It allows first for the differential risk of each 
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CHD symptom for the various ethnic groups as against the white as reference 
category.  Data for educational attainment could not be used as this was not 
available. Brent has a significant number of immigrants and displaced 
population cohort (due to conflicts elsewhere) and this information was 
unavailable and probably not reliable.  
 
The second takes account of inequalities and includes geographic effects but 
without any interactions between area and local attributes. This focused on 
the county level variables such as poverty index. Many geographic influences 
may be unobserved (e.g. various environmental and health behavioural 
influences) and these are represented in the second models by random 
effects. It is sensible to allow unobserved influences to be spatially correlated 
to reflect smoothly varying risk factors in space.  
 
The third approach allows area-person interactions, in that random effects are 
taken to be ethnic specific. Differentiation of area effects by ethnicity reflects 
epidemiological evidence such as that noted by Casper et al (2006) that CHD 
mortality and prevalence disparities between ethnic groups vary by place of 
residence. 
 
The modelling and estimation of the effects of interest was carried out using 
STATA. The initial output consisted of two tables: one with the estimated 
regression coefficients, corresponding p values and 95% confidence intervals, 
and another with the estimated odds ratios (exp(b)), which in the table appear 
as relative risk ratios (RRRs) and 95% confidence intervals. A positive sign of 
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the estimated coefficient is associated with an increase in the odds of the 
outcome had angina or heart attack, and a negative sign is associated with a 
decrease in the odds. Since Prob (A) = Odds (A) / 1+ Odds (A), for uncommon 
outcomes such as CHD, RRR can be assumed to be the same as the odds 
ratio (OR). (See explanation in methodology section page 99). 
 
Assumptions  
It is assumed that the: 
 Proportion of smokers, ex-smokers and never-smokers is the same      
           across ethnic groups 
 Proportion of ex-smokers in each age-sex group is the same in all 
areas 
 Smoking prevalence rates from the model-based estimates of lifestyle 
behaviours are reliable 
 Prevalence of CHD in those aged under 40 is negligible 
 Due to lack of data, it was not possible to treat ex-regular-smokers and 
ex-occasional smokers separately. Ex/occasional smokers are treated 
as non-smokers 
 
In summary, this method is straight-forward and extremely cost-effective 
relative to the implementation of a population survey, but it does assume that 
the local prevalence of a condition or behaviour is entirely dependent upon the 
socio-demographic composition of the area.  Models which combine individual 
and area level effects represent a significant advance, but it has proved 
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difficult to quantify the precision of small area estimates without simplifying 
assumptions.   
 
5.2.2. Model construction:  Validation process 
The methodology supporting model-based estimation for large population has 
been validated and is well established, and it is not the purpose of this study 
to re-examine it. Rather, it aims to validate individual sets of ward-level model-
based estimates of the prevalence of cardiovascular risk factors.  
These estimates should be valid and accurate provided that: 
(a)  The risk factor in question is strongly associated with individual level and 
area level covariates,  
(b)   The developed model is well fitted.  
 
If the first criterion is satisfied then it is possible to create a model that 
explains a large proportion of the variance in the prevalence of risk factors. If 
the second criterion is satisfied then the developed model accurately 
describes the relationship between uptake of the risk factor and the individual 
and area-level covariates.  
The validity assessments focus were on:  
a. Internal 
b. External  
 Predictive validity –  
1. Is there any association with QOF data?  
2. Does it converge with Case findings? 
3. Face validity 
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The extent to which the models supporting the estimates are well fitted—that 
is, they adequately describe the relationship between the health behaviour 
and individual level and area level covariates is assumed as it operates on the 
same principle of the regional model.  
 
a) Internal validation  
The prediction of the model was assessed in two ways: 
 by deriving predicted probabilities of the CHD outcome in Stata from the 
models and comparing these to the observed cases 
 by generating a receiver operating characteristics (ROC) curve using the 
predicted probabilities of the CHD outcome compared to the observed cases 
 
One method of assessing performance is to use regression model to predict 
response for each subject. These predictions are called fitted values. The 
difference between the fitted and the observed values are called residuals. 
Ideally the best prediction should result from utilising the most risk factor 
information in the regression model. Ideally the best prediction should result 
from utilising the best locally available information. However only a limited 
range of HSfE variable data is either available or can be estimated at the 
primary care organisation (PCO) or local authority (LA) level, so there is no 
purpose in including other variables (see Table 6). The study validated the 
local model by comparing it, in terms of prediction, to a model including all 
available and significant HSfE variables. In addition, however, the amount of 
missing data affects the prediction of a model. The Stata10 software package 
was used for analysis. All variables were re-coded to drop negative values for 
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estimation purposes. The methodology applied was multinomial logistics 
regression with the “cluster” adjustment option for local variables. For analysis 
of two categories (where needed), the multinomial regression  was reduced to 
binomial logistic regression. The prevalence in each age group, gender, ethnic 
group, area of residence and level of deprivation were derived from the odds, 
using the formula: prevalence=odds/(1+odds). 
 
In the complete HSfE variables the largest proportion of missing data occurred 
in those variables related to drug treatment for high blood pressure. Treatment 
with ACE inhibitors, beta blockers and calcium blockers are  significant. 
However these may also be used to treat established CHD, so the association 
may be unrelated to hypertension. In addition, the HSfE relies upon patient 
recall for drug treatment. Not unexpectedly, much of the data for these 
variables is missing. Systolic and diastolic BP were added as ordinal variables 
to the model, but this resulted in major changes to ORs for other variables. 
This may simply be related to model instability because of the large numbers 
of variables included. The addition of a single variable for hypertension, either 
treated or untreated, will be explored as a further later step in model 
development. 
 
The prevalence figures generated by the models are estimates of the 
expected prevalence of disease. Discrepancies between modelled estimates 
at practice level and other sources of data such as QOF disease registers 
may be due to local variations not captured by the model and cannot be solely 
attributed to weaknesses in QOF data. For practices with populations that 
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significantly differ from a ‘typical’ population (e.g. large black or ethnic 
minority) were excluded. Hence the model COMP 1 included the “complete” 
list of variables, including BP drugs; model COMP 2 included the “complete” 
list of variables, but excluded BP drugs (table 5). The model included impact 
of age, Index of Multiple Deprivation (IMD) and ethnicity on outcomes (table 
7 and 8). The predicted prevalence by BM category is shown in table 7.  
COMP 1  =  “Complete” variables with BP drugs  
COMP 2  =  “Complete” variables without BP drugs 
LOCAL =  only using locally available data 
* only a selection of variables is shown in table  
 
Table 5: Variables included in merged dataset 
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 Risk 
factor 
RR S-
Error 
z P>z 95% 
CI 
Age 25-34 1     
Age 35-44 6.68 2.98 4.41 0 2.91 
Age 45-54 19.51 8.21 7.06 0 8.55 
Age 55-64 65.71 27.23 11.65 0 29.16 
Age 65+ 154.67 65.16 11.65 0 68.87 
IMD  0.59-8.35 1     
IMD 8.35-13.72 1.27 0.14 1.75 .08 0.97 
IMD 13.73-21.16 1.35 0.15 2.63 .009 1.02 
IMD 21.17-86.36 1.85 0.25 6.49 0 2.12 
White 1     
Mixed 1.23 0.85 0.35 0.72 0.39 
Black 0.76 0.16 -1.23 0.21 0.49 
Asian 1.51 0.24 2.56 0.01 1.12 
Other 0.16 0.17 -1.76 0.07 0.02 
 
Table 6: Odds Ratios for LOCAL (public health datasets) , model with only 
locally available variables Including IMD – Index of Multiple Deprivation 
 
 Age band 
 16-24 25-34 35-44 45-54 55-64 65+ Total 
Don’t know 0 0 0 0 0 3 3 
Yes 2 6 43 97 262 694 1,104 
No 2500 3855 4409 3379 2792 20121 35156 
Total 2502 3861 4452 3476 3054 20818 36363 
 
Table 7: Respondents reporting doctor diagnosed CHD by age band 
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Table  8:  CHD prevalence by BMI category 
 
Table 6 shows the frequency of the CHD outcome by age group in the 
merged dataset. The regression model for risk factors for CHD in the “local” 
prevalence model is shown in table 9. As expected, ORs increase strikingly 
with increasing age in all models. In the prevalence predictions, using 
coefficients (not shown in these tables), this results in age-related increases 
in prevalence which closely match the crude overall prevalence. Surprisingly the 
only significant comparison for smoking is for category 3 “used to smoke 
regularly” i.e. this group is more likely to report CHD compared to the group 
“never smoked cigarettes at all”. There is a significant comparison for 
male sex. ORs, p values and confidence intervals are generally similar to 
the “Complete” models. Unfortunately, however, local synthetic estimates of 
smoking prevalence do not include categories for occasional/regular 
smokers. 
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Risk factor RRR Std 
E 
z P>z 95% 
CI. 
Age 25-34 1.00     
Age 35-44 7.13 6.89 2.03 0.04 1.07 
Age 45-54 18.44 17.4 3.08 0.01 2.89 
Age 55-64 50.09 46.7 4.2 0 8.05 
Age 65-74 121.1 112 5.17 0 19.65 
Female sex 1.00     
Male sex 2.25 0.32 5.74 0 1.71 
Never Smoker 1.00     
Used to smoke occasionally 1.03 0.32 0.13 0.9 0.56 
Used to smoke regularly 1.51 0.23 2.63 0.01 1.11 
Current Smoker 1.11 0.23 0.52 0.61 0.74 
White ethnic group 1.00     
Black/Black British e 0.83 0.35 0.43 0.66 0.36 
Asian/Asian British ethnic  1.51 0.43 1.57 0.11 0.89 
BMI <18.51 1.00     
BMI >18.50 & BMI <25 0.53 0.56 0.59 0.55 0.06 
BMI >25 & BMI <30 0.89 0.93 0.11 0.91 0.11 
BMI >30 & BMI <40 1.02 1.08 0.02 0.98 0.12 
BMI >40 0.69 0.73 0.35 0.72 0.08 
Total cholestrol:HDL ratio 0.74 0.04 4.44 0 0.65 
Diabetes; yes 0.68 0.14 -1.8 0.07 0.45 
Family History of CVC; no 0.62 0.11 -.87 0.01 0.45 
 
Table 9: Odds ratios for CHD model  
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Using  AUROC (Area Under Receiver Operating Characteristics Curve) 
Receiver‐ operating characteristic (ROC) analysis was originally developed 
during World War II to analyse classification accuracy in differentiating signal 
from noise in radar detection. Recently, the methodology has been adapted to 
several clinical areas heavily dependent on screening and diagnostic tests, in 
particular, laboratory testing, epidemiology, radiology, and bioinformatics.  
 
ROC analysis is a useful tool for evaluating the performance of diagnostic 
tests and more generally for evaluating the accuracy of a statistical model 
(e.g. logistic regression, linear discriminant analysis) that classifies subjects 
into one of two categories, diseased or non-‐ diseased. Its function as a 
simple graphical tool for displaying the accuracy of a medical diagnostic test is 
one of the most well‐ known applications of ROC curve analysis. 
 
An ROC curve is a plot of sensitivity on the y axis against specificity on the x 
axis for varying values of the threshold, t. The 45° diagonal line connecting 
(0,0) to (1,1) is the ROC curve corresponding to random chance. The ROC 
curve for the gold standard is the line connecting (0,0) to (0,1) and (0,1) to 
(1,1). Generally, ROC curves lie between these two extremes. The area under 
the ROC curve is a summary measure that essentially averages diagnostic 
accuracy across the spectrum of test values. The area under the curve (AUC) 
is an overall summary of diagnostic accuracy. AUC equals 0.5 when the ROC 
curve corresponds to random chance and 1.0 for perfect accuracy. On rare 
occasions, the estimated AUC is <0.5, indicating that the test does worse than 
chance (figure 16). 
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Figure 16:  AUROC curve 
 
AUROC’s for the model tested above were estimated using Stata10. These 
are shown in the chart below. If both sensitivity and specificity area of 
importance in a CHD model, the optimal threshold of t would be 0.75, where 
sensitivity and specificity equal 0.77  The local model, with an AUROC of 
0.8071 exceeds this level, although the complete model has even better 
performance, with an AUROC of 0.8304 
 
b) External validation 
a) Predictive validity 
Because the intended use of this model is primarily for estimation purposes, 
rather than testing a particular theory, the study sought to focus on the 
predictive accuracy of the model. This was carried out by testing number of 
predicted cases against observed events within GP case loads. 
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Testing the model 
The model was applied locally to test its applicability. Based on Health Survey 
for England data and local demographic distribution,  SMR for CHD in the 
London Borough of Brent is estimated at 112. The estimation increases the 
predicted prevalence of each Brent’s practices by 112%. 
Using .. 
SMR (CHD) = (2.402 × UV67) + 25.24, where 2.402 is the gradient, UV67 is 
the local community (Kilburn) deprivation index and 25.24 the intercept of the 
regression line.  
The  multiplication factor (mf) is identified by: 
mf = ((2.402 x 40) + 25.24)/100  (**40 is local deprivation index) >> 1.21 
To get the Llocal prevalence rate for GP Practice X, the local CHD (SMR) is 
divided by national CHD (SMR) and multiplied by the mf  ie 1.21 
           
where LocEst (local estimate) and NatEst (national estimate) 
Thus  
  =  1.31 ,  
where 121.32 (local predicted SMR); 112 (national SMR (see above ) and 
1.21 is the mf 
This shows that Practice X (in Kilburn locality)  has a higher prevalence than 
Brent (as a borough). This was calculated for each GP practice in the Kilburn 
area and for the other four localities in the borough localities (table 10). A 
comparative prevalence of CHD for Brent localities calculated through this 
model giving a predicted number of cases (table 11) 

LocEst
NatEst
 MF

121.32
112
1.21
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Table 10: CHD prevalence estimation - Kilburn location 
 
 
 
Table 11: Prevalence estimates for CHD cases for all the localities 
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To test the association between the number of registered cases and  the 
predicted numbers by the model, a series of chi-square tests ( 2 ) (table 12). 
Results show that there is a significant association between predicted and 
actual cases.  
 
The model does not necessarily represent the actual number of people who 
should be diagnosed with CHD for each practice; it is only a guide. The 
characteristics of each practice differ and needs to be considered. 
Furthermore, it does not include undiagnosed cases of CHD. In Brent, it is 
anticipated that there could be relatively large levels of undiagnosed disease 
compared to more affluent areas where people are more likely to present to 
their GP with symptoms.  
 
 CHD (cases) Chi-sq ( 2)  Sig. 
 Registered Predicted   
Kilburn 2082 1259 4.87 P<0.05 
Harness 1914 1567 3.78 P<0.05 
Wembley 1751 2315 3.81 P<0.05 
Kingsbury 1748 1459 3.35 P<0.05 
Willesden 1388 2017 4.04 P<0.05 
 
Table 12: Chi-square tests to demonstrate the association between the various 
localities (within and between). 
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A CHD funnel plot “observed vs expected” prevalence by GP practices in 
Brent (2009-10) carried out using QOF datasets for Brent is estimated to be 
3.1% in 2009 (n=295,678) gave further support to the findings. This is higher 
than the prevalence reported by Brent PCT (2.2%) (figure 17). However, this 
was not unexpected due to the data quality issues and the quirkiness of QOF. 
It does indicate that NHS Brent is under-reporting its CHD prevalence. 
 
 
   
Figure 17: Funnel chart for CHD indicating an under reporting of CHD cases for 
2010-11 
 
5.3. Estimating prevalence of co-morbidities 
This phase is concerned with estimating the prevalence of CHD within the SMI 
patient population. This is undertaken (a) calculating the prevalence of the 
concurrent disease and (b) using the Bayesian method to determine the 
probability of having this condition in the SMI group. The determination of the 
prevalence rate of CHD in the local population has been carried out in the 
precedent phase. The SMI prevalence rate is taken from the QOF’s dataset at 
practice level and as expected the level is uneven across the borough. The 
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model assumes that the SMI population via QOF represents the “true level” of 
SMI within the locality. At the time of the study, local estimate of mental illness 
is not sufficiently robust to make a more accurate estimation.  
 
The extrapolation algorithm has been explained in the methodology section.  
Using this probability equation, the prevalence rate of CHD is extrapolated from 
the SMI group using the following formulation:  
    P (CHD I SMI)= P(CHD)(PSMI) / (PSMI I CHD)  
Where   (see figure 18 for a schematic view) 
P(CHD) is the probability of CHD in the local population 
P(SMI) is the probability of SMI in the population (using QOFs) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Schema to show the relative prevalence (%) of SMI with CHD within the 
population 
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pop 
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Worked example: 
Testing the model  
In order to test the predictive value of the model five localities in Brent agreed 
to participate in this project. Five case studies below explain how the disease 
prevalence models could be used by health commissioners to factor local 
variances. 
 
Example 
a. Calculation for the presence of CHD in the SMI population within 
locality 
 Establish probability of CHD prevalence (based on the estimate model 
methodology). 
 Use SMI prevalence rate as determined by QOF.  
 Use the probability estimate (based on systematic reviews) to establish the 
likelihood of CHD with SMI. 
 Calculate the likelihood with SMI to have CHD. 
 Test against case finding. In order to find this statistic, the GPs had 
undertaken a complex search of the system to match the two conditions.   
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b.  Estimation of CHD in SMI population 
The prevalence rate of the SMI was based on QOF data (as reported by GPs). 
It should be noted that due to technical difficulties, it is not possible (to-date) to 
make regional estimation of the mentally ill. Since 2008, QOF have been used 
as a proxy measure to determine prevalence. Given that QOF is an incentive 
scheme and that many patients do not regularly go for checks up, this source 
of data is at best unreliable. Using Bayesian probability, we have  
P (CHD I SMI)= P(CHD)(PSMI) / (PSMI I CHD)  
Worked example: 
P (CHD I SMI) = P(CHD)(PSMI) / (PSMI I CHD) 
P (CHD I SMI) =  (0.04)*(0.011) / (0.23) = 0.00191 
** 0.04 (the probability of having CHD) ; 0.11 (the probability of having SMI) – 
(refer to schematic illustration above) 
Kilburn locality 
The formula was applied to the GP practices within the Kilburn locality. Using 
Bayesian probability and the predicted prevalence of CHD (adjusted value), an 
estimation of patients having SMI and CHD was calculated (table 13). Figure 19 
graphically demonstrate the difference between the number of cases derived 
from the national prediction against the local estimates numbers.  
 
Figure 19: Graph showing SMI with CHD (expected vs recorded) within 
Kilburn locality. 
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Table 13: SMI with CHD co-morbidity – Kilburn locality (Actual vs Expected) 
 
Modelled CHD prevalence and prevalence probability estimate of its co-
morbidity with SMI are shown on table 14. Results show a significant 
difference between  observed and case notes findings (table 15).  For each 
locality the modelled prevalence estimates were higher than the register 
prevalence, which would be expected if the model reflected the level of 
diagnosed plus undiagnosed CHD in the community .  
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Table 14 : Number of expected cases and observed cases of SMI with CHD. 
 
 
 
Table 15: T-tests show significance difference between expected and 
recorded cases across all localities. 
 
5.4. Summary 
There are significant differences between the numbers of patients with a 
diagnosis of CHD as recorded by their GP (based on the Quality and 
Outcomes Framework (QOF) register and those reported by the modelled 
data. One possible explanation is that the GP registers are not always up-to-
date (due to boundary movements) and patients not informing their practices. 
Such issues tend to inflate practice patient numbers which affect the 
denominator line. 
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However, this does not tell us total prevalence, only how many have been 
diagnosed. If conditions such as CHD are undiagnosed, and therefore 
unmanaged, outcomes are likely to be poor (for example, premature death or 
disability due to heart attack). However, by comparing the QOF registers with 
the modelled prevalence it is possible to estimate the level of unmet need, in 
this case, the number of patients thought to have CHD who have not been 
diagnosed. 
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6. COPD 
6.1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a chronic condition 
characterised by progressive airflow obstruction, which is not completely 
reversible. It has been called the "silent epidemic" and is the fourth leading 
cause of death in the general population (Information Centre. GP Extraction 
Service. 2010). This disease accounts for nearly 30,000 deaths each year in 
the United Kingdom (UK), corresponding to 5.7 percent of adult male and 4 
percent of adult female deaths, including a significant number of premature 
deaths (Billings et al. 2006). A meta-analysis of studies of the general 
population published between 1990 and 2004 revealed geographical 
disparities in the pattern of the disease due to socio-economic variables (Dr 
Foster Intelligence 2010). The prevalence of COPD was estimated to be 7.6% 
(95% CI 6–9.2%) independent of the defined diagnostic criteria. On the basis 
of 38 studies, the prevalence of chronic bronchitis was estimated to be 6.4% 
(95% CI 5.3–7.7%). The prevalence of emphysema (via chest radiograph) 
was estimated to be 1.8% (95% CI 1.3–2.6%) on the basis of eight studies. 
 
In addition, 1.4% of the population consults their general practitioners (GPs) 
for COPD each year. It accounts for 2% of hospital admissions and over 3 
percent of bed-days in adults, costing the NHS £800 million, and leading to 24 
million working days lost each year (Billings et al. 2006; Dr Foster Intelligence 
2010). 
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Risks factors of public health importance include; air pollution, socio-economic 
deprivation, occupational exposures and possibly ethnicity. Stopping smoking 
prevents the development of COPD, or slows its progress and reduces the 
risk of hospital admissions. Not surprisingly, smoking is the strongest 
independent predictor of COPD, with smokers having over eight times the 
odds of having COPD than the non-smokers (Soljak and Flowers 2008; Dr 
Foster Intelligence 2010).  
 
This "epidemic" seems to be even more silent among individuals with serious 
mental illness who are at particular risk of developing this condition from 
smoking, which is a modifiable risk factor. A team at Queen Mary university, 
London (Congdon 2001) reported that patients with serious mental illness had 
over three times the odds of having chronic bronchitis and over five times the 
odds of having emphysema than a matched group of national comparison 
subjects (Goddard 2005). In their study, they reported prevalence of COPD 
among those with serious mental illness in the order of 22.6% (Congdon 
2006). Consistent with previous research, they found the prevalence of current 
smoking to be 60.5%, which is more than twice the average (27.4%) and 
nationally (22.6%).  
 
COPD is measured by degree of airflow obstruction to the lungs. It is 
measured by spirometric testing, in which the patient performs a forced 
expiration into an airflow measurement device called a spirometer, and the 
volume of the air they exhale is measured over time until they can exhale no 
more. According to the current Global initiative for Chronic Obstructive Lung 
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Disease (GOLD) guidelines, COPD is diagnosed when the ratio of the air 
exhaled in one second (FEV1) to the total exhaled volume of air (FVC) is less 
than 0.7, indicating the presence of obstruction (Horgan et al. 2010). The 
severity of the disease is determined by the variance between the FEV1 
measured and that predicted by age. Mild COPD is diagnosed when FEV1 is 
greater than or equal to 80% of the predicted value. Very severe COPD is 
diagnosed when FEV1 is less than 30% of the predicted value. Conversely, a 
person’s lung age is defined as the age of the average healthy individual 
performing a similar spirometric test; someone with a low FEV1 compared 
with what is predicted for his or her actual age would have a high lung age. 
 
6.2. National prevalence model  
Developing the model 
The national prevalence model used the HSfE as a representative population-
based annual survey, which in 2001 included the assessment of respiratory 
function using spirometry, as well as comprehensive data on risk factors. The 
variables included in the model, based on their association with COPD in 
logistic regression analysis, were age group, gender, ethnicity, smoking 
prevalence, area of residence (rural, suburban or urban) and area-based 
deprivation score (McFadden et al. 2009). The 2001 data refers to 5269 men 
(98%) and 6133 women (95%) over the age of 15 years tested using 
spirometry (Morris et al. 2005. Additional data for multivariate analysis were 
available for 94.3% of the sample. COPD was defined using the British 
Thoracic Society (BTS) criteria: forced expiratory volume in 1s (FEV1) divided 
by forced vital capacity (FVC) under 0.70, and FEV1 <80% of predicted using 
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reference values from the HSfE. The approach used a complex synthetic 
estimation technique using logistic regression.  
 
The baseline odds of COPD in non-smokers was obtained directly from the 
data set (Graubard et al. 2007). The strength of association between each 
explanatory variable and COPD caseness was used to calculate the relative 
odds, which were applied to the baseline odds to derive the prevalence 
estimates for subgroups of risk factors. The main results were expressed as 
expected/predicted prevalence of COPD for population subgroups. The model 
was applied to obtain the total COPD prevalence for 354  local authorities in 
England. The prevalence in each age group, ethnic group, area of residence 
and level of deprivation and smoking status category were derived from the 
odds, using the formula: 
prevalence = odds/(1+odds).  
 
The APHO accepts that this current model is rather crude and that prevalence 
model based on a more comprehensive regression model using more 
sensitive local data would be more discriminative.   
 
 Model Validity 
The model validity was tested by comparing COPD expected prevalence 
results to an alternative model, based on a survey of prevalence studies. An 
additional test involved testing the population of Belfast, Northern Ireland 
population and compared the results with those from a population survey of 
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the same population. The results were slightly lower but within the 95% CI of 
those estimated from the survey (4.9% total prevalence in the 40-69 year olds 
compared with 6.1% (95% CIs = 4.5-7.7) in the survey. The prevalence 
estimates for the whole of England were similar to the Health Needs 
Assessment Report and to other studies that used the BTS definition of 
COPD. The significant correlation between expected prevalence and 
diagnosed COPD and COPD mortality gives reassurance of validity. 
 
Findings 
Table 16 shows the prevalence of COPD by age and gender in England. The 
overall prevalence in the population over 15 years of age was 3.1% (3.9% in 
men and 2.4% in women). For those over 45 years old, the estimated 
prevalence was 5.3% (6.8% and 3.9% in men and women respectively). This 
corresponds to over 1.3 million people in England with COPD, of whom nearly 
800,000 or 60% are men. The odds ratio calculated for gender among current 
and ex-smokers show a wide difference between men and women smoking 
history (table 17). The assumption that ethnicity is not associated with being a 
case of COPD, i.e. that all population has the same risk as the white 
population did not change the total national prevalence estimates 
considerably (1,297 thousand in 15 year-olds and over and 1,065 thousand 
over 45s under this assumption). When we considered the risk of COPD in 
under 45s as equal to the average baseline risk in this age group (in non- 
smokers), the total number of cases estimated was reduced by 60,800, 
resulting in an overall prevalence of 1.25 million or 3% (3.8% in men and 
2.3% in women) (table 18).  
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Age 
group 
Men  
number (%)  
Women 
number (%) 
Both sexes  
number (%) 
15 -44 137,530 
(1.30) 
93,450 (0.89) 230,980 
(1.10) 
45-54 75,720 (2.38) 64,840 (2.00) 140,560 
(2.19) 
55-64 198,400 
(6.90) 
122,440 
(4.11) 
320,840 
(5.48) 
65-74 199,840 
(10.03) 
105,704 
(4.81) 
305,580 
(7.29) 
75+ 172,700 
(11.65) 
132,400 
(5.55) 
305,100 
(7.89) 
Total 784,190 
(3.89) 
518,870 
(2.41) 
1,303,060 
(3.15) 
Table 16: Number and proportion of people estimated to have COPD by age group   
and gender in England (estimates for 2009). 
Values in brackets correspond to mean values in extreme quintiles of deprivation 
score ore approximately the 10th and 90th percentiles of the prevalence distribution 
 
 
Variables Odds ratio (95%) 
Smoking Status Men Women 
Never 1 1 
Former 3.63 (2.54 – 5.21) 1.70 (1.07 – 2.64) 
Current 3.81 (2.64- 5.52) 2.3 (2.23 – 5.14) 
   Table 17: Risk factors for COPD and selection of variables for COPD model 
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Age (p<0.01)  
<35 0.56 (0.13 – 1.65) 0.32 (0.11 – 1.2) 
35-54 2.05 (1.33 – 4.50) 1.65 (1.3 – 3.6) 
55-64 6.91 (4.02-11.89) 1.9 (3.2 – 7.9) 
65+ 10.40 (6.08 – 
17.80) 
8.68 (5.2 – 
14.88) 
Regional locality 
Urban  1 1 
Suburban 0.70 (0.50 – 0.97) 0.45 (0.3 – 0.87 
Rural 0.58 (0.39 – 0.86) 0.34 (0.12 – 
0.86) 
           
         Table 18:  Risk factor COPD – Age and locality 
The latter estimates assume that all cases of airflow obstruction in the 
younger age groups are due to other diagnoses than COPD, such as 
asthma. Table 18 shows the estimated prevalence of COPD in urban, 
suburban and rural England, based on the national population distribution and 
smoking prevalence. The values in brackets show the estimated average 
prevalence for areas in the lower and highest quintiles of deprivation. The 
average prevalence in over 35s varies 4-fold, with the highest values in men in 
deprived urban areas, and the lowest in women in wealthy rural areas. 
When the effect of ethnicity is also considered, the variation in prevalence 
reaches 7-fold, from 1.7% in Asian women from rural areas in the lower 
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quintile of deprivation to 12.5% in black men from urban areas in the upper 
quintile of deprivation. 
 
Model validation 
a. Predictive Validity 
The model validity was tested by comparing COPD expected prevalence 
results to an alternative model, based on a survey of prevalence studies. An 
additional test involved testing the population of another West London locality 
population and compared the results with those from a population survey of a 
similar locality from another borough of London. Using a desktop assessment 
approach, the results were slightly lower but within the 95% CI of those 
estimated from the survey (4.9% total prevalence in the 40-69 year olds 
compared with 6.1% (95% CIs = 4.5-7.7) in the survey. The prevalence 
estimates for the sector were similar to the Health Needs Assessment report 
and to other studies that used the BTS definition of COPD. The significant 
correlation between expected prevalence and diagnosed COPD and COPD 
mortality gives reassurance of validity. The significant correlations between 
expected prevalence and both diagnosed COPD and COPD mortality, gives 
us further reassurance of validity. 
 
b. Density location 
Demand for health care provision in the community is assumed to be evenly 
distributed according to needs and demand. The location of  health care 
services depends largely on the local health care system mediated by needs 
to have rapid  access  services, historical factors and so on. However, access 
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to primary care is a significant part of that process and where there is a high 
density population of a particular condition in a given location this brings 
enormous pressure on the system.   
 
The possibility that there may be a high expected risk in some small areas and 
as part of the validity of the model proposed, the study looked at the density 
issue for COPD. This is equally applicable to any long term condition. 
 
The use of multinomial logistic regression which uses odd ratios based on 
age, sex, ethnicity, rurality, smoking and deprivation scores logistic use of 
prevalence measures for prevalence estimates is generally accepted and 
recommended by the Association of Public Health Observatories (APHO).  
 
From the results in this study suggested that the ratio of recorded to expected 
prevalence was not synchronous. Whist this was not unexpected and 
considering that has a problem of health inequality within the borough, this 
may suggest that there is a north-south problem. The south (with its high 
deprived areas) will have a higher recorded prevalence and there may be a 
problem of under-diagnosis. This may be also helped by the fact that there is 
a high mobile population in this area.  
 
Using the same parameters for COPD prevalence estimates e.g. age, gender 
and post-code, the odds ratios for each person was calculated. As odds ratio 
are multiplicative, an overall odds ratio for each person is derived as the 
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product of the individual odds ratios. In general, if a patient has a set of n odds 
ratios for a particular condition, the patient’s odds ratio is expressed as 
 
where 0p = Odds ratio of population n  
The overall prevalence rate P was calculated as the expected total number of 
COPD patients (from the model) derived by the number of residents in the age 
range. 
The calculated risk population for an area C(a) was defined as:  
 
The expected number of COPD patients [E(a)] in an area C(a) was calculated 
as: 
 
The risk per registered person in an area [R(a)] was calculated as: 
 
    where m is the total number of residents 
The results were mapped at postcode level in the GIS System (software used 
in public health) using boundary files to plot COPD risk density across the 
borough. 
 
The map (figure 20) shows the risk density at post code level (the sum of the 
odds ratios for all registered patients living in the post code boundary). The 
shading can be interpreted that the chance of finding a COPD case in a post 
code with the darkest colour is more than 20 times that of finding a COPD 

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patient in a postcode with the lightest shading, which may suggest an efficient 
strategy for a targeted approach by the health authority.   
 
Discrepancies between modelled estimates at practice level and other 
sources of data such as QOF disease registers may be due to local variations 
not captured by the model and cannot be solely attributed to weaknesses in 
QOF data. For practices with populations that significantly differ from a 
‘typical’ population (e.g. large black or ethnic minority population that has a 
very different smoking pattern to the local average) the assumptions of the 
model may not apply and discrepancies may occur. 
 
While some quite wide areas have low risk density and others are overall high, 
in many areas postcodes having a high risk of COPD are very close to post 
codes of low risk. Also, the pattern of risk does not always reflect the overall 
deprivation in the borough. For example, patients resident in parts of the north 
of the borough, which is very affluent, have a relatively high risk of COPD, 
whilst the reverse is also true of the south. 
 
The local area model predicts individual numbers of cases in an area, a 
method that becomes less reliable as the size of the population decreases. It 
would be inappropriate to use it on a population  as small as one post code. 
By aggregating the individual risks within an area and expressing the result as 
the relative probability of finding a case in the area, rather than predicting 
actual number of cases, case findings strategies based on looking where the 
risks are the highest, can be formulated. 
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The model described here is open to investigation and question and the 
results can be aggregated to any defined geographical area. Output as post 
code level enables GPs to identify where in their catchment areas they have 
the greatest likelihood of finding a previously undiagnosed patient with COPD, 
especially where their catchments have highly varied COPD densities. 
 
 
 
 
 
 
 
 
 
 
 
Figure  (20) – Map showing the density location of COPD cases in Brent. 
 
c. Expected versus Observed  
The model was evaluated by comparing COPD expected prevalence results to 
an alternative model, based on a survey of prevalence studies. 
For the predictive validity, GP-diagnosed and registered prevalence of COPD, 
obtained from the QOF were used. QOF COPD prevalence estimates are 
based on populations registered with GPs. The study derived residence-based 
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registered prevalence estimates for LAs using a look-up table—a pooled 
extract of England GP registers—from the National Strategic Tracing Service 
(NSTS). These were applied to the GP registered population in NHS Brent. 
HES (hospital admission data) from one calendar year was used, patients 
were counted once in each year they were admitted rather than once over the 
three year period.  
 
The overall prevalence in the population over 15 years of age was estimated 
at 3.1% (3.9% in men and 2.4% in women). For those over 45 years old, the 
estimated prevalence was 5.3% (6.8% and 3.9% in men and women 
respectively). The gender difference may be related to their longer history and 
intensity of smoking, as compared to women. The effects of ethnicity and area 
of residence are more evident in women, among whom deprivation score is 
not apparently relevant, after other variables are considered. Urban 
environment increases the risk of COPD, possibly through higher air pollution 
levels.  
 
Social deprivation may increase the risk of COPD through complex 
mechanisms in addition to the higher prevalence of smoking. This may include 
different smoking habits (the model does not take into account duration and 
intensity of smoking as such information is not readily available) and a higher 
likelihood of exposure to other risk factors, which are not easily measured, 
such as passive exposure to tobacco smoking, history of respiratory infections 
and less access to health services and information. Ethnic differences in 
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susceptibility are less clear and less well understood, but might involve a 
combination of behavioural, environmental and possibly genetic factors.  
 
The assumption that ethnicity is not associated with being a case of COPD, 
i.e. that all population has the same risk as the white population did not 
change the total national prevalence estimates considerably (1,297 thousand 
in 15 year-olds and over and 1,065 thousand over 45s under this assumption).  
 
A key advantage of the COPD model is that it is based on high quality data 
from a large representative sample of the population and uses standard and 
specific diagnostic criteria for COPD, which is based on lung function rather 
than symptoms. Response rates were high in the survey with the achieved 
samples matching the target populations closely. Prevalence estimates are 
based on the strength of association between key risk factors for COPD, 
including the effects of ethnicity, area of residence and deprivation, which 
were shown to be independent risk factors for COPD in the HSfE survey. This 
represents a significant advantage in relation to previous COPD prevalence 
models, (Rushton 2005; Barnes 1999) which were based only on smoking 
status, age and gender (also used in the COPD model) of mostly white 
populations outside the United Kingdom. The distribution patterns of COPD  
cases is shown below (figure 21).It would be noted that there is a significant 
number of under reporting of COPD. 
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Figure 21: Funnel plot showing under reporting of COPD  prevalence in Brent. 
 
6.3.  Developing the local model 
Phase I 
As discussed, the national model becomes less reliable as the size of the 
population decreases. An effective local model (at GP level) has to consider 
the variances and nature of local data.  
 
The three-stage process as described previously for CHD (page 100) is 
applied  to the prevalence estimate of COPD. The predictions made concern 
the five (5) localities of the borough focussing on GP practice populations. As 
with CHD modelling framework, the approach used the national datasets to 
make a crude estimate of Brent COPD SMR. The model assumes that SMR is 
correlated with prevalence rate. 
 
Taking into consideration the various risk factors within nd between local 
authorities,  SMR for Brent  was estimated to be 120. So the model would 
predict that GP practices will have an increased predicted SMR by 20%. The 
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model makes the assumption that areas with higher COPD mortality rates 
have comparably higher prevalence of COPD.  
 
Using a linear regression model in the form of Y= mx ± c, the prevalence 
estimate for  locality (a) is calculated sequentially. First, the local SMR 
(adjusted) is determined by  COPD SMR = (4.389 × UV67) – 26.04       
where 4.389 is the gradient, UV67 the deprivation index (for Brent) and 26.04 
is the intercept.  This is fully explained in the CHD section.  
 
The second stage gives the multiplication factor using an UVF score for a 
named locality. To get the adjusted prevalence measure, the adjusted local 
SMR is divided by the national SMR estimation for Brent.  
 
Model assumptions 
The model assumptions include: 
 The real prevalence of COPD in non-smokers under 35 years of age (baseline 
prevalence) is the same as the prevalence in non-smokers of the same age 
group and gender in the 2001 HSfE population. 
 The ratio of odds and prevalence of COPD in the various age groups 
compared to the baseline group is the same as in the HSfE for each gender, 
smoking status and other risk factors. The risks in those falling within each of 
the risk categories are uniform. 
 The model outputs are the prevalence of COPD for the relevant geographic 
area as defined by the user. In this instance, we are focusing on the Borough 
of Brent through its 5 localities based on the estimated population (2009-10). 
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6.4. APPLYING THE MODEL  
Applying the prevalence estimate model to 1 local GP practice datasets (from 
Kilburn) we have: 
 
Worked example 
COPD SMR  
Based on linear regression (fitted factors) 
120 
Estimated prevalence All GP practices are expected to have an 
excess of 20% above baseline 
UV67 for practice X * derived from 2001 Census 35 
Adjusted COPD SMR local Y = mx c 
=  (4.389 x UV67) -26.04 
 
= 127.6 
Multiplication factor =((4.389 x 127.6)-26.04))/100 = 1.3 
Adjusted prevalence rate 
=  mf 
= (127.6/120) x 1.3 
= 1.4 
 
This shows that  GP practice X within the Kilburn locality  had a higher 
prevalence than borough estimated by national formula. The formula was 
applied to each GP practice in Kilburn (table 19) and extended to the localities 
in the borough. A summary of all localities is summarised below (table 20). 
Analysis of the data show that the difference between the two sets showing a 
deficit of 83 cases for Kilburn and 313 for the whole borough. As the NHS is 
based on programme-based budgeting this would lead to significant reduction 
in fundings for this case-mix. 
 



Loc_ adj _ SMR
Nat _est _ SMR
x
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Practice Population 
Prev 
prob Adj_est Nat_est 
1 1844 0.013 24 22 
2 2398 0.017 41 38 
3 2568 0.016 41 38 
4 2838 0.01 28 26 
5 2914 0.013 38 35 
6 3069 0.011 34 31 
7 3079 0.013 40 37 
8 3124 0.013 41 37 
9 7155 0.017 72 62 
10 7409 0.013 96 89 
11 13521 0.013 126 112 
12 14367 0.03 188 154 
13 5466 0.023 126 116 
14 6020 0.013 78 72 
15 6811 0.015 102 94 
   1074 991 
     
Under estimation of cases 83   
     
Table 19   : Adjusted COPD prevalence estimation using the local modelling 
framework against national estimates for Kilburn GP practices. 
 
 
Locality Population Adj_est Nat_est 
Harness 32014 416 384 
Wembley 72171 938 866 
Kingsbury 70153 912 842 
Willesden  55824 726 670 
Kilburn 82583 1074 991 
  4066 3753 
    
Under estimation of cases 313  
Table 20   : Adjusted prevalence estimation for COPD in all localities (local versus 
national estimates) 
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Figure 22:  COPD predicted prevalence of local adjusted estimates against 
national data within the  localities.  
 
6.5. Prevalence estimate of SMI population with COPD at 
local levels 
There is a good body of evidence that there is a high risk of COPD among the 
SMI population (Osborne et al 2007). However, as with CHD, there is no 
national template for estimating this co-morbidity within the SMI population. 
Using the Bayesian probability estimation rationale, it is possible to derive this 
estimate (see chapter 4). Applying it to the Kilburn locality as an example, a 
step-wise calculation is shown on how this derivation is determined (figure 
23).  
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Figure 23.  A schema to illustrate the relationship between COPD and SMI in 
a given population.  
 
 
 
 
 
 
 
SMI+COPD (COPD within SMI – 22.6%) 
COPD (Prevalence estimate 3.5%%)    
 
 
Applying to local setting 
Calculation for the presence of COPD in the SMI population within the locality 
was undertaken by the following process: 
1. Establish probability of COPD prevalence (based on the estimate 
model methodology). 
2. Use SMI prevalence rate as determined by QOF.  
3. Use the probability estimate (based on systematic reviews) to 
establish the likelihood of COPD with SMI. 
4. Calculate the likelihood with SMI to have COPD. 
5. Test against case finding. In order to find this statistic, the GPs had 
undertaken a complex search of the system to match the two 
conditions.   
SMI (1.1%) 
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Estimation of COPD in SMI population 
The prevalence rate of the SMI was based on QOF data (as reported by GPs) 
P (COPD I SMI)= P(COPD)(PSMI) / (PSMI I COPD)  
Where  
 P(COPD I SMI) is the probability of having COPD given that one has SMI 
 P(COPD) is the probability of COPD in the local population 
 P(SMI) is the probability of SMI in the population (using QOFs) 
Worked example: 
P (COPD I SMI) = P(COPD)(PSMI) / (PSMI I COPD) 
P (COPD I SMI) =  (0.02)*(0.11) / (0.23) = 0.00973 
 
Applying the formula to the Kilburn practices, the number of cases of SMI with 
COPD were calculated (table 21). Case findings showed  the actual numbers 
were less than the predicted numbers. It is possible that (a) the number of 
actual cases in practices are under reported (b) prediction is “inaccurate” or a 
combination of both.  Figure 24 (a-e) show the expected versus predicted 
numbers in the district. 
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Table 21: SMI with COPD – Expected vs Registered 
 
 
Fig. 24 (a)      Fig. 24 (b) 
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Fig. 24 (e) 
Figure 24 (a-e): Graphical representation of SMI with COPD in five localities 
 
Table 22 T-tests showed difference between the case findings and the 
predicted prevalence (p<0.0013, df =14) for the Kilburn locality. Tests  for the 
other localities are summarised in tables 23 and 24 . 
  
        
       
 
 
 
 
Table 22: t-test for SMI and COPD (Kilburn) 
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Willesden locality - SMI with 
COPD (observed vs expected)  
MH +
COPD
(observed
)
Kilburn locality 
t-test: Paired 2 sample for means 
 Register 
count 
Predicted 
Mean 89.73 128 
Variance 1153.35 2355.71 
observations 15 15 
df 14  
t (2 tailed) 7.61E-08  
t critical 
value 
2.14  
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Table 23:  COPD predicted prevalence against observed cases 
within the  localities.  
 
 
H
a
rn
e
s
s
 
W
e
m
b
le
y
 
W
ille
s
d
e
n
 
K
in
g
s
b
u
ry
 
Mean 104.47 93.14             112.33 102.44 
Variance 2692.84 881.65 3183.77 987.78 
Observations 15 10 10 13 
df 14 9 9 12 
t stat 7.785 9.86 6.3 5.67 
P (2 tailed) 1.8E-06 4.3E-06 0.00004 0.003 
 
Table 24 T-tests – Showing the difference within and between localities. For 
all localities (t-test, df 9-12; p< 0.01) 
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6.6. Multiple co-morbidity 
Multiple co-morbidity is the co-occurrence of a  number of diseases within the 
existence of another disorder.  This study sought to estimate the prevalence of 
two physical disorders namely CHD and COPD within the SMI population at a 
local level. The prevalence estimation was based on a one-year incidence, 
based on data available for the last full year.  After the estimated prevalence 
of the physical disorders was calculated, the model was then adjusted to 
calculate the expected number of SMI within that estimated prevalence. In 
order to estimate the prevalence of SMI with condition (X), Bayesian statistics 
were applied in the form:  
Estimation of population size = ((P COPD local Population) X P SMI (SMI in 
local Population)), where P is the probability. 
 
The generic formulation was used to estimate prevalence values for any 
population for which appropriate demographic information is available. As 
such, the model could be adapted to calculate any co morbid chronic 
disorders provided we had the relative risk ratios.  
 
Pathway for determining prevalence estimate for SMI. 
The CHD prevalence in Brent is estimated to be 7.8% in 2009 (n=295,678). 
This is higher than the prevalence reported by Brent PCT (2.2%). However, 
this was not unexpected due to the data quality issues and the quirkiness of 
QOF. 
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Having established the prevalence estimate for the two conditions CHD and 
COPD within the SMI group for the locality, the next step was to calculate the 
likelihood of the prevalence of these conditions simultaneously. The 
estimation of concurrent co-morbidity was carried out through probability 
modelling (using bayesian statistics). 
 
A.  The probability of having two conditions is a product of the separate 
prevalence, namely 
P(A,B) =  (P(a))(P(b)) 
P (CHD,COPD) = { (Probability (CHD))*{Probability (COPD)} 
Alternatively,  
B.   The probability of having none of these conditions 
P(0)  = (1-P(a))(1-P(b)) 
C. To calculate the probability of having one of the diseases, namely 
 Having A and not B  
 Having B but not A  
P(1)  = {(Pa)(1-P(b))}{(Pb)(1-P(a))}  
   The probability of having two (2) diseases, 
P(2)  = {(Pa)(1-P(b))}{(Pb)(1-P(a))}  
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Locality -  Kilburn 
Using the above formula, the predicted number of cases of the SMI 
population that suffer from CHD and COPD for Kilburn is 52. (table 
25).  
 
Table 25: Estimated prevalence probability (and numbers) for SMI with 
CHD and COPD for the Kilburn locality. 
  
 
 
161 
The calculations were extended to the rest of the localities (table 
26). The total number expected to have these multi co-morbidities 
is 206.  
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Harness 1.06 0.0048 0.0274 0.00132 42 
Wembley 0.84 0.02 0.02 0.003 35 
Kingsbury 1 0.028 0.027 0.00143 43 
Willesden 0.92 0.03 0.04 0.001 34 
 
Table 26 – Estimation of SMI with CHD and COPD in the other localities. 
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7. Discussion 
 
The aim of the study was to develop a model for estimating the prevalence of 
multiple physical co-morbidity within the SMI group at local area level. As 
direct estimation is not possible, this was carried out in stages. The first stage 
was to estimate the prevalence of the physical disorders within the 
geographical locality followed by a synthetic estimation of these conditions 
within the local SMI population (based on QOF registers). The estimation was 
made using Bayesian methodology. This discussion focuses on the extent to 
which the research undertaken can answer the research questions originally 
posed in 2009 These are: 
i. How do estimations of chronic disease for local areas compare in terms of 
their validity? 
ii. What is the best methodology for estimating the prevalence of multiple co-
morbidity within the SMI population? 
iii. How useful are these prevalence models compared with case findings? Can 
they be used instead of case registers? 
iv. What are the implications of the findings for public mental health planning 
policy? 
v. What are the potential impacts of this study? 
 
These questions are obviously closely related. The answer depends on the 
criteria which should be used to compare prevalence modelling 
methodologies, their “fitness for purpose” in providing reasonably robust local, 
small population/area estimates which can be used by PCTs/ GP practices 
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and in future GP commissioning groups and LA public health departments. It 
is important to distinguish between decision-analysis “cost-effectiveness” 
models and population-based “surveillance” models. A surveillance or 
prevalence model differs from decision-analysis models in that rather than 
representing a hypothetical cohort, it models the population, that is, a 
collection of birth cohorts, over a specified period of time. 
 
7.1. Validity of prevalence estimation of chronic disorders at 
local level 
In order to consider this question, we need to reflect on the purpose of a 
methodology for prevalence modelling at local levels. National prevalence 
estimates are designed to provide rough but reliable estimates at a macro 
level and estimates for a particular geographical area described as more 
"direct" are more preferable for local commissioning. National prevalence 
surveys are not designed to produce "direct" estimates for counties as the 
sample sizes are too small, and hence, the estimates are not reliable or stable 
(Department of Health 2001). 
 
A geographical area is regarded as "small" if the area sample is insufficient to 
yield direct estimates with adequate precision and reliability. In order to make 
estimates for small areas with adequate levels of precision, it is standard to 
use indirect estimates that utilize information from outside areas with similar 
characteristics to the area of interest. To that effect, this study used a 
statistical model to obtain indirect estimates for geographical areas considered 
to be "small".  The use of such a model decreases the variability of the small 
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area estimate, but if some of the characteristics which the model relies upon 
e.g. QOF, are not stable, it may introduce bias into the estimates. For 
example, the movement of patients within and between localities (which could 
be as much as 30%) could be significant in prevalence calculations.  
 
The statistical methodology proposed could be viewed as a proof of concept. 
This model-based estimate is intended to be an improvement on national 
estimates, if the models used are appropriate. However, that may not mean 
that the model-based estimates are close to the true values for every area.  
 
The International Society for Pharmaco-economics and Outcomes Research 
(ISPOR) has published principles of good practice for decision analytic 
modelling in health-care evaluation (Anselin 2006). This is a comprehensive 
framework for validating population-based chronic disease simulation models 
and has been used in a review of published model validation guidelines 
(Leung et al. 2000). Based on the review, a set of recommendations were 
formulated for gathering evidence of model credibility. Evidence of model 
credibility derives from examining: 
a. Model development process 
i. Is it conceptually robust? Are the theories and assumptions underlying the 
conceptual model correct and are the model’s structure, logic and 
mathematical and causal relationships reasonable for the intended purpose of 
the exercise? 
ii. Are the parameters of variables justified? Are relationships between the 
variables specified correctly and do they come from both theory and empirical 
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data? Evidence generally comes from examining the process used to derive a 
value for the parameter (primary source, method of derivation) and 
comparisons with data from other sources. 
  
b. Evidence from examining model performance   
1. Has it face validity?  Is it plausible? Do we have evidence involving 
comparisons of output with expectations? 
2. Internal consistency: assessed by considering functional and logical 
relationships between different output variables. 
3. Between-model comparisons: “modellers should co-operate in comparing 
results and articulating the reasons for discrepancies”. This could be achieved 
by comparing the APHO prevalence models with, for example, Congdon’s 
prevalence models (SB P 2004). 
4. Can the data be used in comparison with external data? Available data should 
be used in model development and data should not be withheld for the 
purpose of external validation.  
 
Using this approach as a broad framework for our validity assessment, the 
study has to satisfy the major components.  We can start by stating that the 
use of simulation models to provide local estimates is a new trend. Such 
approaches have until now focused on model construction - the iterative 
process of scope selection, hypothesis generation, causal diagramming, 
quantification, and reliability testing in large populations, rather than   
combining simulation models with small area co-variates. However, it is 
feasible to do this and it will certainly be done in the future. 
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It is likely, but by no means certain, that more sophisticated methods of model 
development provide better predictions, but a notable feature of the literature 
is that very little comparative validation has been carried out and most have 
compared similar methods.  
 
The use of Discrete Event Stimulation (DES) technique as opposed to  
Markov chains may be more popular with decision makers as it gives superior 
face validity. Furthermore, this model automatically provided a probabilistic 
sensitivity analysis, which is cumbersome to perform with a Markov model. 
DES models also allow inclusion of more variables without aggregation, which 
may improve model precision. However, the differences were not significant in 
terms of the actual predictions. Moreover, these comparisons are only one 
aspect of model validation. The use of the more recent technique of GWR has 
yet to be fully considered.  
 
For example, two or more modelling methodologies could be compared to a 
validation gold standard of local prevalence. This data is difficult to obtain; one 
option would be using data from populations in which extensive case-finding 
has apparently detected nearly all cases of disease. NHS Health Checks data 
might serve this purpose, once a large enough proportion of the population 
has been screened. Unfortunately, although the present national policy 
excludes cases currently on QOF registers, it does not specify that questions 
about patient-reported doctor-diagnosed disease be asked to ensure that 
cases not on practice registers are found. 
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An important step of the validation framework involves determining the 
minimum sample size needed to achieve sufficient correspondence against a 
gold standard. The gold standard serves as a benchmark judged to be the 
best available direct estimate for the small area domain (Audit Commission 
2009). The IHME gold standard is to use sufficiently large sample sizes, which 
can be obtained by choosing small domains with large sample sizes in a 
single survey year, pooling multiple survey years, or increasing domain size. 
They used as their gold standard the direct, age-standardized, sex-specific 
estimates for counties that had more than 900 observations in both periods 
1996-2004 and 2000-2008 (the validation sets). 
 
Such a validation environment allows the selection of a modelling strategy that 
optimally mixes the three approaches of pooling data across time, harnessing 
spatial patterns in the distribution of the outcome of interest and adjusting for 
estimates for local area characteristics. This approach is analogous to that 
used in the development of risk predictions models, where derivation and 
validation cohorts are often initially derived from the same population: for 
example, in the case of QRISK2 derivation, random sampling was used to 
assign practices to the derivation or validation cohort and then their population 
data was used. However, validation should still be carried out in other 
populations if possible. 
 
Finally, two comments on the statistical analyses used in the study. The first 
concerns the procedures used in the study. These were drawn from extensive 
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work, mostly outside  the mental health field. However, this work remains 
experimental and vulnerable to several methodological limitations (Kisely et al. 
2009). The associated inferential techniques have not been fully validated and 
not incorporated into available statistical packages. Secondly, is the use of 
Bayesian methodology. This is at the root of local estimation paradigm. The 
advantage of using the Bayesian iterative calculations is that it gives a 
practical usefulness for commissioners compared to classical analysis 
(Nasrallah et al. 2006). Bayesian modelling provides an ease of obtaining 
predictions and the possible extension to incorporate other relevant 
information or beliefs. However, it does have some disadvantages in that it 
requires specialist software and the difficulties that are sometimes 
encountered in achieving Markov chain Monte Carlo convergence (Burns and 
Cohen 1998). 
 
In summary, although the model has a working validity, the use of small-area 
analysis techniques for sub-population (multiple co-morbidity within a specific 
group of illnesses e.g. SMI) has not been fully validated and is an area for 
future research. The model developed in this study needs to be tested with 
data from parallel yet independent research. There are gaps in establishing 
model credibility e.g. credible interval estimates; the majority of the above 
criteria have been satisfied. 
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7.2. What is the best methodology for estimating the 
prevalence of co-morbidity within the SMI population? 
The study focus was on establishing the prevalence of specific disorders 
within the SMI group and in that context looked at individual conditions 
sequentially e.g. co-existence of CHD, followed by COPD etc. The rationale 
for this approach was determined by availability of data and other practical 
constraints such as the extraction tool that was available for GP systems i.e. 
EMIS (Information centre for Health and Social care 2011). The methodology 
used was both appropriate and justified. 
 
However, patients with SMI have multiple- pathology and as such some 
methodological choices and different analytical strategies have to be 
considered (Wang et al. 2002). Of importance is to consider if co-morbidity or 
multi-morbidity should be used as the dependent variable or an independent 
variable. Hudson (2009) points out, for example, the proportion of subjects in 
the over 65 suffering from two or more disorders from a list of four 
(hypertension, emphysema, psoriasis and osteoporosis) was 2.8%. When 
glaucoma, diabetes and gout were added to this selection of diseases, the 
prevalence of multi-morbidity in the same population increased to 8.9%. The 
same rationale is applicable to the SMI populations. 
 
A key decision to be made before the start of future studies is whether or not 
to account for known patho--physiological relationships between diseases. For 
example, do diabetes mellitus, retinopathy and a diabetic foot in one person 
count as one or as three diseases? The research question should be the main 
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guide in decision making. For example, in a study on the complications of 
diabetes, one is probably interested in the whole spectrum of co-occurring 
diseases, whereas in other studies it might be more interesting to gain insight 
into various disease entities. An obvious difficulty when taking patho-
physiological relations into account is that present knowledge of those 
relations is still limited. 
 
Another important point to consider when analysing co-morbidity is the 
influence of effect modifying or confounding variables. For example, as age is 
a strong determinant of many diseases, it is generally important to take this 
variable into consideration when analysing the co-occurrence of diseases. The 
model did not take this into consideration. If these influences are not taken 
into account or at least described, this can lead to unrealistic or irrelevant 
outcomes. An important conceptual consideration in this context is whether 
the co-variable is an element of the causal chain to be or just a confounder 
without relevance to the causal chain of primary interest (when adjustment is 
useful). Evaluation of effect modification may be helpful to identify different co-
occurrence patterns in the sub-groups. 
 
A suggestion is that when analysing combinations of three or more co- 
occurring diseases, stratified analyses are a good option as long as the study 
population is sufficiently large, giving the opportunity to account for the main 
co-variables. Another option is to carry out a stepwise multiple logistic 
regression analysis, evaluating the determinants of the presence of a disease 
additional to a specific disease or combination of diseases. 
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7.3. How useful are these prevalence models compared to 
case findings? Can they be used instead of case registers?  
 
The regionally observed prevalence data, to which the national estimates are 
compared, may not be representative of the national situation (Halliwell et al. 
2007). Prevalence variations show distinct geographic ‘contextual’ effects that 
are differentiated between ethnic and other demographic categories (Barnard 
et al. 1999). This study identified similar findings to that of other studies which 
found that major geographic variations  do not seem to be explained by area 
demography alone.  
 
As an example of how local estimates can be generated and used, a local 
Canadian public health agency (population 250,000) recently published a 
“textbook” for local disease incidence modelling. Age standardized incidence 
ratios for cancer and the prevalence of Census co-variates were calculated for 
each of 331 dissemination areas. The standardized incidence ratios (SIRs) for 
cancer varied dramatically across these areas. Employing Bayesian 
hierarchical models, areas in the urban core were found to have significantly 
higher SIRs for male lung cancer than the remainder; and neighbourhoods in 
some urban and surrounding rural areas exhibited significantly higher SIRs for 
prostate cancer (Druss 2007). After adjustment for age and spatial 
dependence, average household income attenuated much of the spatial 
pattern of lung cancer, but not for prostate cancer (Goldman et al. 1981). 
 
Because both models are based on the assumption that incidence and 
prevalence are in a steady state, the occurrence of trends in incidence or 
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mortality would lead to discrepancies between the model estimates and the 
observations. Prevalence is a stock variable, comprising all past incident 
cases that are still alive. It is therefore dependent on incidence and case-
fatality from the past as well as the present. 
 
In the SMI group, where multiple medical problems are frequent and 
pathological examinations are performed relatively infrequently, 
misclassification of some disorders like COPD may lead to the over 
registration for the more frequent types of COPD (National Institute for Health 
and Clinical Excellence 2009). This incompleteness seems to be concentrated 
in geographical areas often proximal to acute mental health institutions. This 
would cause distorted prevalence estimates and could contribute to the wrong 
conclusion of our prevalence estimates. 
 
The under registration of incidence may also help to explain the impossible 
negative prevalence calculated for physical illnesses. Under registration 
cannot, however, explain the finding that the prevalence estimates are 
generally higher than the observations for the other age groups.  
 
However, this present study demonstrates the feasibility and utility of local 
datasets to obtain more accurate estimations. This is what the Informing 
Healthier Choices project aimed to do with the APHO/ICL prevalence models. 
Further work is needed to evaluate the impact of using case registers routinely 
at local level.  
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7.4.  Impact of the study 
The findings from this study provide some useful context for health care 
planning. They support the general view that data surrounding co-morbidity in 
general and specifically among the serious mentally ill is not readily being 
addressed by mainstream public health departments in the UK. Information 
available at local levels are of limited use to the commissioners.  
 
Results show that prevalence estimates of multi-morbidity vary widely among 
the localities. The largest difference was observed in geographical areas with 
high deprivation. It could be argued that differences of this magnitude are 
unlikely to reflect real differences between populations and more likely to be 
due to biases in methods. In addition to their differing geographic settings, 
prevalence studies differed in recruitment method and sample size, data 
collection and operational definition of multi-morbidity, including the number of 
conditions and the conditions selected. All of these factors may affect 
prevalence estimates. 
 
Some of the implications are serious in that we are aware that people with 
serious mental illness die, on average, 25 years earlier than the general 
population. This has been demonstrated in a number of recent studies 
(Information Centre for Health and Social Care 2009). While suicide accounts 
for about 30% of excess mortality, about 60% of premature deaths are due to 
“natural causes”, such as cardiovascular and pulmonary disease. 
Cardiovascular mortality in schizophrenia has increased from 1976 to 1995, 
with the greatest increase in Standardized Mortality Ratios in men from 1991 
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to 1995 (Information Centre for Health and social Care 2009). This is a serious 
public health problem that is poorly recognised and rarely addressed. Many of 
the risk factors for these “natural causes” of death, such as smoking, obesity 
and inadequate medical care, are modifiable. Increased attention from policy 
makers as well as persons served, family members and the mental health and 
general health care system is needed (Virgo et al. Journal of Mental Health 
2010, volume 14).  
 
The estimation of medical co-morbidities within the SMI group is a real 
challenge. As indicated, the presence of these co-morbidities is a variable 
constant as it depends on various socio-economic factors. The application of a 
simple adjustment tool has a potential pragmatic value. It allows us to have a 
broad measure of the underlying epidemiological trends. 
 
7.5.  What this study adds 
Work by Phelan et al (2000) has shown that the chronically mentally ill have 
serious risks of developing physical health problems. The current 
commissioning model is based on a single disease framework and does not 
address issues of co-morbidity. Part of the problem is that there is lack of 
relevant information needed for policy planning. Within public health, not much 
work has been conducted in prevalence estimates for multiple comorbidities .  
 
The present study sought to address the complexity of estimating the 
prevalence of concurrent medical disorders (using CHD and COPD as 
exemplars) within the serious mentally ill population in small population 
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samples. To-date very few studies have investigated estimation of prevalence 
rates linking these diseases together for commissioning intentions.  
 
The part of the problems lie in that national prevalence models in the UK use 
a wide number of population characteristics such as socio-economic 
parameters which  are derived outdated information sources e.g. from 10-
yearly population censuses. More pertinent, is that these national data are out 
of date and very often not relevant to local settings. Allowance are not made 
for the effect of deprivation, but to do this quantitatively requires a numerical 
estimate of the likely extent of its effect in any area.  
 
As such, the present prevalence models do not reflect the local variations and 
do not produce satisfactory predictive power as they do not take into 
consideration geographical patterns. Thornicroft (1991) and Carr-Hill et al. 
(1994) argued that prevalence modelling work should entail defining specially 
tailored combinations of individual census items, rather than taking the simpler 
approach of using national estimates.  
 
The study showed that the prevalence estimate for the borough was not in 
synchrony with that indicated by Public Health (England) and used by the local 
commissioning group. The wide variability within the locality points for the 
adoption of a focussed risk adjustment for mental health service planning 
policy for the borough. The finding that over 60% of SMI group live within 1 
mile radius of the local acute mental health services needs  further 
investigation. 
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The findings also suggest that the projected costs for the physical health care 
treatment of adults with SMI should be adjusted for risk in the same way as 
costs for  mental illness treatment. Under use of medical services by the 
seriously mentally ill is a growing concern and if projected costs for adequate 
health care are under estimated because severity and prevalence of physical 
health were not taken into consideration, medical services may not be 
available to everyone who needs them. This would be a gross health 
inequality.   
 
Within that context local commissioners face are two folds (a) develop an 
approach to undertake  local estimates methodology for diseases (b) 
determining a methodology for estimating co-morbidity prevalence within 
serious mental illness.   
 
The model proposed by this study suggests that in order to obtain prevalence  
estimates  that are more sensitive to local variations, a set of sequential 
procedures should be initiated: 
 
1. Use annual needs assessment to ensure veracity of local indicators 
2. Revise national regional estimates considering local variances to estimate 
prevalence of CHD/COPD within GP localities 
3. Test prevalence estimates using case findings. This can been done routinely 
via annual audits e.g. QOF. Bi- annual mental health needs assessment 
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should be part of the commissioners requirements as they provide a unique 
opportunity to explore local variances.  
4.  Use a simple algorithm(as developed by the study) and some basic statistical 
techniques, to develop a better estimate forecast of co-morbidity within SMI 
population.  
The model described here is open to investigation and question, and the 
results can be applied to any defined geographical area. Commissioners can 
have a better understanding of  high pockets of needs and risk densities.  
 
7.6.  Limitations 
Possible confounding variables 
An important point to consider when analysing co-morbidity is the influence of 
effect modifying or confounding variables. For example, as age is a strong 
determinant of many diseases, it is generally important to take this variable 
into consideration when analysing the co-occurrence of diseases. Part of the 
co-occurrence of diseases can be explained by known influences of age (e.g., 
benign prostate hypertrophy and osteoarthritis). Of course other variables 
such as socio-economic status, environmental factors and psychological 
features can also be very influential (Majeed et al 2000). If these influences 
are not taken into account or at least described, this can lead to unrealistic or 
irrelevant outcomes. An important consideration in this context is whether the 
co-variable is an element of the causal chain to be evaluated or just a 
confounder without relevance to the causal chain of primary interest (when 
adjustment is useful - Diez-Roux 2000).  
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Evaluation of effect modification may be helpful to identify different co-
occurrence patterns in various subgroups. When analysing combinations of 
two diseases, known co-variables can be adjusted by using a multiple 
regression analysis (using one of the diseases as the dependent variable) or a 
stratified analysis according to when analysing combinations of two or more 
co-occurring diseases, stratified analyses are a good option as long as the 
study population is sufficiently large, giving the opportunity to account for the 
main co-variables. Another option is to carry out a stepwise multiple logistic 
regression analysis, evaluating the determinants of the presence of a disease 
additional to a specific disease or combination of diseases. 
 
Because of the influence of various factors on the occurrence of diseases in 
general, it is also important to pay attention to confounders and effect 
modifiers when analysing multi-morbidity. Again, age is an obvious 
determinant. In multiple regression analysis with the presence or absence of 
multi-morbidity as the dependent variable, it is fairly simple to adjust for age or 
any other co-variable by including it as an independent variable. Also in this 
context, the consideration of the conceptual framework of the possible 
relationship between the evaluated associations of primary interest, possible 
confounding and effect modification is important. 
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Weaknesses 
The study has a number of weaknesses including technical and systemic 
difficulties. The baseline prevalence for SMI was taken from QOFs data, which 
are generally recognised as weak. From this baseline, the levels of multi-co-
morbidity were established. The framework was designed to deliver evidence-
based interventions into general practice. Prior to its introduction, GPs worked 
reactively and in an uncoordinated way by dealing with the problems patients 
brought to the surgery. Although QOF data are routinely collected for patients 
with schizophrenia, bipolar disorders and other psychoses, elements like 
follow up are not completed because the Gps do not chase their patients.   
The reported rates is close to, but usually above, the reported rate of 
psychiatric admissions provided by the National Centre for Health Outcomes 
Development (NCHOD). It is important to recognise that since QOF datasets 
include patients who are managed in the community without admissions, there 
is a disparity between NCHOD and QOFs rates. A degree of under reporting 
will always appear in QOFs.  
 
There are some problems regarding the fullness and timeliness of the data.  
For example, the SMI population is known to have a tendency to engage in 
smoking behaviour and are also likely to be very heavy smokers. This has not 
been factored into the regression equation. The local smoking cessation 
teams do not routinely gather data for that group for the time being (Nijhuis et 
al 2006).  As such, the data used for the prevalence estimates do not 
discriminate within the population. This is likely to increase the odds ratio and 
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will further increase the prevalence estimates. Further studies in this area will 
need to address this issue.  
 
The risk factors were derived from data that may not be current. Ethnicity 
assumptions derived from census data almost ten years old may well be 
questionable, in the light of changing patterns of immigration in the period.  
 
Modelling provides estimates, not answers. Any model is strictly “wrong”, but 
may be useful within certain limits. The methodology by means of which the 
models were created does not easily permit the calculation of confidence 
intervals on the expected numbers of patients even though 95% confidence 
intervals were presented for the individual factors’ odds ratios, so the models’ 
outputs do not incorporate an indication of the strength of belief we can have 
in their results. The statistical procedure used is rather basic and needs to be 
modified and refined. However, it nevertheless provides a new way of 
undertaking prevalence estimates at local levels.  
 
7.7.  Personal account 
The idea of prevalence modelling was germinated in the early 1990s and was 
further developed by Nita Farouli and the team at Brent PCT when the 
diabetes prevalence model was tested. The use of prevalence modelling as a 
public health tool for planning, has gained momentum since then. However, 
availability of good health intelligence for local health planning remains a 
challenge, especially where the outcome of interest has multiple causes or 
influences. In the course of this study, I have developed a greater appreciation 
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for the possibilities and limitations of public health epidemiological research 
methodology. Public health units within primary care within the UK are 
struggling to juggle the conflicting roles of delivering a public health strategy 
which reflects national trends and meeting local variances. This is a 
particularly big concern for mental health.  
 
While there may be mileage from using national data which bring a baseline of 
information from which we can plan services, there are some serious 
problems within this approach when dealing with mental health data. 
Unfortunately, the doctrine of evidence based medicine and the hierarchy of 
evidence means operational management data is often under-valued. This 
may lead to the under-utilisation of routinely collected data. 
 
During the 1970s, a number of approaches were developed to use time series 
data to study the effect of interventions. I found the textbook by Cook and 
Campbell provided an excellent overview of these approaches. However, 
these methods are not commonly seen in current public health literature, even 
though many important public health questions cannot be answered by RCTs.  
 
In my study I have considered a number of such issues and their impact on 
service delivery, such as ineffective primary care interventions in mental 
health, lack of good routine data collection, rigid (poor) health commissioning 
principles leading to a “silo” approach to health care planning.  
  
In the course of this work, it has become apparent to me that to understand 
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the good public health research approach to deal with such complex issues 
such mental health co-morbidity requires data from multiple sources to 
triangulate the findings. This is especially important for health outcomes which 
are influenced by multiple factors.  
 
From an epidemiological perspective, I felt that the biggest limitation of my 
study was the inability to define the population at risk. This was particularly 
problematic when considering the chronic mental health population. Without 
knowing the mortality risk among those with physical co-morbidity, it is difficult 
to interpret the drivers behind changes in trend. Finally, I have become more 
cautious when interpreting short time series or year-on-year trends. Both of 
these are frequently presented in public health documents or publications and 
it is easy to over-interpret annual fluctuations or short-term changes in trend 
 
7.8. Conclusions  
The methods described offer a potentially usefully way forward for identifying 
undiagnosed cases. They are applicable to other long term conditions for 
which similar models are available on the APHO website. Ultimately, the 
validity or otherwise of the approach will depend on empirical results of its 
use.  
 
The future 
a. Linkages with risk factor prevalence data from GP systems 
The case has been made on how the current models can be linked, both with 
each other and with other modelled data such as smoking prevalence ( eg 
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Chronic Obstructive Pulmonary Disease Model). As noted above, local 
estimates of prevalence or population means (for continuous variables) of 
disease risk factors and lifestyle behaviours e.g. current smoking, obesity, 
blood pressure and physical activity, are of great interest to policy-makers, 
and increasingly to local organisations for planning and performance 
monitoring purposes e.g. in Local Area Agreements. They are also of interest 
to researchers examining the relationships between health determinants, such 
as income and education, and health outcomes such as disease prevalence, 
SRHS and death, because risk factor prevalence and means provide a linkage 
between determinants and outcomes and may be used to predict the latter. 
 
Until now, risk factor prevalence estimates have come mainly from the HSfE, 
from local surveys either run independently from the HSfE, or from synthetic 
estimates. The traditional ("direct") approach to estimation used for the HSfE 
uses classical design-based survey sampling. However, sample sizes are 
typically small within small areas, so the direct estimators have large sampling 
errors (and hence large confidence intervals) even when pooling years of 
survey data (which prevents trend estimates). When there are no sample 
observations in the small areas of interest, direct estimations cannot even be 
calculated. 
 
Potential use of primary care data for risk factor prevalence/mean  
estimation 
The quality and quantity of population-based data collected by primary 
healthcare teams has improved dramatically in recent years, as a result of 
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overall quality improvement, specific data quality initiatives and the impact of 
pay for performance through the QOF (Cox et al. 2006; Mc Fadden et al. 
2009; Fotheringham et al. 2010). The data is also becoming more accessible 
through national GP databases, local IT projects and, eventually, aggregation 
through the Secondary Uses Service via GPES, which could cover over 50% 
of English practices. This would allow near to real-time monitoring of risk 
factor prevalence data. 
 
There is a large volume of risk factor and lifestyle data in GP systems. For 
example, our analysis of the 2005-6 IMS national GP database (about 1million 
active patients) shows that overall about 30% of patients have their smoking 
status recorded in the last 12 months and 17% had their BMI recorded in that 
period. There is therefore the potential to use this data, either alone or in 
combination with other data, to improve local prevalence estimation but data is 
incomplete. It is also easier to measure risk factor prevalence through 
population-based programmes such as NHS Health Checks than it is to 
ensure QOF registers reflect actual disease prevalence. However, there are a 
number of methodological problems to resolve. For example, the data is non-
random - sicker and older people and females are more likely to be sampled 
and these may introduce a bias. 
 
 Case for the development of a simulation model 
A major disadvantage of the current prevalence models is that they are static, 
with a cross-sectional structure. In the US, the Centres for Diseases Control 
are already well advanced in the development of dynamic models (Cortes and 
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Vapnik 1995). In San Francisco, Archimedes is continuing to expand both in 
its scope and functionality. The UK should be developing equally dynamic 
epidemiological models. This requires at the very least a multi-disciplinary 
team with on-going support, not a lone researcher and a single injection of 
funding. 
 
In the UK, in addition to the prevalence models described here, there is 
already a great deal of academic expertise in mathematical modelling, 
particularly for mental health. Examples include work by Gyles Glover for the 
quantitative modelling on the Mental Health Minimum Data Set (MHMDS)  
(Glover 2003). After very promising initial work in the late 1990s and early 
2000s there has been very little support for work in this area. 
 
There is a need for a UK modelling research for physical disease in mental 
health. As indicated above, this is probably because of a lack of public health 
interest in this area of work. This concern was voiced at the Faculty of Public 
Health Annual conference in 2011. A possible way forward would be to make 
this a public health epidemiological research priority. 
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Annex 1 
 
Mental health needs assessment 
 
1. A section of the data compiled as part of the MHNA exercise for Brent GP 
practices. Colour coding reflects levels of concerns for various metrics used to 
monitor performance. 
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KENTON MEDICAL CENTRE Wembley 3024 0.6 31.20 88.33 3.4 70.5 0.68 2.04 0.11 6.80 37.03704 4.7661197 68.428 10.07 1.7 0.0 1.0 15.47
SUDBURY COURT SURGERY Wembley 4012 1.7 98.11 84.00 56.3 77.2 1.21 2.41 0.25 7.39 26.17149 17.6813341 207.354 32.15 2.4 8.0 5.2 19.76
LANFRANC MEDICAL CENTRE Wembley 6995 0.5 26.87 86.65 14.9 64.0 1.33 2.28 0.81 2.52 21.01501 4.74131391 111.326 11.90 0.9 1.5 1.7 19.79
SUDBURY & ALPERTON MEDICAL CENTREWembley 8726 0.9 43.16 86.18 11.0 63.1 1.31 2.30 0.27 6.91 19.94041 13.1386622 159.963 18.02 2.3 1.0 3.6 22.40
BEECHCROFT MEDICAL CENTREWembley 5583 1.2 16.84 86.55 16.8 65.7 2.33 2.33 0.36 18.62 34.03188 26.6597645 1462.663 58.92 4.1 1.7 3.6 23.85
PRESTON MEDICAL CENTRE Wembley 3332 0.5 9.77 85.05 8.6 69.0 0.00 2.42 0.30 3.40 7.803121 3.22906155 41.171 6.47 2.0 0.0 2.4 24.03
EAGLE EYE Wembley 2459 0.5 23.40 88.00 5.1 55.8 0.00 2.09 0.14 1.89 5.286702 3.13136058 30.792 5.08 1.6 0.0 3.7 26.25
ALPERTON MEDICAL CENTRE Wembley 5543 0.5 5.91 86.82 2.0 64.1 0.72 2.17 0.24 5.17 18.22118 6.76442877 77.791 14.03 1.9 0.0 1.9 26.27
STANLEY CORNER MEDICAL CENTREWembley 5231 1 62.38 86.71 25.2 60.8 1.50 2.25 0.76 9.83 26.38119 14.2510688 181.264 31.45 4.3 2.1 2.3 26.58
HAZELDENE MEDICAL CENTRE Wembley 3264 0.5 15.31 84.81 2.5 63.3 0.88 2.20 0.51 12.37 20.52696 5.72233471 94.639 10.13 3.5 2.5 3.5 26.71
PREMIER MEDICAL CENTRE Wembley 4016 1 43.41 85.89 19.8 61.3 0.70 2.45 0.33 15.79 34.86056 14.0281967 260.924 23.72 4.9 0.0 4.2 26.94
THE SURGERY (WCHC) Wembley 2990 0.6 26.13 85.86 15.6 65.6 1.72 2.15 0.11 6.80 22.40803 6.0132291 85.044 31.25 3.0 0.0 3.0 27.07
SMS MEDICAL PRACTICE Wembley 2372 0.8 72.46 84.81 3.7 58.6 0.00 2.52 0.56 3.23 17.28499 6.30477271 83.853 10.99 2.5 0.0 1.9 27.71
SUNFLOWER MEDICAL CENTREWembley 3323 0.9 30.55 88.39 6.8 67.6 3.71 2.32 0.90 15.51 41.52874 25.0719658 246.541 23.65 5.6 3.4 6.5 28.23
LANCELOT MEDICAL CENTRE Wembley 4314 0.3 9.05 86.02 12.6 58.6 0.29 2.31 0.08 3.24 9.272137 5.77617329 47.653 16.74 2.3 0.0 4.0 29.35
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2. Based on the model developed by the study, prevalence estimates of the 
locality by the public health unit. Example 2011-12 
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Annex 2 
 
 
Routine data collected by GPs regarding chronic diseases. Please note 
that exceptional reporting routine can distort figures. 
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Annex 3 
 
Map showing density of population with COPD (based on mapping 
based on  the sum of the odds ratios for all registered patients living in 
the post code boundary within Brent). The south (high deprivation 
locality) is a high risk area. 
 
 
 
 
 
 
 
 
                 South 
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Annex 4 
 
 
DATA SOURCE FOR MENTAL HEALTH NEEDS ASSESSMENT 
 
 
These included: 
Nationally available statistics – NHS Information Centre for Health and Social 
Care. 
 Data at GP practice level,  PCT level,  Borough level,  provider level covering 
i. Hospital Episode Statistics and Mental Health Minimum Datasets 
ii. Prescribing data 
iii. QOF returns 
 Public Health Information service (Health observatories) statistics 
 Data Submissions to national collection services by Providers 
 Data Submissions to commissioners by Providers 
 Research Studies at Local, Regional and National level 
 
Qualitative, Policy and Guidance sources included: 
 NICE 
 Department of Health 
 Sainsbury Centre 
 Kings Fund 
 
Local Information and reports has been provided by: 
 Brent Public Health 
 Brent Mind 
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 Central and Northwest London Mental Health Trust (CNWL) 
 Brent Finance Department 
 Brent Carers 
A coarse estimated prevalence from mental health profile was based on 
various sources of information (national and local) was carried out. Information 
sources were derived from: 
 Adult Psychiatric Morbidity Study 2007 - APMS Reports  
 Dr Foster (HES/SUS data) 2003-10 – Dr Foster data is based on HES data 
from secondary care, profiled nationally against practice list sizes. Specifically, 
data was filtered for the London Borough of Brent. These included data on: 
o GP records - QOF information 
o Mental health register (recording adults who have a serious mental health 
diagnosis 
o Prescribing evidence (number of prescriptions and rate of prescribing per 
head of population) 
Others included: 
 Indexes of deprivation: IMD (Index of multiple deprivation) – available at ward 
level 
 Mental Health Needs Index: MINI/Mini2000 and National Psychiatric Morbidity 
Survey 1993 (NPMS) – available  at ward level 
 Local Index of Need (LIN): Borough level 
 
 
 
 
 
 
 
 
231 
 
 
Annex 5 
 
A presentation of the MHNA to the commissioners as part of the 
study 
 
